Professor Jacob George
Director, Storr Liver Centre, The Westmead Institute for Medical Research
Head, Department of Gastroenterology &
Hepatology, Westmead Hospital and Sydney West Local Health District
Professor Jacob George is a renowned hepatologist and liver research scientist who studies the causes of and mechanisms for the development of liver disease and liver cancer. He contributes to investigator-initiated and multicentre international clinical trials on therapeutics for liver diseases, and leads a program of research on viral hepatitis, fatty liver disease, liver fibrosis, host genetics/liver immunology and the epidemiology, prevention and management of liver cancer. His research has a strong translational component, linking laboratory and clinical research. Professor George’s work has made significant contributions to clinical practice. His team first identified the role of interferon lambda 3 gene polymorphisms for predicting treatment response in chronic hepatitis C, and a second gene polymorphism that interacts with interferon lambda 3. These discoveries are considered major advances in the field and the finest examples of ‘personalised medicine’. Professor George was an author on the groundbreaking study of combination telaprevir, pegylated interferon and ribavirin therapy for hepatitis C, which changed the landscape of hepatitis C treatments, heralding the era of direct-acting antivirals. His work identifying insulin resistance as the universal underlying pathophysiological abnormality in fatty liver disease underpins the majority of research on this condition and is the cornerstone of current therapy (lifestyle intervention; exercise; insulin-sensitising agents). He also first described the association between hepatitis C and insulin resistance. Professor George is an advisor to Hepatitis Australia, the Transfusion Related AIDS and Infectious Diseases Service, and at state and national levels, on viral hepatitis. He oversees research for the Asian Pacific Association for the Study of Liver. He is a Fellow of the American Association for the Study of Liver Disease.
Professor George’s research broadly covers liver disease and cancer, with specific themes in the fields of viral hepatitis, liver cancer, fatty liver disease, hepatic drug metabolism, and the contribution of host genetics and immunology to liver disease, liver injury and fibrosis. He has particular interests in basic and clinical research on non-alcoholic steatohepatitis and on the role of host genetics in treatment response and disease progression in viral hepatitis.
Professor George leads an international genetics hepatitis C consortium that includes 4,200 patients from Australia, Egypt, Germany, Italy, the UK, Hong Kong, etc. The consortium provides the opportunity to access patients with distinct genetic backgrounds to help identify host factors that are associated with treatment response and/or the development of liver fibrosis and disease progression. His team is attempting to develop diagnostic tests to non-invasively predict liver fibrosis stage, thereby avoiding liver biopsies. Additionally, with the aid of a major grant from the Cancer Council of NSW and the Cancer Institute, NSW, Professor George is undertaking a program of research investigating the epidemiology, pathogenesis and treatment of liver cancer, a malignancy that is rapidly increasing in incidence in NSW. The aim of the work is to develop new preventative and early detection strategies and treatments.
Project title | Research student |
---|---|
Screening Approaches for Non-Cirrhotic MAFLD Patients at the Risk of Developing HCC: An Early Intervention | Fatema SAFRI |
Exploring the potential of ctDNA and the Notch Signalling Pathway as biomarkers for the early detection of Hepatocellular Carcinoma (HCC) | William YANG |
Selected publications
(Bentham Science Publishers, 2012)
Publications
Edited Books
- Qiao, L., Li, Y., Yan, X., George, J. (2012). Molecular Aspects of Hepatocellular Carcinoma. Sharjah: Bentham Science Publishers.
Book Chapters
- Walker, S., George, J., Hebbard, L. (2012). Animal Models of Hepatocellular Carcinoma. In Liang Qiao, Yumin Li, Xiang Yan and Jacob George (Eds.), Molecular Aspects of Hepatocellular Carcinoma, (pp. 116-128). Sharjah: Bentham Science Publishers. [More Information]
- Pattullo, V., George, J. (2012). The Problem of Insulin Resistance and its Effect on Therapy. In Geoffrey W. McCaughan, John G. McHutchison, Jean-Michel Pawlotsky (Eds.), Advanced Therapy for Hepatitis C, (pp. 169-176). Chichester, United Kingdom: Wiley-Blackwell Publishing. [More Information]
- Pattullo, V., George, J. (2010). Managing the Patient with Chronic Viral Hepatitis Receiving Chemotherapy. In Monica Robotin, Ian Olver, Afaf Girgis (Eds.), When Cancer Crosses Disciplines: A Physicians Handbook, (pp. 813-832). London: Imperial College Press. [More Information]
- van der Poorten, D., Milner, K., George, J. (2009). Effect of adipokines on liver disease in females. In Ichiro Shimizu (Eds.), Female Hepatology: Impact of female sex against progression of liver disease, (pp. 191-212). India: Research Signpost.
- George, J., Talley, N., Segal, I., Weltman, M. (2008). Evaluating abnormal liver tests. In N Talley, I Segal, M Weltman (Eds.), Gastroenterology and Hepatology: a clinical handbook, (pp. 316-326). Australia: Elsevier.
- Teoh, N., George, J. (2007). Abnormal Liver Function Tests. In N Talley, I Segal, M Weltman (Eds.), Gastroenterology and Hepatology: a clinical handbook. Australia: Elsevier.
Journals
- Pan, Z., Alharthi, J., Bayoumi, A., George, J., Eslam, M. (2024). A Cell Specific Effect of MBOAT7 MAFLD-risk Variant on Immune Cells. Frontiers in Bioscience - Landmark, 29(4), 148. [More Information]
- Zhang, H., Crespo, J., Grønbæk, H., Yang, W., Eslam, M., Wong, R., Machado, M., Yu, M., Ghanem, O., Okanoue, T., George, J., et al (2024). A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease. Hepatology International. [More Information]
- Feng, G., Schattenberg, J., Labenz, C., Mahadeva, S., Chan, W., Chi, X., Delamarre, A., De Ledinghen, V., Petta, S., Bugianesi, E., George, J., et al (2024). acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study. Clinical Gastroenterology and Hepatology. [More Information]
- Clark, P., Sinclair, M., George, J., Sievert, W., MacQuillan, G., Tse, E., Nicoll, A., Wade, A., Cheng, W., Roberts, S., et al (2024). Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study (OPERA-C). Drug and Alcohol Review. [More Information]
- Zhang, L., Turan, S., Alisi, A., Weiss, R., Faienza, M., Ashraf, A., Sundaram, S., Srivastava, A., De Bruyne, R., Kang, Y., Baur, L., George, J., et al (2024). An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease. Med, 5(7), 797-815.e2. [More Information]
- Kouvari, M., Mantzoros, C., Valenzuela-Vallejo, L., Guatibonza-Garcia, V., Verrastro, O., Axarloglou, E., Mylonakis, S., George, J., Papatheodoridis, G., Mingrone, G. (2024). Apolipoprotein C-III in association with metabolic-dysfunction associated steatotic liver disease: A large, multicenter study. Clinical Nutrition, 43(12), 101-108. [More Information]
- Kim, D., Choi, Y., Lee, J., Choi, H., Yoon, K., Yim, S., Park, C., Kim, D., Lee, H., Choi, W., George, J., et al (2024). Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation. Hepatology International. [More Information]
- Yuan, H., Targher, G., Tian, N., Li, G., Zhang, X., George, J., Zhou, M., Wang, F., Zheng, M., Liu, W., et al (2024). Associations between cuprotosis-related genes and the spectrum of metabolic dysfunction-associated fatty liver disease: An exploratory study. Diabetes, Obesity and Metabolism. [More Information]
- Tang, Y., Jiang, X., Zhu, C., Audsley, J., Tangkijvanich, P., Avihingsanon, A., Song, S., Liu, S., Lewin, S., George, J., Douglas, M., et al (2024). Circulating capsid-antibody-complexes (CACs) drive intrahepatic complement deposition and inform subclinical liver inflammation in chronic hepatitis B. Antiviral Research, 231, 106017. [More Information]
- Nash, E., Chitturi, S., Flores, J., Braund, A., Bonnichsen, M., Riordan, S., Humphris, J., Duong, T., Mckenzie, C., Liu, K., Strasser, S., George, J., et al (2024). Drug-induced liver injury from selective androgen receptor modulators, anabolic-androgenic steroids and bodybuilding supplements in Australia. Alimentary Pharmacology and Therapeutics, 59(8), 953-961. [More Information]
- Pan, Z., Bayoumi, A., Metwally, M., George, J., Eslam, M. (2024). Exportin 4 DNA promoter methylation in liver fibrosis. PloS One, 19(2024-05-05 00:00:00). [More Information]
- Bajaj, J., Topazian, M., Torre, A., Xie, Q., George, J., Kamath, P., Choudhury, A., Kumaran, V., Wong, F., Seto, W., et al (2024). Geographic disparities in access to liver transplant for advanced cirrhosis: Time to ring the alarm!. American Journal Of Transplantation. [More Information]
- Cao, Z., Seto, W., Desalegn, H., Alvares-da-Silva, M., Bush, B., Thacker, L., Xie, Q., Bajaj, J., Wong, F., Choudhury, A., George, J., et al (2024). Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium. The Lancet Gastroenterology & Hepatology. [More Information]
- Tu, T., Eslam, M., Berg, T., Chan, H., George, J., Douglas, M., Ajoyan, H., Nur Umami, R., Veeraraghavan, V., Boldbaatar, D., et al (2024). Inhibition of Cellular Factor TM6SF2 Suppresses Secretion Pathways of Hepatitis B, Hepatitis C, and Hepatitis D Viruses. The Journal of Infectious Diseases, 230(4), 970-981. [More Information]
- Tomic, D., Salim, A., George, J., Magliano, D., Shaw, J. (2024). Liver disease mortality and hospitalisations among people with type 2 diabetes mellitus: A population-based study. Liver International, 44(2), 508-517. [More Information]
- Eslam, M., George, J. (2024). MAFLD: from a disease framework to patient care. Hepatology International. [More Information]
- Howell, J., De Santis, T., Muller, K., Nguyen, B., Olynyk, J., Shackel, N., Valery, P., Wigg, A., George, J., Roberts, S., et al (2024). Overcoming disparities in hepatocellular carcinoma outcomes in First Nations Australians: a strategic plan for action. Medical Journal of Australia. [More Information]
- Pennisi, G., Enea, M., Romero-Gomez, M., Bugianesi, E., Wai-Sun Wong, V., Fracanzani, A., de Lédinghen, V., George, J., Berzigotti, A., Viganò, M., et al (2024). Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria. Hepatology, 79(4), 912-925. [More Information]
- Armandi, A., Ampuero, J., Pennisi, G., Aller, R., Tiniakos, D., Burt, A., David, E., Vecchio, F., Maggioni, M., Cabibi, D., Eslam, M., George, J., et al (2024). Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease. Gut, , 330815. [More Information]
- Tang, L., Jiang, P., Wang, C., Chen, Q., Byrne, C., Targher, G., Eslam, M., George, J., Wong, V., Zheng, M., et al (2024). Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort. Liver International. [More Information]
- Perananthan, V., George, J. (2024). Severe liver injury following use of RAD-140, a selective androgen receptor modulator, for body building. Australian Prescriber, 47(1), 26-28. [More Information]
- Genovese, F., Fahy, W., Wain, L., Vestbo, J., Nanthakumar, C., Shaker, S., Hoyer, N., Leeming, D., George, J., Trebicka, J., et al (2024). The fibroblast hormone Endotrophin is a biomarker of mortality in chronic diseases. Matrix Biology, 132, 1-9. [More Information]
- Kalo, E., Müller, L., Kloeckner, R., George, J., Thimme, R., Bettinger, D., Ahlenstiel, G., Sturm, L., Schultheiss, M., Moore, O., et al (2024). The Freiburg Index of Post-TIPS Survival accurately predicts mortality in patients with acute decompensation of cirrhosis. Liver International. [More Information]
- Zeng, X., George, J., Newberry, C., Zheng, J., George, E., Spearman, C., Kontogianni, M., Ristic-Medic, D., Peres, W., Depboylu, G., et al (2024). The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus. Metabolism: Clinical and Experimental, 161, 156028. [More Information]
- Kouvari, M., Valenzuela-Vallejo, L., Axarloglou, E., Verrastro, O., Papatheodoridis, G., Mingrone, G., George, J., Mantzoros, C. (2024). Thyroid function, adipokines and mitokines in metabolic dysfunction-associated steatohepatitis: A multi-centre biopsy-based observational study. Liver International. [More Information]
- Le, H., Fajardo Lubian, A., Bowring, B., Van Der Poorten, D., Iredell, J., George, J., Venturini, C., Ahlenstiel, G., Read, S. (2024). Using a human colonoid-derived monolayer to study bacteriophage translocation. Gut Microbes, 16(1), 2331520. [More Information]
- Kurup, R., Kalo, E., Read, S., Ma, W., George, J., Ahlenstiel, G. (2024). Validation and Comparison of Non-Invasive Tests for the Exclusion of High-Risk Varices in Compensated Advanced Chronic Liver Disease. Livers, 4(2), 182-192. [More Information]
- Kalo, E., Baig, A., Gregg, E., George, J., Read, S., Ma, W., Ahlenstiel, G. (2023). A novel, nurse-led ‘one stop’ clinic for patients with liver cirrhosis results in fewer liver-related unplanned readmissions and improved survival. BMC Gastroenterology, 23(1). [More Information]
- Fischer, J., Long, S., Koukoulioti, E., Müller, T., Fueloep, B., Heyne, R., Eslam, M., George, J., Finkelmeier, F., Waidmann, O., et al (2023). Association of Common Polymorphisms in the Interleukin-1 Beta Gene with Hepatocellular Carcinoma in Caucasian Patients with Chronic Hepatitis B. Pathogens, 12(1). [More Information]
- Ramírez-Mejía, M., Jiménez-Gutiérrez, C., Eslam, M., George, J., Méndez-Sánchez, N. (2023). Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification? Hepatology International. [More Information]
- Clark, P., Sinclair, M., George, J., Bollipo, S., McGarity, B., Sievert, W., MacQuillan, G., Tse, E., Nicoll, A., Wade, A., Levy, M., et al (2023). Broadening and strengthening the health providers caring for patients with chronic hepatitis C may improve continuity of care. Journal of Gastroenterology and Hepatology. [More Information]
- Valenzuela-Vallejo, L., Papatheodoridis, G., Mingrone, G., George, J., Mantzoros, C., Chrysafi, P., Kouvari, M., Guatibonza-Garcia, V., Mylonakis, S., Katsarou, A., Eslam, M., et al (2023). Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study. Metabolism: Clinical and Experimental, 148, 155694. [More Information]
- Roder, D., Banham, D., George, J., Rushton, S., O’Brien, T. (2023). Demographic, health, and prognostic characteristics of Australians with liver cancer: a cohort study of linked data in New South Wales for informing cancer control. BMC Public Health, 23(1). [More Information]
- Rauff, B., Ramezani-Moghadam, M., Tay, E., George, J., Douglas, M. (2023). Development of an in vitro model to study hepatitis C virus-induced fibrosis. Future Virology, 18(12), 757-766. [More Information]
- Lu, H., George, J., Eslam, M., Villanueva, A., Bolondi, L., Reeves, H., McCain, M., Chambers, E., Ward, C., Sartika, D., et al (2023). Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease. Liver Cancer, 12(1), 19-31. [More Information]
- Chai, T., Byth Wilson, K., George, J., Pasupathy, D., Cheung, N. (2023). Elevated Hepatic Steatosis Index is Associated with the Development of Adverse Maternal, but Not Adverse Neonatal, Outcomes: A Retrospective Cohort Study. International Journal of Women's Health, 15, 589-598. [More Information]
- Kalo, E., George, J., Read, S., Majumdar, A., Ahlenstiel, G. (2023). Evolution of risk prediction models for post-operative mortality in patients with cirrhosis. Hepatology International. [More Information]
- Keating, S., Sabag, A., Hallsworth, K., Hickman, I., MacDonald, G., Stine, J., George, J., Johnson, N. (2023). Exercise in the Management of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Position Statement from Exercise and Sport Science Australia. Sports Medicine, 53(12), 2347-2371. [More Information]
- Valerio, H., Grebely, J., Matthews, G., Dore, G., Alavi, M., Marshall, A., Hajarizadeh, B., Amin, J., Law, M., Tillakeratne, S., George, J., et al (2023). Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia: A population-based study. Drug and Alcohol Review. [More Information]
- Wai-Sun Wong, V., Anstee, Q., Nitze, L., Geerts, A., George, J., Nolasco, V., Kjær, M., Ladelund, S., Newsome, P., Ratziu, V. (2023). FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial. EClinicalMedicine, 66. [More Information]
- Bajaj, J., Choudhury, A., Xie, Q., Kamath, P., Topazian, M., Hayes, P., Torre, A., Desalegn, H., Idilman, R., Cao, Z., George, J., et al (2023). Global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium. The Lancet Gastroenterology & Hepatology, 8(7), 611-622. [More Information]
- Zhang, H., Rios, R., Boursier, J., Anty, R., Chan, W., George, J., Yilmaz, Y., Wong, V., Fan, J., Dufour, J., et al (2023). Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-Alcoholic steatohepatitis risk diagnosis: An international registry study. Chinese Medical Journal, 136(3), 341-350. [More Information]
- Jia, X., Song, E., Liu, Y., Chen, J., Wan, P., Hu, Y., Ye, D., Chakrabarti, S., Mahajan, H., George, J., et al (2023). Identification and multicentric validation of soluble CDCP1 as a robust serological biomarker for risk stratification of NASH in obese Chinese. Cell Reports Medicine, 4(11). [More Information]
- Currenti, J., Mishra, A., Wallace, M., George, J., Sharma, A. (2023). Immunosuppressive mechanisms of oncofetal reprogramming in the tumor microenvironment: implications in immunotherapy response. Biochemical Society Transactions, 51(2), 597-612. [More Information]
- Gofton, C., Clark-Dickson, M., George, J. (2023). Lean Metabolic-Associated Fatty Liver Disease. Endocrinology and Metabolism Clinics of North America. [More Information]
- Kouvari, M., Valenzuela-Vallejo, L., Guatibonza-Garcia, V., Polyzos, S., Deng, Y., Kokkorakis, M., Agraz, M., Mylonakis, S., Katsarou, A., Verrastro, O., Eslam, M., George, J., et al (2023). Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study. Metabolism: Clinical and Experimental, 147. [More Information]
- Clark, P., Valery, P., Strasser, S., Weltman, M., Thompson, A., Levy, M., Leggett, B., Zekry, A., Rong, J., George, J., et al (2023). Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort. Digestive Diseases and Sciences, 68(1), 291-303. [More Information]
- Alharthi, J., Pan, Z., Gloss, B., McLeod, D., Weltman, M., George, J., Eslam, M. (2023). Loss of metabolic adaptation in lean MAFLD is driven by endotoxemia leading to epigenetic reprogramming. Metabolism: Clinical and Experimental, 144. [More Information]
- Gofton, C., Upendran, Y., Zheng, M., George, J. (2023). MAFLD: How is it different from NAFLD? Clinical and Molecular Hepatology, 29, S17-S31. [More Information]
- Tang, L., Li, G., Eslam, M., Zhu, P., Chen, S., Leung, H., Huang, O., Wong, G., Zhou, Y., Karsdal, M., George, J., et al (2023). N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD. Hepatology International, 17(1), 190-201. [More Information]
- Fernandez, M., Pal, S., Arrese, M., Arab, J., George, J., Mendez-Sanchez, N. (2023). Nonalcoholic Fatty Liver Disease in Latin America and Australia. Clinics in Liver Disease, 27(2), 301-315. [More Information]
- Abomughaid, M., Tay, E., Pickford, R., Malladi, C., Read, S., Coorssen, J., Gloss, B., George, J., Douglas, M. (2023). PEMT Mediates Hepatitis C Virus-Induced Steatosis, Explains Genotype-Specific Phenotypes and Supports Virus Replication. International Journal of Molecular Sciences, 24(10). [More Information]
- El-Khobar, K., Tay, E., Diefenbach, E., Gloss, B., George, J., Douglas, M. (2023). Polo-like kinase-1 mediates hepatitis C virus-induced cell migration, a drug target for liver cancer. Life Science Alliance, 6(11). [More Information]
- Ramandi, A., George, J., Merat, S., Jafari, E., Sharafkhah, M., Radmard, A., Nateghi Baygi, A., Delavari, A., Mohammadi, Z., Poustchi, H., et al (2023). Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial. Hepatology International, 17(4), 882-888. [More Information]
- Calzadilla-Bertot, L., Jeffrey, G., Wang, Z., Huang, Y., Garas, G., Wallace, M., De Boer, B., George, J., Eslam, M., Phu, A., et al (2023). Predicting liver-related events in NAFLD: A predictive model. Hepatology, 78(4), 1240-1251. [More Information]
- Fischer, J., van Bömmel, F., Koukoulioti, E., Müller, T., Heyne, R., Eslam, M., George, J., Finkelmeier, F., Waidmann, O., Berg, T. (2023). Sex-differences in the association of interleukin-10 and interleukin-12 variants with the progression of hepatitis B virus infection in Caucasians. Hepatology Research, 53(12), 1156-1168. [More Information]
- Yeoh, Y., Hajarizadeh, B., Dore, G., Lockart, I., Danta, M., Flynn, C., Blackmore, C., Levy, M., George, J., Alavi, M. (2023). Temporal change in aetiology and clinical characteristics of hepatocellular carcinoma in a large cohort of patients in New South Wales, Australia. Internal Medicine Journal. [More Information]
- Kouvari, M., Mylonakis, S., Katsarou, A., Valenzuela-Vallejo, L., Guatibonza-Garcia, V., Kokkorakis, M., Verrastro, O., Angelini, G., Markakis, G., Eslam, M., George, J., et al (2023). The first external validation of the Dallas steatosis index in biopsy-proven Non-alcoholic fatty liver Disease: A multicenter study. Diabetes Research and Clinical Practice, 203. [More Information]
- Canivet, C., Lange, N., Blanchet, O., Moal, V., Ibrahim Kamal Jouness, R., Roux, M., Chan, W., Sturm, N., Eslam, M., Bugianesi, E., George, J., et al (2023). Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients. Clinical Gastroenterology and Hepatology, 21(12), 3097-3106.e10. [More Information]
- Janko, N., Majeed, A., Clements, W., Fink, M., Lubel, J., Goodwin, M., Nicoll, A., Strasser, S., Sood, S., Bollipo, S., George, J., et al (2023). Wide variation in pre-procedural blood product transfusion practices in cirrhosis: a national multidisciplinary survey. Hepatology Communications, 7(5). [More Information]
- Younossi, Z., Ong, J., Takahashi, H., Yilmaz, Y., Eguc`hi, Y., El Kassas, M., Buti, M., Diago, M., Zheng, M., Fan, J., George, J., et al (2022). A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 20(6), e1456-e1468. [More Information]
- Alharthi, J., Bayoumi, A., Thabet, K., Pan, Z., Gloss, B., Latchoumanin, O., Lundberg, M., Twine, N., McLeod, D., Alenizi, S., Liddle, C., George, J., Eslam, M., et al (2022). A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes. Nature Communications, 13(1). [More Information]
- Lazarus, J., Anstee, Q., Arab, J., Batterham, R., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M., Francque, S., George, J., et al (2022). Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews. Gastroenterology & Hepatology, 19(1), 60-78. [More Information]
- Tang, L., Ma, H., Eslam, M., Wong, G., Zhu, P., Chen, S., Leeming, D., Karsdal, M., Li, G., Huang, O., George, J., et al (2022). Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. Metabolism: Clinical and Experimental, 128, 154958. [More Information]
- Zhou, K., Huo, X., Nguyen, R., Bae, D., Han, S., Zhang, Z., Duan, W., Yuen, L., Lam, V., George, J., Qiao, L. (2022). Aptamer-mediated doxorubicin delivery reduces HCC burden in 3D organoids model. Journal of Controlled Release, 341, 341-350. [More Information]
- Younes, R., Govaere, O., Petta, S., Miele, L., Tiniakos, D., Burt, A., David, E., Vecchio, F., Maggioni, M., Cabibi, D., Eslam, M., George, J., et al (2022). Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach? Gut, 71(2), 382-390. [More Information]
- Coupland, H., Day, C., Haber, P., Pritchard-Jones, J., McKee, K., George, J., McCaughan, G. (2022). Client resistance to hepatitis C treatment initiation in opioid agonist treatment clinics in Sydney, Australia: A qualitative study. Drug and Alcohol Review, 41(3), 706-714. [More Information]
- Younossi, Z., Yilmaz, Y., Yu, M., Wai-Sun Wong, V., Fernandez, M., Isakov, V., Duseja, A., Mendez-Sanchez, N., Eguchi, Y., Bugianesi, E., George, J., et al (2022). Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. Clinical Gastroenterology and Hepatology, 20(10), 2296-2306000000. [More Information]
- Jefferies, M., Rashid, H., Graham, R., Read, S., Banik, G., Lam, T., Njiomegnie, G., Eslam, M., Zhao, X., Ahmed, N., Douglas, M., George, J. (2022). COVID-19 Impact on Australian Patients with Substance Use Disorders: Emergency Department Admissions in Western Sydney before Vaccine Roll Out. Vaccines, 10(6). [More Information]
- Gofton, C., Agar, M., George, J. (2022). Early Implementation of Palliative and Supportive Care in Hepatocellular Carcinoma. Seminars in Liver Disease, 42(4), 514-530. [More Information]
- Willumsen, N., Jensen, C., Green, G., Nissen, N., Neely, J., Nelson, D., Pedersen, R., Frederiksen, P., Chen, I., Boisen, M., Eslam, M., George, J., et al (2022). Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types. Cellular and Molecular Life Sciences, 79(4), 204. [More Information]
- Bae, D., George, J., Qiao, L. (2022). From MAFLD to hepatocellular carcinoma and everything in between. Chinese Medical Journal, 135(5), 547-556. [More Information]
- Mendez-Sanchez, N., Bugianesi, E., Gish, R., Lammert, F., Tilg, H., Nguyen, M., Sarin, S., Fabrellas, N., Zelber-Sagi, S., Fan, J., George, J., et al (2022). Global multi-stakeholder endorsement of the MAFLD definition. The Lancet Gastroenterology & Hepatology, 7(5), 388-390. [More Information]
- Clark, P., Valery, P., Ward, J., Strasser, S., Weltman, M., Thompson, A., Levy, M., Leggett, B., Zekry, A., Rong, J., et al (2022). Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up. BMC Gastroenterology, 22(1). [More Information]
- Cassidy, S., Kroeger, C., Wang, T., Mitra, S., Liu, C., Ribeiro, R., Dai, A., Lau, J., Huang, R., Masedunkas, A., Jose, S., Liu, N., McGrady, M., Lo, S., George, J., Cistulli, P., Khor, L., Kozor, R., Ugander, M., Wilcox, I., Hunyor, I., Fontana, L., et al (2022). Impact of an intensive lifestyle program on low attenuation plaque and myocardial perfusion in coronary heart disease: A randomised clinical trial protocol. Nutrition and Healthy Aging, 7(1-2), 9-22. [More Information]
- Fukunaga, S., Nakano, D., Tsutsumi, T., Kawaguchi, T., Eslam, M., Yoshinaga, S., Abe, H., Nouno, R., Joh, S., Mitsuyama, K., George, J., et al (2022). Lean/normal-weight metabolic dysfunction-associated fatty liver disease is a risk factor for reflux esophagitis. Hepatology Research, 52(8), 699-711. [More Information]
- George, J., Kawaguchi, T. (2022). Liver fat and a perturbed metabolic milieu: a consilience of factors driving liver cancer development. Hepatology International, 16(4), 733-736. [More Information]
- Kawaguchi, T., Tsutsumi, T., Nakano, D., Eslam, M., George, J., Torimura, T. (2022). MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. Clinical and Molecular Hepatology, 28(2), 150-163. [More Information]
- Sarin, S., Eslam, M., Fan, J., Lin, H., George, J., Omata, M. (2022). MAFLD, patient-centred care, and APASL. Hepatology International, 16(5), 1032-1034. [More Information]
- Eslam, M., El-Serag, H., Francque, S., Sarin, S., Wei, L., Bugianesi, E., George, J. (2022). Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nature Reviews. Gastroenterology and Hepatology, 19(10), 638-651. [More Information]
- Speliotes, E., George, J. (2022). Metabolic and genetic contributions to NAFLD: Really distinct and homogeneous? Journal of Hepatology, 76(3), 498-500. [More Information]
- Zhou, X., Cai, J., Targher, G., Byrne, C., Shapiro, M., Sung, K., Somers, V., Chahal, C., George, J., Chen, L., et al (2022). Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovascular Diabetology, 21(1). [More Information]
- Tu, T., Zehnder, B., Wettengel, J., Zhang, H., Coulter, S., Ho, V., Douglas, M., Protzer, U., George, J., Urban, S. (2022). Mitosis of hepatitis B virus-infected cells in vitro results in uninfected daughter cells. JHEP Reports, 4(9). [More Information]
- Maharaj, A., Lubel, J., Lam, E., Clark, P., Duncan, O., George, J., Jeffrey, G., Lipton, L., Liu, H., McCaughan, G., Tu, T., et al (2022). Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus. Hepatology Communications, 6(11), 3260-3271. [More Information]
- Chan, M., Huo, Y., Trieu, N., Mitchelle, A., George, J., He, E., Lee, A., Chang, J., Yang, J. (2022). Noncontrast MRI for Hepatocellular Carcinoma Detection: A Systematic Review and Meta-analysis – A Potential Surveillance Tool? Clinical Gastroenterology and Hepatology, 20(1), 44-5.60E+03. [More Information]
- George, J., Zhou, G., Qiao, L. (2022). Response to the letter by Dr. Renba Liang. Cancer Letters, 540, 215650. [More Information]
- Chen, H., van Reyk, D., Oliveira, A., Chan, Y., Town, S., Rayner, B., Pollock, C., Saad, S., George, J., Padula, M., Oliver, B. (2022). Sex-dependent responses to maternal exposure to PM2.5 in the offspring. Antioxidants, 11(11). [More Information]
- Zhou, K., Nguyen, R., Qiao, L., George, J. (2022). Single cell RNA-seq analysis identifies a noncoding RNA mediating resistance to sorafenib treatment in HCC. Molecular Cancer, 21(1), 6. [More Information]
- Sabag, A., Barr, L., Armour, M., Armstong, A., Baker, C., Twigg, S., Chang, D., Hackett, D., Keating, S., George, J., Johnson, N. (2022). The Effect of High-intensity Interval Training vs Moderate-intensity Continuous Training on Liver Fat: A Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 107(3), 862-881. [More Information]
- Al-Omary, A., Blyth, K., Weltman, M., George, J., Eslam, M. (2022). The importance and impact of recognizing metabolic dysfunction-associated fatty liver disease in patients with chronic hepatitis C. Journal of Digestive Diseases, 23(1), 33-43. [More Information]
- Chai, T., Deng, D., Byth Wilson, K., George, J., Pasupathy, D., Cheung, N. (2022). The prevalence of metabolic dysfunction–associated fatty liver disease and its association on adverse pregnancy outcomes in women with gestational diabetes mellitus. Diabetes Research and Clinical Practice, 191. [More Information]
- Saleh, S., George, J., Kott, K., Meikle, P., Figtree, G. (2022). The Translation and Commercialisation of Biomarkers for Cardiovascular Disease—A Review. Frontiers in Cardovascular Medicine, 9. [More Information]
- Tshori, S., Livschitz, S., Volodarsky, I., Goland, S., Shimoni, S., Fabrikant, J., George, J. (2022). Transthyretin Cardiac Amyloidosis Scintigraphy Using Planar D-SPECT on Dedicated Cardiac CZT Camera. Journal of Nuclear Cardiology, 29(4), 1995-2000. [More Information]
- Shah, S., Alavi, M., Hajarizadeh, B., Matthews, G., Martinello, M., Danta, M., Amin, J., Law, M., George, J., Valerio, H., et al (2022). Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales. JHEP Reports, 4(10). [More Information]
- Khadija, H., Gandelman, G., Ayyad, O., Poles, L., Jonas, M., Paz, O., George, J., Blatt, A. (2022). Trends in Transfemoral Aortic Valve Implantation Related Thrombocytopenia. Journal of Clinical Medicine, 11(3). [More Information]
- Heinze, K., Nazeran, T., Lee, S., Krämer, P., Cairns, E., Chiu, D., Leung, S., Kang, E., Meagher, N., Kennedy, C., Boros, J., Sharma, R., Brand, A., George, J., et al (2022). Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. Journal of Pathology, 256(4), 388-401. [More Information]
- Eslam, M., Wong, G., Hashem, A., Chan, H., Nielsen, M., Leeming, D., Chan, A., Chen, Y., Duffin, K., Karsdal, M., George, J., et al (2021). A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. American Journal of Gastroenterology, 116(5), 984-993. [More Information]
- Calzadilla-Bertot, L., Vilar-Gomez, E., Wong, V., Romero-Gomez, M., Aller-de la Fuente, R., Wong, G., Castellanos, M., Eslam, M., Desai, A., Jeffrey, G., George, J., et al (2021). ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. Hepatology, 73(6), 2238-2250. [More Information]
- Lockart, I., Hajarizadeh, B., Buckley, N., Davison, S., Prakoso, E., Levy, M., George, J., Dore, G., Danta, M. (2021). All-cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy. Journal of Gastroenterology and Hepatology, 36(12), 3515-3523. [More Information]
- Zhou, G., Bae, D., Nguyen, R., Huo, X., Han, S., Zhang, Z., Hebbard, L., Duan, W., Eslam, M., Liddle, C., Qiao, L., George, J., et al (2021). An aptamer-based drug delivery agent (CD133-apt-Dox) selectively and effectively kills liver cancer stem-like cells. Cancer Letters, 501, 124-132. [More Information]
- Deng, D., George, J., Pasupathy, D., Cheung, N. (2021). Antenatal FibroScan® assessment for metabolic-associated fatty liver in pregnant women at risk of gestational diabetes from a multiethnic population: a pilot study. Internal Medicine Journal. [More Information]
- Gao, F., Zheng, K., Yan, H., Sun, Q., Pan, K., Wang, T., Chen, Y., Targher, G., Byrne, C., George, J., et al (2021). Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019. Frontiers in Endocrinology, 12, 604100. [More Information]
- Liu, W., Eslam, M., Zheng, K., Ma, H., Rios, R., Lv, M., Li, G., Tang, L., Zhu, P., Wang, X., George, J., et al (2021). Associations of hydroxysteroid 17-beta dehydrogenase 13 variants with liver histology in chinese patients with metabolic-associated fatty liver disease. Journal of Clinical and Translational Hepatology, 9(2), 194-202. [More Information]
- Khadija, H., Gandelman, G., Ayyad, O., Poles, L., Jonas, M., Paz, O., Goland, S., Shimoni, S., Meledin, V., George, J., et al (2021). Comparative analysis of the kinetic behavior of systemic inflammatory markers in patients with depressed versus preserved left ventricular function undergoing transcatheter aortic valve implantation. Journal of Clinical Medicine, 10(18). [More Information]
- Metwally, M., Bayoumi, A., Khan, A., Adams, L., Aller, R., García-Monzón, C., Arias-Loste, M., Bugianesi, E., Miele, L., Anna, A., Latchoumanin, O., Han, S., Alenizi, S., El Sharkawy, R., Elattar, A., Liddle, C., George, J., Eslam, M., et al (2021). Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. EBioMedicine, 70, 103521. [More Information]
- Esmaili, S., Langfelder, P., Belgard, T., Vitale, D., Azardaryany, M., Alipour Talesh, G., Ramezani-Moghadam, M., Ho, V., Dvorkin, D., Dervish, S., Liddle, C., George, J., et al (2021). Core liver homeostatic co-expression networks are preserved but respond to perturbations in an organism- and disease-specific manner. Cell Systems, 12(5), 432-4.45E+09. [More Information]
- Kjær, M., George, J., Kazankov, K., Grønbæk, H. (2021). Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy? Expert Review of Gastroenterology and Hepatology, 15(1), 51-64. [More Information]
- Liu, C., Chu, D., Kalantar-Zadeh, K., George, J., Young, H., Liu, G. (2021). Cytokines: From Clinical Significance to Quantification. Advanced Science, 8(15), 2004433-1-2004433-29. [More Information]
- Eslam, M., Alkhouri, N., Vajro, P., Baumann, U., Weiss, R., Socha, P., Marcus, C., Lee, W., Kelly, D., Porta, G., Baur, L., George, J., et al (2021). Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. The Lancet Gastroenterology & Hepatology, 6(10), 864-873. [More Information]
- Nguyen, R., Bae, D., Qiao, L., George, J. (2021). Developing liver organoids from induced pluripotent stem cells (iPSCs): An alternative source of organoid generation for liver cancer research. Cancer Letters, 508, 13-17. [More Information]
- Khadija, H., Gandelman, G., Ayyad, O., Jaber, M., Poles, L., Jonas, M., Paz, O., Abu Sbaih, F., Sella, G., Shimoni, S., et al (2021). Differential systemic inflammatory responses after TAVI: The role of self versus balloon expandable devices. PloS One, 16(10 October). [More Information]
- Devarbhavi, H., Aithal, G., Treeprasertsuk, S., Takikawa, H., Mao, Y., Shasthry, S., Hamid, S., Tan, S., Philips, C., George, J., et al (2021). Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatology International, 15(2), 258-282. [More Information]
- Kuscuoglu, D., Bewersdorf, L., Wenzel, K., Gross, A., Kobazi Ensari, G., Luo, Y., Kilic, K., Hittatiya, K., Golob-Schwarzl, N., Leube, R., George, J., Metwally, M., Eslam, M., et al (2021). Dual proteotoxic stress accelerates liver injury via activation of p62-Nrf2. Journal of Pathology, 254(1), 80-91. [More Information]
- Rittig, N., Aagaard, N., Villadsen, G., Sandahl, T., Jessen, N., Grønbæk, H., George, J. (2021). Editorial: metformin for portal hypertension—old dog, new tricks? Authors' reply. Alimentary Pharmacology and Therapeutics, 54(3), 347. [More Information]
- Papaluca, T., Roberts, S., Strasser, S., Stuart, K., Farrell, G., MacQuillan, G., Dore, G., Wade, A., George, J., Hazeldine, S., et al (2021). Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients with Difficult to Cure Characteristics. Clinical Infectious Diseases, 73(9), E3288-E3295. [More Information]
- Fassler, M., Rappaport, M., Cuño, C., George, J. (2021). Engagement of TREM2 by a novel monoclonal antibody induces activation of microglia and improves cognitive function in Alzheimer’s disease models. Journal of Neuroinflammation, 18(1). [More Information]
- Wijaya, R., Read, S., Schibeci, S., Han, S., Azardaryany, M., van der Poorten, D., Lin, R., Yuen, L., Lam, V., Douglas, M., George, J., Ahlenstiel, G. (2021). Expansion of dysfunctional CD56-CD16+ NK cells in chronic hepatitis B patients. Liver International, 41(5), 969-981. [More Information]
- Wijaya, R., Read, S., Truong, N., Han, S., Chen, D., Shahidipour, H., Fewings, N., Schibeci, S., Azardaryany, M., Parnell, G., Booth, D., van der Poorten, D., Lin, R., George, J., Douglas, M., Ahlenstiel, G. (2021). HBV vaccination and HBV infection induces HBV-specific natural killer cell memory. Gut, 70(2), 357-369. [More Information]
- Robotin, M., Wallace, J., Gallego, G., George, J. (2021). Hepatitis b and liver cancer: Community awareness, knowledge and beliefs of middle eastern migrants in sydney, australia. International Journal of Environmental Research and Public Health, 18(16), 8534-1-8534-11. [More Information]
- Wijaya, R., Read, S., Selvamani, S., Schibeci, S., Azardaryany, M., Ong, A., van der Poorten, D., Lin, R., Douglas, M., George, J., Ahlenstiel, G. (2021). Hepatitis C Virus (HCV) Eradication With Interferon-Free Direct-Acting Antiviral-Based Therapy Results in KLRG1+ HCV-Specific Memory Natural Killer Cells. The Journal of Infectious Diseases, 223(7), 1183-1195. [More Information]
- Lockart, I., Hajarizadeh, B., Alavi, M., Davison, S., Prakoso, E., Levy, M., George, J., Dore, G., Danta, M. (2021). Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival. Journal of Viral Hepatitis, 28(5), 710-718. [More Information]
- Valerio, H., Alavi, M., Law, M., Tillakeratne, S., Amin, J., Janjua, N., Krajden, M., George, J., Matthews, G., Hajarizadeh, B., et al (2021). High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. Journal of Hepatology, 74(2), 293-302. [More Information]
- Shek, D., Read, S., Nagrial, A., Carlino, M., Gao, B., George, J., Ahlenstiel, G. (2021). Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates. The Oncologist, 26(7), e1216-e1225. [More Information]
- Eslam, M., Ahmed, A., Després, J., Jha, V., Halford, J., Wei Chieh, J., Harris, D., Nangaku, M., Colagiuri, S., Targher, G., George, J., et al (2021). Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. The Lancet Gastroenterology & Hepatology, 6(9), 743-753. [More Information]
- Read, S., Gloss, B., Liddle, C., George, J., Ahlenstiel, G. (2021). Interferon-λ3 Exacerbates the Inflammatory Response to Microbial Ligands: Implications for SARS-CoV-2 Pathogenesis. Journal of Inflammation Research, 14, 1257-1270. [More Information]
- Gantzel, R., Kjær, M., Laursen, T., Kazankov, K., George, J., Møller, H., Grønbæk, H. (2021). Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis. Frontiers in Medicine, 7, 615599. [More Information]
- George, J., Gish, R., Geier, A. (2021). MAFLD and Cardiovascular Events: What Does the Evidence Show? Clinical Gastroenterology and Hepatology, 19(10), 2025-2028. [More Information]
- Tsutsumi, T., Eslam, M., Kawaguchi, T., Yamamura, S., Kawaguchi, A., Nakano, D., Koseki, M., Yoshinaga, S., Takahashi, H., Anzai, K., George, J., et al (2021). MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach. Hepatology Research, 51(11), 1115-1128. [More Information]
- Eslam, M., George, J. (2021). MAFLD: A game changer redefining fatty liver disease for adults and children. Journal of Hepatology, 74(4), 992-994. [More Information]
- Eslam, M., George, J. (2021). MAFLD: A holistic view to redefining fatty liver disease. Journal of Hepatology, 74(4), 983-985. [More Information]
- Eslam, M., George, J. (2021). MAFLD: Now is the time to capitalize on the momentum. Journal of Hepatology, 74(5), 1262-1263. [More Information]
- Gao, F., Zheng, K., Wang, X., Yan, H., Sun, Q., Pan, K., Wang, T., Chen, Y., George, J., Zheng, M. (2021). Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. Journal of Gastroenterology and Hepatology, 36(1), 204-207. [More Information]
- Bayoumi, A., Elsayed, A., Han, S., Petta, S., Adams, L., Aller, R., Khan, A., García-Monzón, C., Arias-Loste, M., Miele, L., Latchoumanin, O., Alenizi, S., Metwally, M., Qiao, L., Liddle, C., George, J., Eslam, M., et al (2021). Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. Advanced Science, 8(11), 2004168. [More Information]
- Teodorovich, N., Jonas, M., Haberman, D., Khadija, H., Ayyad, O., Gandelman, G., Poles, L., George, J., Blatt, A. (2021). Natural anti-endothelial cell antibodies in patients undergoing coronary angiography. IMAJ, 23(10), 657-661.
- Curran, F., Bhalraam, U., Mohan, M., Singh, J., Anker, S., Dickstein, K., Doney, A., Filippatos, G., George, J., Metra, M., et al (2021). Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction. ESC Heart Failure, 8(4), 3168-3179. [More Information]
- Fukunaga, S., Nakano, D., Kawaguchi, T., Eslam, M., Ouchi, A., Nagata, T., Kuroki, H., Kawata, H., Abe, H., Nouno, R., George, J., et al (2021). Non-obese mafld is associated with colorectal adenoma in health check examinees: A multicenter retrospective study. International Journal of Molecular Sciences, 22(11), 5462. [More Information]
- Grimaudo, S., Dongiovanni, P., Pihlajamäki, J., Eslam, M., Yki-Järvinen, H., Pipitone, R., Baselli, G., Cammà, C., Di Marco, V., Enea, M., George, J., et al (2021). NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. Liver International, 41(11), 2712-2719. [More Information]
- Valerio, H., Alavi, M., Law, M., McManus, H., Tillakeratne, S., Bajis, S., Martinello, M., Matthews, G., Amin, J., Janjua, N., George, J., et al (2021). Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study. Clinical Infectious Diseases, 73(11), 2037-2044. [More Information]
- Bishay, R., Tonks, K., George, J., Samocha-Bonet, D., Meyerowitz-Katz, G., Chisholm, D., James, D., Greenfield, J. (2021). Plasma Bile Acids More Closely Align With Insulin Resistance, Visceral and Hepatic Adiposity Than Total Adiposity. Journal of Clinical Endocrinology and Metabolism, 106(3), e1131-e1139. [More Information]
- Wu, C., Smet, M., Heath, S., Curnow, J., Lin, M., George, J., Alahakoon, T. (2021). Pregnancy complicated by refractory severe hypercholanaemia from sodium taurocholate co-transporting polypeptide deficiency. The Journal of Obstetrics and Gynaecology Research, 47(2), 822-826. [More Information]
- Rittig, N., Aagaard, N., Villadsen, G., Sandahl, T., Jessen, N., Grønbæk, H., George, J. (2021). Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension. Alimentary Pharmacology and Therapeutics, 54(3), 320-328. [More Information]
- Calzadilla-Bertot, L., Vilar-Gomez, E., George, J., Adams, L. (2021). REPLY. Hepatology, 74(1), 531-532. [More Information]
- Bae, S., Nguyen, R., Qiao, L., George, J. (2021). Role of the constitutive androstane receptor (CAR) in human liver cancer. Biochimica et Biophysica Acta-Reviews on Cancer, 1875 (2), 188516. [More Information]
- Shimoni, O., Korenfeld, R., Goland, S., Meledin, V., Haberman, D., George, J., Shimoni, S. (2021). Subclinical myocardial dysfunction in patients recovered from covid-19 disease: Correlation with exercise capacity. Biology, 10(11). [More Information]
- Chai, T., Rajaratnam, R., Deng, D., George, J., Pasupathy, D., Cheung, N. (2021). The prevalence of gestational diabetes mellitus in women diagnosed with non-alcoholic fatty liver disease during pregnancy: A systematic review and meta-analysis. Journal of Diabetes and Its Complications, 35(9), 107991. [More Information]
- Deng, D., George, J., Pasupathy, D., Cheung, N. (2021). The prevalence of metabolic associated fatty liver detected by FibroScan(R) in women with gestational diabetes in a multiethnic population. Diabetes Research and Clinical Practice, 174, 108757. [More Information]
- Vilar-Gomez, E., Calzadilla-Bertot, L., Wong, V., Castellanos, M., Aller-de la Fuente, R., Eslam, M., Wong, G., George, J., Romero-Gomez, M., Adams, L. (2021). Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis–Related, Child–Pugh A Cirrhosis. Clinical Gastroenterology and Hepatology, 19(1), 136-145.e6. [More Information]
- Gofton, C., George, J. (2021). Updates in fatty liver disease: Pathophysiology, diagnosis and management. Australian Journal of General Practice, 50(10), 702-707. [More Information]
- Liu, Y., Veeraraghavan, V., Pinkerton, M., Fu, J., Douglas, M., George, J., Tu, T. (2021). Viral Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Occurrence and Recurrence. Frontiers in Microbiology, 12, 665201. [More Information]
- Goland, S., Volodarsky, I., Fabricant, Y., Livschitz, S., Tshori, S., Cuciuc, V., Zilberman, L., Fugenfirov, I., Meledin, V., Shimoni, S., et al (2021). Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction. PloS One, 16(7 July). [More Information]
- Eslam, M., Ratziu, V., George, J. (2021). Yet more evidence that MAFLD is more than a name change. Journal of Hepatology, 74(4), 977-979. [More Information]
- Eslam, M., Newsome, P., Sarin, S., Anstee, Q., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J., Schattenberg, J., George, J., et al (2020). A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology, 73(1), 202-209. [More Information]
- Tu, T., Zehnder, B., Qu, B., Ni, Y., Main, N., Allweiss, L., Dandri, M., Shackel, N., George, J., Urban, S. (2020). A novel method to precisely quantify hepatitis B virus covalently closed circular (ccc)DNA formation and maintenance. Antiviral Research, 181, 104865. [More Information]
- George, J., Rappaport, M., Shimoni, S., Goland, S., Voldarsky, I., Fabricant, Y., Edri, O., Cuciuc, V., Lifshitz, S., Tshori, S., et al (2020). A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model. European Heart Journal, 41(12), 1260-1270. [More Information]
- Dewdney, B., Roberts, A., Qiao, L., George, J., Hebbard, L. (2020). A Sweet Connection? Fructose's Role in Hepatocellular Carcinoma. Biomolecules, 10(4), 496. [More Information]
- Nguyen, R., Bae, D., Zhou, G., Read, S., Ahlenstiel, G., George, J., Qiao, L. (2020). Application of organoids in translational research of human diseases with a particular focus on gastrointestinal cancers. Biochimica Et Biophysica Acta-Reviews On Cancer, 1873 (2), 1-12. [More Information]
- Karsdal, M., Daniels, S., Holm Nielsen, S., Bager, C., Rasmussen, D., Loomba, R., Surabattula, R., Villesen, I., Luo, Y., Shevell, D., George, J., et al (2020). Collagen biology and non-invasive biomarkers of liver fibrosis. Liver International, 40(4), 736-750. [More Information]
- Gao, F., Zheng, K., Gu, J., George, J., Zheng, M. (2020). COVID-19 and liver transplantation: Lessons learned from three reported cases. Transplant Infectious Disease, 22(4), e13335. [More Information]
- Zhand, S., Jazi, M., Mohammadi, S., Rasekhi, R., Rostamian, G., Kalani, M., Rostamian, A., George, J., Douglas, M. (2020). Covid-19: The immune responses and clinical therapy candidates. International Journal of Molecular Sciences, 21(15), 1-34. [More Information]
- Jensen, C., Nielsen, S., Eslam, M., Genovese, F., Nielsen, M., Vongsuvanh, R., Uchila, R., van der Poorten, D., George, J., Karsdal, M., et al (2020). Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma – A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients. Journal of Hepatocellular Carcinoma, 7, 301-313. [More Information]
- Targher, G., Mantovani, A., Byrne, C., Wang, X., Yan, H., Sun, Q., Pan, K., Zheng, K., Chen, Y., Eslam, M., George, J., et al (2020). Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19. Diabetes and Metabolism, 46(6), 505-507. [More Information]
- Li, G., Chan, Y., Wang, B., Saad, S., George, J., Oliver, B., Chen, H. (2020). E-cigarettes damage the liver and alter nutrient metabolism in pregnant mice and their offspring. Annals of the New York Academy of Sciences, 1475 (1), 64-77. [More Information]
- Roberts, S., Strasser, S., Nicoll, A., Kemp, W., Majeed, A., Mitchell, J., Stuart, K., Gow, P., Sood, S., MacQuillan, G., George, J., et al (2020). Efficacy and safety profile of calcineurin inhibitor salvage therapy in autoimmune hepatitis. Scandinavian Journal of Gastroenterology, 55(11), 1309-1317. [More Information]
- Huang, J., Zheng, K., George, J., Gao, H., Wei, R., Yan, H., Zheng, M. (2020). Fatal outcome in a liver transplant recipient with COVID-19. American Journal Of Transplantation, 20(7), 1907-1910. [More Information]
- Zheng, K., Fan, J., Shi, J., Wong, V., Eslam, M., George, J., Zheng, M. (2020). From NAFLD to MAFLD: a "redefining" moment for fatty liver disease. Chinese Medical Journal, 133(19), 2271-2273. [More Information]
- Eslam, M., George, J. (2020). Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nature Reviews. Gastroenterology and Hepatology, 17(1), 40-52. [More Information]
- Bayoumi, A., Jalil, I., Metwally, M., Adams, L., Aller, R., García-Monzón, C., Arias-Loste, M., Miele, L., Petta, S., Craxì, A., Qiao, L., Liddle, C., George, J., Eslam, M., et al (2020). Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. PloS One, 15, e0243590. [More Information]
- Njiomegnie, G., Read, S., Fewings, N., George, J., McKay, F., Ahlenstiel, G. (2020). Immunomodulation of the Natural Killer Cell Phenotype and Response during HCV Infection. Journal of Clinical Medicine, 9(4), 1-19. [More Information]
- Douglas, M., Tay, E., Wang, D., Ong, A., Wilson, C., Phu, A., Kok, J., Dwyer, D., Bull, R., Lloyd, A., George, J., et al (2020). Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance. Hepatology Communications, 4(6), 904-915. [More Information]
- Chen, F., Esmaili, S., Rogers, G., Bugianesi, E., Petta, S., Marchesini, G., Bayoumi, A., Metwally, M., Azardaryany, M., Coulter, S., Liddle, C., George, J., Eslam, M., et al (2020). Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. Hepatology, 71(4), 1213-1227. [More Information]
- Zheng, K., Gao, F., Wang, X., Sun, Q., Pan, K., Wang, T., Ma, H., Chen, Y., Liu, W., George, J., et al (2020). Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism: Clinical and Experimental, 108, 154244. [More Information]
- Sarin, S., Kumar, M., Eslam, M., George, J., Al Mahtab, M., Akbar, S., Jia, J., Tian, Q., Aggarwal, R., Muljono, D., et al (2020). Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology & Hepatology, 5(2), 167-228. [More Information]
- Schneider, C., Hamesch, K., Gross, A., Mandorfer, M., Moeller, L., Pereira, V., Pons, M., Kuca, P., Reichert, M., Benini, F., Eslam, M., George, J., et al (2020). Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi*Z Variant of AAT (Pi*MZ vs Pi*ZZ genotype) and Noncarriers. Gastroenterology, 159(2), 534-5.48. [More Information]
- Laursen, T., Sandahl, T., Kazankov, K., George, J., Gronbaek, H. (2020). Liver-related effects of chronic hepatitis C antiviral treatment. World Journal of Gastroenterology, 26(22), 2931-2947. [More Information]
- Alharthi, J., Latchoumanin, O., George, J., Eslam, M. (2020). Macrophages in metabolic associated fatty liver disease. World Journal of Gastroenterology, 26(16), 1861-1878. [More Information]
- Yamamura, S., Eslam, M., Kawaguchi, T., Tsutsumi, T., Nakano, D., Yoshinaga, S., Takahashi, H., Anzai, K., George, J., Torimura, T. (2020). MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver International, 40(12), 3018-3030. [More Information]
- Eslam, M., Sanyal, A., George, J. (2020). MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 158(7), 1999-2014. [More Information]
- Zhou, Y., Zheng, K., Wang, X., Sun, Q., Pan, K., Wang, T., Ma, H., Chen, Y., George, J., Zheng, M. (2020). Metabolic-associated fatty liver disease is associated with severity of COVID-19. Liver International, 40(9), 2160-2163. [More Information]
- Eslam, M., Chen, F., George, J. (2020). NAFLD in Lean Asians. Clinical Liver Disease, 16(6), 240-243. [More Information]
- Adams, L., Roberts, S., Strasser, S., Mahady, S., Powell, E., Estes, C., Razavi, H., George, J. (2020). Nonalcoholic fatty liver disease burden: Australia, 2019–2030. Journal of Gastroenterology and Hepatology, 35(9), 1628-1635. [More Information]
- Huang, J., Wang, X., Zheng, K., Liu, W., Chen, J., George, J., Zheng, M. (2020). Obesity hypoventilation syndrome and severe COVID-19. Metabolism: Clinical and Experimental, 108, 154249. [More Information]
- Gao, F., Zheng, K., Wang, X., Sun, Q., Pan, K., Wang, T., Chen, Y., Targher, G., Byrne, C., George, J., et al (2020). Obesity Is a Risk Factor for Greater COVID-19 Severity. Diabetes Care, 43(7), E72-E74. [More Information]
- Targher, G., Mantovani, A., Wang, X., Yan, H., Sun, Q., Pan, K., Byrne, C., Zheng, K., Chen, Y., Eslam, M., George, J., et al (2020). Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes and Metabolism, 46(4), 335-337. [More Information]
- Eslam, M., George, J. (2020). Reply to: Correspondence on “A new definition for metabolic associated fatty liver disease: an international expert consensus statement”: MAFLD: Moving from a concept to practice. Journal of Hepatology, 73(5), 1268-1269. [More Information]
- Eslam, M., George, J. (2020). Reply to: correspondence regarding “A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement”: Bringing evidence to the NAFLD-MAFLD debate. Journal of Hepatology, 73(6), 1575. [More Information]
- Targher, G., Mantovani, A., Byrne, C., Wang, X., Yan, H., Sun, Q., Pan, K., Zheng, K., Chen, Y., Eslam, M., George, J., et al (2020). Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut, 69(8), 1545-1547. [More Information]
- Eslam, M., Sarin, S., Wong, V., Fan, J., Kawaguchi, T., Ahn, S., Zheng, M., Shiha, G., Yilmaz, Y., Gani, R., George, J., et al (2020). The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatology International, 14(6), 889-919. [More Information]
- Sabag, A., Way, K., Sultana, R., Keating, S., Gerofi, J., Chuter, V., Byrne, N., Baker, M., George, J., Caterson, I., Twigg, S., Johnson, N. (2020). The Effect of a Novel Low-Volume Aerobic Exercise Intervention on Liver Fat in Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care, 43(10), 2371-2378. [More Information]
- Dewdney, B., Alanazy, M., Gillman, R., Walker, S., Wankell, M., Qiao, L., George, J., Roberts, A., Hebbard, L. (2020). The effects of fructose and metabolic inhibition on hepatocellular carcinoma. Scientific Reports, 10(1), 16769. [More Information]
- Bayoumi, A., Gronbaek, H., George, J., Eslam, M. (2020). The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease. Trends in Genetics, 36(6), 429-441. [More Information]
- Haberman, D., Chernin, G., Meledin, V., Zikry, M., Shuvy, M., Gandelman, G., Goland, S., George, J., Shimoni, S. (2020). Urea level is an independent predictor of mortality in patients with severe aortic valve stenosis. PloS One, 15(3). [More Information]
- Méndez-Sánchez, N., Valencia-Rodríguez, A., Qi, X., Yoshida, E., Romero-Gomez, M., George, J., Eslam, M., Abenavoli, L., Xie, W., Teschke, R., et al (2020). What has the COVID-19 pandemic taught us so far? Addressing the problem from a hepatologist’s perspective. Journal of Clinical and Translational Hepatology, 8(2), 24. [More Information]
- Zheng, K., Eslam, M., George, J., Zheng, M. (2020). When a new definition overhauls perceptions of MAFLD related cirrhosis care. Hepatobiliary Surgery and Nutrition, 9(6), 801-804. [More Information]
- Zhou, Y., Zheng, K., Wang, X., Yan, H., Sun, Q., Pan, K., Wang, T., Ma, H., Chen, Y., George, J., et al (2020). Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis. Journal of Hepatology, 73(3), 719-721. [More Information]
- Li, G., Chan, Y., Sukjamnong, S., Anwer, A., Vindin, H., Padula, M., Zakarya, R., George, J., Oliver, B., Saad, S., et al (2019). A Mitochondrial Specific Antioxidant Reverses Metabolic Dysfunction and Fatty Liver Induced by Maternal Cigarette Smoke in Mice. Nutrients, 11(7), 1-14. [More Information]
- Metwally, M., Bayoumi, A., Romero-Gomez, M., Thabet, K., John, M., Adams, L., Huo, X., Aller, R., Garcia-Monzon, C., Arias-Loste, M., Liddle, C., Qiao, L., George, J., Eslam, M., et al (2019). A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3 ' UTR. Journal of Hepatology, 70(3), 494-500. [More Information]
- El Sharkawy, R., Bayoumi, A., Metwally, M., Mangia, A., Berg, T., Romero-Gomez, M., Abate, M., Irving, W., Sheridan, D., Dore, G., Latchoumanin, O., Thabet, K., Najim, M., Douglas, M., Liddle, C., Qiao, L., George, J., Eslam, M., et al (2019). A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms. Scientific Reports, 9(1), 1-10. [More Information]
- Daniels, S., Leeming, D., Eslam, M., Hashem, A., Nielsen, M., Krag, A., Karsdal, M., Grove, J., Neil Guha, I., Kawaguchi, T., George, J., et al (2019). ADAPT: An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology, 69(3), 1075-1086. [More Information]
- Shah, N., Ventura-Cots, M., Abraldes, J., Alboraie, M., Alfadhli, A., Argemi, J., Badia-Aranda, E., Arús-Soler, E., Barritt, S., et al, George, J., Siow, W. (2019). Alcohol-related Liver Disease is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide. Clinical Gastroenterology and Hepatology, 17(11), 2320-2329. [More Information]
- Hu, L., Su, L., Dong, Z., Wu, Y., Lv, Y., George, J., Wang, J. (2019). AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model. Journal of Molecular Medicine, 97(3), 423-434. [More Information]
- Nicoll, A., Roberts, S., Lim, R., Mitchell, J., Weltman, M., George, J., Wigg, A., Stuart, K., Gow, P., MacQuillan, G., Strasser, S., et al (2019). Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels. Alimentary Pharmacology and Therapeutics, 49(10), 1314-1322. [More Information]
- Strasser, S., Thompson, A., Roberts, S., George, J. (2019). Clinical Cases in Hepatitis: Towards improving liver disease management in Australia. Journal of Gastroenterology and Hepatology, 34, 5-15. [More Information]
- Thomas, E., George, J., Sruthi, D., Vineetha, N., Gracious, N. (2019). Clinical course of dengue fever and its impact on renal function in renal transplant recipients and patients with chronic kidney disease. Nephrology, 24(5), 564-568. [More Information]
- Rosso, C., Kazankov, K., Younes, R., Esmaili, S., Marietti, M., Sacco, M., Carli, F., Gaggini, M., Salomone, F., Møller, H., George, J., et al (2019). Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. Journal of Hepatology, 71(5), 1012-1021. [More Information]
- Alavi, M., Law, M., Valerio, H., Grebely, J., Amin, J., Hajarizadeh, B., Selvey, C., George, J., Dore, G. (2019). Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. Journal of Hepatology, 71(2), 281-288. [More Information]
- Semo, J., Chernin, G., Jonas, M., Shimoni, S., George, J. (2019). Deletion of the Mir-106b~ 25 MicroRNA cluster attenuates atherosclerosis in Apolipoprotein e knockout mice. Lipids in Health and Disease, 18(1). [More Information]
- Parker, H., Cohn, J., O'Connor, H., Garg, M., Caterson, I., George, J., Johnson, N. (2019). Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial. Nutrients, 11(2), 1-15. [More Information]
- Younossi, Z., Stepanova, M., Ong, J., Yilmaz, Y., Duseja, A., Eguchi, Y., Kassas, M., Castellanos-Fernandez, M., George, J., Jacobson, I., et al (2019). Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients with Nonalcoholic and Alcohol-Related Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 17(8), 1625-1633. [More Information]
- Wei, L., Jia, J., Wang, F., Niu, J., Zhao, X., Mu, S., Liang, L., Wang, Z., Hwang, P., George, J., et al (2019). Efficacy and safety of elbasvir/grazoprevir in participants with HCV genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: final results from the randomized C-CORAL study. Journal of Gastroenterology and Hepatology, 34(1), 12-21. [More Information]
- Eslam, M., George, J. (2019). Genetic Insights for Drug Development in NAFLD. Trends In Pharmacological Sciences, 40(7), 506-516. [More Information]
- Younossi, Z., Tacke, F., Arrese, M., Sharma, B., Mostafa, I., Bugianesi, E., Wong, V., Yilmaz, Y., George, J., Fan, J., et al (2019). Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. Hepatology, 69(6), 2672-2682. [More Information]
- Douglas, M., Tay, E., Eden, J., George, J. (2019). Hepatitis C Virus Genotype 8 - successful treatment with sofosbuvir/velpatasvir. The Journal of Infectious Diseases, 220(4), 720-722. [More Information]
- Metwally, M., Thabet, K., Bayoumi, A., Nikpour, M., Stevens, W., Sahhar, J., Zochling, J., Roddy, J., Tymms, K., Strickland, G., Liddle, C., Manolios, N., George, J., Eslam, M., et al (2019). IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis. Scientific Reports, 9(1), 1-5. [More Information]
- Eslam, M., Ahlenstiel, G., George, J. (2019). Interferon Lambda and Liver Fibrosis. Journal of Interferon and Cytokine Research, 39(10), 627-635. [More Information]
- Wijaya, R., Read, S., Schibeci, S., Eslam, M., Azardaryany, M., El-Khobar, K., van der Poorten, D., Lin, R., Yuen, L., Lam, V., George, J., Douglas, M., Ahlenstiel, G. (2019). KLRG1+ natural killer cells exert a novel antifibrotic function in chronic hepatitis B. Journal of Hepatology, 71(2), 252-264. [More Information]
- Read, S., Wijaya, R., Ramezani-Moghadam, M., Tay, E., Schibeci, S., Liddle, C., Lam, V., Yuen, L., Douglas, M., Booth, D., George, J., Ahlenstiel, G. (2019). Macrophage Coordination of the Interferon Lambda Immune Response. Frontiers in Immunology, 10, 1-16. [More Information]
- Scott, C., Stokes, R., Cha, K., Clouston, A., Eslam, M., Metwally, M., Swarbrick, M., George, J., Gunton, J. (2019). Myeloid cell deletion of Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) induces non-alcoholic steatohepatitis. PloS One, 14(12), 1-20. [More Information]
- Younossi, Z., Stepanova, M., Ong, J., Jacobson, I., Bugianesi, E., Duseja, A., Eguchi, Y., Wong, V., Negro, F., Yilmaz, Y., George, J., et al (2019). Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clinical Gastroenterology and Hepatology, 17(4), 748-755. [More Information]
- Ong, A., Tay, E., Dwyer, D., George, J., Douglas, M. (2019). Pre-treatment antiviral resistance in Australians with chronic hepatitis C: prevalence of NS3 and NS5A resistance data in the state of New South Wales. Antiviral Therapy, 24(4), 281-290. [More Information]
- Eslam, M., George, J. (2019). Refining the role of epicardial adipose tissue in non-alcoholic fatty liver disease. Hepatology International, 13(6), 662-664. [More Information]
- John, M., Kim, K., Bae, S., Qiao, L., George, J. (2019). Role of BMP-9 in human liver disease. Gut, 68(11), 2097-2100. [More Information]
- Walker, S., Wankell, M., Ho, V., White, R., Deo, N., Devine, C., Dewdney, B., Bhathal, P., Govaere, O., Roskams, T., Qiao, L., George, J., Hebbard, L. (2019). Targeting mTOR and Src restricts hepatocellular carcinoma growth in a novel murine liver cancer model. PloS One, 14(2), 1-16. [More Information]
- Levy-Neuman, S., Meledin, V., Gandelman, G., Goland, S., Zilberman, L., Edri, O., Shneider, N., Abaeh, N., Bdolah-Abram, T., George, J., et al (2019). The Association Between Longitudinal Strain at Rest and Stress and Outcome in Asymptomatic Patients With Moderate and Severe Aortic Stenosis. Journal of the American Society of Echocardiography, 32(6), 722-729. [More Information]
- Wong, M., Huang, J., George, J., Huang, J., Leung, C., Eslam, M., Chan, H., Ng, S. (2019). The changing epidemiology of liver diseases in the Asia-Pacific region. Nature Reviews. Gastroenterology and Hepatology, 16(1), 57-73. [More Information]
- Møhlenberg, M., Terczynska-Dyla, E., Thomsen, K., George, J., Eslam, M., Gronbaek, H., Hartmann, R. (2019). The role of IFN in the development of NAFLD and NASH. Cytokine, 124, 1-6. [More Information]
- Kazankov, K., Jorgensen, S., Thomsen, K., Moller, H., Vilstrup, H., George, J., Schuppan, D., Gronbaek, H. (2019). The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nature Reviews. Gastroenterology and Hepatology, 16(3), 145-159. [More Information]
- Gupta, S., Read, S., Shackel, N., Hebbard, L., George, J., Ahlenstiel, G. (2019). The Role of Micronutrients in the Infection and Subsequent Response to Hepatitis C Virus. Cells, 8(6), 1-20. [More Information]
- Eslam, M., Sanyal, A., George, J. (2019). Toward More Accurate Nomenclature for Fatty Liver Diseases. Gastroenterology, 157(3), 590-593. [More Information]
- D'Avigdor, W., Budzinska, M., Lee, M., Lam, R., Kench, J., Stapelberg, M., McLennan, S., Farrell, G., George, J., McCaughan, G., Shackel, N., et al (2019). Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected Liver. Scientific Reports, 9(1), 1-12. [More Information]
- Kawaguchi, T., Tokushige, K., Hyogo, H., Aikata, H., Nakajima, T., Ono, M., Kawanaka, M., Sawada, K., Imajo, K., Honda, K., George, J., et al (2018). A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. Scientific Reports, 8(1), 1-13. [More Information]
- Kabir, T., Ganda, C., Brown, R., Beveridge, D., Richardson, K., Chaturvedi, V., Candy, P., Epis, M., Wintle, L., Kalinowski, F., George, J., et al (2018). A miR-7/GAS6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. Hepatology, 67(1), 216-231. [More Information]
- El Sharkawy, R., Thabet, K., Lampertico, P., Petta, S., Mangia, A., Berg, T., Metwally, M., Bayoumi, A., Douglas, M., Khan, A., et al (2018). A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 48(5), 564-573. [More Information]
- Zhou, G., Latchoumanin, O., Hebbard, L., Duan, W., Liddle, C., George, J., Qiao, L. (2018). Aptamers as targeting ligands and therapeutic molecules for overcoming drug resistance in cancers. Advanced Drug Delivery Reviews, 134, 107-121. [More Information]
- Younossi, Z., Loomba, R., Rinella, M., Bugianesi, E., Marchesini, G., Neuschwander-Tetri, B., Serfaty, L., Negro, F., George, J., et al (2018). Current and Future Therapeutic Regimens for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology, 68(1), 361-371. [More Information]
- Younossi, Z., Loomba, R., Anstee, Q., Rinella, M., Bugianesi, E., Marchesini, G., Neuschwander-Tetri, B., Serfaty, L., Negro, F., Caldwell, S., George, J., et al (2018). Diagnostic Modalities for Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis and Associated Fibrosis. Hepatology, 68(1), 349-360. [More Information]
- El Sharkawy, R., George, J., Eslam, M. (2018). Editorial: STAT-4 polymorphism - a tool to personalise clinical practice in chronic HBV infection Authors' reply. Alimentary Pharmacology and Therapeutics, 48(7), 769-770. [More Information]
- Eslam, M., George, J. (2018). Editorial: weight change, liver histology and the metabolic effects of obeticholic acid in NASH. Alimentary Pharmacology and Therapeutics, 47(7), 1038-1039. [More Information]
- Roberts, S., Lim, R., Strasser, S., Nicoll, A., Gazzola, A., Mitchell, J., Siow, W., Khoo, T., Hamarneh, Z., Weltman, M., George, J., et al (2018). Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy. Clinical Gastroenterology and Hepatology, 16(2), 268-277. [More Information]
- George, J., Burnevich, E., Sheen, I., Heo, J., Van Kinh, N., Tanwandee, T., Cheng, P., Kim, D., Tak, W., Kizhlo, S., et al (2018). Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection. Hepatology Communications, 2(5), 595-606. [More Information]
- Furer, V., Hazan, E., Mor, A., Segal, M., Katav, A., Aloush, V., Elkayam, O., George, J., Ablin, J. (2018). Elevated Levels of Eotaxin-2 in Serum of Fibromyalgia Patients. Pain Research and Management, 2018. [More Information]
- Vilar-Gomez, E., Calzadilla-Bertot, L., Wong, V., Castellanos, M., de la Fuente, R., Metwally, M., Eslam, M., Gonzalez-Fabian, L., Alvarez-Quinones Sanz, M., Conde-Martin, A., George, J., et al (2018). Fibrosis Severity as a Determinant of Cause-specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease. Gastroenterology, 155(2), 443-457.e17. [More Information]
- Younossi, Z., Anstee, Q., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., Bugianesi, E. (2018). Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature Reviews. Gastroenterology and Hepatology, 15(1), 11-20. [More Information]
- Katoonizadeh, A., Motamed-Gorji, N., Sharafkhah, M., Ostovaneh, M., Esmaili, S., Eslami, L., Gharravi, A., Khoshnia, M., Shayanrad, A., Katouli, F., George, J., et al (2018). Intra-familial Transmission of Chronic Hepatitis B Infection: A Large Population-Based Cohort Study in Northern Iran. Archives of Iranian Medicine, 21(10), 436-442.
- Goland, S., Fugenfirov, I., Volodarsky, I., Aronson, H., Zilberman, L., Shimoni, S., George, J. (2018). Left ventricular reverse remodeling in recent onset idiopathic dilated cardiomyopathy using contemporary echo techniques. IMAJ, 20(12), 749-753.
- Sublette, V., Smith, S., George, J., McCaffery, K., Douglas, M. (2018). Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals' perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion. Journal of Health Psychology, 23(13), 1720-1731. [More Information]
- Alavi, M., Grebely, J., Hajarizadeh, B., Amin, J., Larney, S., Law, M., George, J., Degenhardt, L., Dore, G. (2018). Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012. BMC Infectious Diseases, 18(1), 215. [More Information]
- George, J., Anstee, Q., Ratziu, V., Sanyal, A. (2018). NAFLD: The evolving landscape. Journal of Hepatology, 68(2), 227-229. [More Information]
- Mahady, S., George, J. (2018). Predicting the future burden of NAFLD and NASH. Journal of Hepatology, 69(4), 774-775. [More Information]
- Laursen, T., Siggard, C., Kazankov, K., Sandahl, T., Moller, H., Ong, A., Douglas, M., George, J., Tarp, B., Kristensen, L., et al (2018). Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology. Scandinavian Journal of Gastroenterology, 53(8), 986-993. [More Information]
- McCaughan, G., Thwaites, P., Roberts, S., Strasser, S., Mitchell, J., Morales, B., Mason, S., Gow, P., Wigg, A., George, J., et al (2018). Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15). Alimentary Pharmacology and Therapeutics, 47(3), 401-411. [More Information]
- Laursen, T., Wong, G., Kazankov, K., Sandahl, T., Moller, H., Hamilton-Dutoit, S., George, J., Chan, H., Gronbaek, H. (2018). Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. Journal of Gastroenterology and Hepatology, 33(2), 484-491. [More Information]
- Read, S., Parnell, G., Booth, D., Douglas, M., George, J., Ahlenstiel, G. (2018). The antiviral role of zinc and metallothioneins in hepatitis C infection. Journal of Viral Hepatitis, 25(5), 491-501. [More Information]
- Alavi, M., Janjua, N., Chong, M., Grebely, J., Aspinall, E., Innes, H., Valerio, H., Hajarizadeh, B., Hayes, P., Krajden, M., George, J., et al (2018). The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: an international study. Journal of Hepatology, 68(3), 393-401. [More Information]
- Simpson, S., Raubenheimer, D., Cogger, V., Macia, L., Solon-Biet, S., Le Couteur, D., George, J. (2018). The nutritional geometry of liver disease including non-alcoholic fatty liver disease (NAFLD). Journal of Hepatology, 68(2), 316-325. [More Information]
- Alzahrani, B., Iseli, T., Ramezani-Moghadam, M., Ho, V., Wankell, M., Sun, E., Qiao, L., George, J., Hebbard, L. (2018). The role of AdipoR1 and AdipoR2 in liver fibrosis. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1864 (3), 700-708. [More Information]
- Zeuzem, S., Serfaty, L., Vierling, J., Cheng, W., George, J., Sperl, J., Strasser, S., Kumada, H., Hwang, P., Robertson, M., et al (2018). The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. Journal of Gastroenterology, 53(5), 679-688. [More Information]
- Alavi, M., Janjua, N., Chong, M., Grebely, J., Aspinall, E., Innes, H., Valerio, H., Hajarizadeh, B., Hayes, P., Krajden, M., George, J., et al (2018). Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: an international comparison. Journal of Viral Hepatitis, 25(5), 473-481. [More Information]
- Robotin, M., Masgoret, X., Porwal, M., Goldsbury, D., Khoo, C., George, J. (2018). Using a chronic hepatitis B Registry to support population-level liver cancer prevention in Sydney, Australia. Clinical Epidemiology, 10, 41-49. [More Information]
- Sheppard-Law, S., Zablotska-Manos, I., Kermeen, M., Holdaway, S., Lee, A., George, J., Zekry, A., Maher, L. (2018). Utilisation of hepatocellular carcinoma screening in Australians at risk of hepatitis B virus-related carcinoma and prescribed anti-viral therapy. Journal of Clinical Nursing, 27(13-14), 2673-2683. [More Information]
- Siddiqui, M., Maroteau, C., Veluchamy, A., Tornio, A., Tavendale, R., Carr, F., Abelega, N., Carr, D., Bloch, K., Hallberg, P., et al (2017). A common missense variant of LILRB5 is associated with statin intolerance and myalgia. European Heart Journal, 38(48), 3569-3575. [More Information]
- Gauthiez, E., Habfast-Robertson, I., Rueger, S., Kutalik, Z., Aubert, V., Berg, T., Cerny, A., Gorgievski, M., George, J., Heim, M., et al (2017). A systematic review and meta-analysis of HCV clearance. Liver International, 37(10), 1431-1445. [More Information]
- Baatarkhuu, O., Lee, H., George, J., Munkh-Orshikh, D., Enkhtuvshin, B., Ariunaa, S., Eslam, M., Ahn, S., Han, K., Kim, D. (2017). Acute hepatitis A, B and C but not D is still prevalent in Mongolia: a time trend analysis. Clinical and Molecular Hepatology, 23(2), 147-153. [More Information]
- Obeid, S., Wankell, M., Charrez, B., Sternberg, J., Kreuter, R., Esmaili, S., Ramezani-Moghadam, M., Devine, C., Read, S., Bhathal, P., Ahlenstiel, G., Qiao, L., George, J., Hebbard, L., et al (2017). Adiponectin confers protection from acute colitis and restricts a B cell immune response. Journal of Biological Chemistry, 292(16), 6569-6582. [More Information]
- Hashida, R., Kawaguchi, T., Bekki, M., Omoto, M., Matsuse, H., Nago, T., Takano, Y., Ueno, T., Koga, H., George, J., et al (2017). Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. Journal of Hepatology, 66(1), 142-152. [More Information]
- Zhou, G., Latchoumanin, O., Bagdesar, M., Hebbard, L., Duan, W., Liddle, C., George, J., Qiao, L. (2017). Aptamer-based therapeutic approaches to target cancer stem cells. Theranostics, 7(16), 3948-3961. [More Information]
- Siddiqui, M., Veluchamy, A., Maroteau, C., Tavendale, R., Carr, F., Pearson, E., Colhoun, H., Morris, A., George, J., Doney, A., et al (2017). CKM Glu83Gly Is Associated with Blunted Creatine Kinase Variation, but Not with Myalgia. Circulation Cardiovascular Genetics, 10(4). [More Information]
- Mahady, S., Macaskill, P., Craig, J., Wong, G., Chu, W., Chan, H., George, J., Wong, V. (2017). Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis. Clinical Gastroenterology and Hepatology, 15(9), 1453-1460. [More Information]
- Huo, X., Han, S., Wu, G., Latchoumanin, O., Zhou, G., Qiao, L., George, J., Hebbard, L. (2017). Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: Implications for tumorigenesis, disease progression, and liver cancer stem cells. Molecular Cancer, 16(1), 1-10. [More Information]
- Keating, S., Hackett, D., Parker, H., Way, K., O'Connor, H., Salis (nee Sainsbury), A., Baker, M., Chuter, V., Caterson, I., George, J., Johnson, N. (2017). Effect of resistance training on liver fat and visceral adiposity in adults with obesity: A randomized controlled trial. Hepatology Research, 47(7), 622-631. [More Information]
- Rødgaard-Hansen, S., St George, A., Kazankov, K., Bauman, A., George, J., Grønbæk, H., Møller, H. (2017). Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease. Scandinavian Journal of Clinical and Laboratory Investigation, 77(7), 498-504. [More Information]
- Mahady, S., Wong, G., Turner, R., Mitchell, P., Macaskill, P., Craig, J., George, J. (2017). Elevated Liver Enzymes and Mortality in Older Individuals: A Prospective Cohort Study. Journal of Clinical Gastroenterology, 51(5), 439-445. [More Information]
- Sabag, A., Way, K., Keating, S., Sultana, R., O'Connor, H., Baker, M., Chuter, V., George, J., Johnson, N. (2017). Exercise and ectopic fat in type 2 diabetes: a systematic review and meta-analysis. Diabetes and Metabolism, 43(3), 195-210. [More Information]
- Sheppard-Law, S., Zablotska-Manos, I., Kermeen, M., Holdaway, S., Lee, A., Zekry, A., Dore, G., George, J., Maher, L. (2017). Factors associated with HBV virological breakthrough. Antiviral Therapy, 22(1), 53-60. [More Information]
- Sheppard-Law, S., Zablotska-Manos, I., Kermeen, M., Holdaway, S., Lee, A., Zekry, A., Dore, G., George, J., Maher, L. (2017). Factors associated with non-adherence to HBV antiviral therapy. Antiviral Therapy, 22(1), 53-60. [More Information]
- Lim, L., Thompson, A., Patterson, S., George, J., Strasser, S., Lee, A., Sievert, W., Nicoll, A., Desmond, P., Roberts, S., et al (2017). Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy. Liver International, 37(6), 827-835. [More Information]
- Scott, C., Cha, K., Ngai, J., Jiang, C., Cheng, K., Stokes, R., Ho, K., George, J., Gonzalez, F., Gunton, J. (2017). Hepatic Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) regulates metabolism in mice. PloS One, 12(11), 1-14. [More Information]
- Waziry, R., Hajarizadeh, B., Grebely, J., Amin, J., Law, M., Danta, M., George, J., Dore, G. (2017). Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. Journal of Hepatology, 67(6), 1204-1212. [More Information]
- Eslam, M., McLeod, D., Kelaeng, K., Mangia, A., Berg, T., Thabet, K., Irving, W., Dore, G., Sheridan, D., Gronbaek, H., Booth, D., Weltman, M., Douglas, M., Liddle, C., George, J., et al (2017). IFN-(lambda)3, not IFN-(lambda)4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nature Genetics, 49(5), 795-800. [More Information]
- Bipi, P., George, J., Gomathy, S., Gracious, N., Kumar, S., Mohandas, M. (2017). Lactate levels and risk of lactic acidosis with metformin in diabetic kidney disease patients. Saudi Journal of Kidney Diseases and Transplantation, 28(6), 1356-1361. [More Information]
- Sublette, V., Smith, S., George, J., McCaffery, K., Douglas, M. (2017). Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals' perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion. Journal of Health Psychology, 22(10), 1300-1311. [More Information]
- Robotin, M., Porwal, M., Hopwood, M., Nguyen, D., Sze, M., Treloar, C., George, J. (2017). Listening to the consumer voice: developing multilingual cancer information resources for people affected by liver cancer. Health Expectations, 20(1), 171-182. [More Information]
- Petta, S., Eslam, M., Valenti, L., Bugianesi, E., Barbara, M., Camma, C., Porzio, M., Rosso, C., Fargion, S., George, J., et al (2017). Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. Liver International, 37(9), 1389-1396. [More Information]
- Keating, S., Parker, H., Hickman, I., Gomersall, S., Wallen, M., Coombes, J., Macdonald, G., George, J., Johnson, N. (2017). NAFLD in clinical practice: Can simple blood and anthropometric markers be used to detect change in liver fat measured by 1H-MRS? Liver International, 37(12), 1907-1915. [More Information]
- Wu, G., Wilson, G., George, J., Liddle, C., Hebbard, L., Qiao, L. (2017). Overcoming treatment resistance in cancer: Current understanding and tactics. Cancer Letters, 387, 69-76. [More Information]
- Rankin, S., Elder, D., Ogston, S., George, J., Lang, C., Choy, A. (2017). Population-level incidence and monitoring of adverse drug reactions with long-term amiodarone therapy. Cardiovascular Therapeutics, 35(3). [More Information]
- Mahady, S., Gale, J., Macaskill, P., Craig, J., George, J. (2017). Prevalence of elevated alanine transaminase in Australia and its relationship to metabolic risk factors: A cross-sectional study of 9,447 people. Journal of Gastroenterology and Hepatology, 32(1), 169-176. [More Information]
- Lubel, J., Strasser, S., Stuart, K., Dore, G., Thompson, A., Pianko, S., Bollipo, S., Mitchell, J., Fragomeli, V., Jones, T., George, J., et al (2017). Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 – final results of the REV1TAL study. Antiviral Therapy, 22(8), 699-710. [More Information]
- Han, S., Latchoumanin, O., Wu, G., Zhou, G., Hebbard, L., George, J., Qiao, L. (2017). Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors. Cancer Letters, 390, 188-200. [More Information]
- Gane, E., DeJesus, E., Janczewska, E., George, J., Diago, M., Da Silva, M., Reesink, H., Nikitin, I., Hinrichsen, H., Bourgeois, S., et al (2017). Simeprevir with peginterferon (alpha)-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: An open-label, rollover study. BMC Infectious Diseases, 17(1), 1-13. [More Information]
- Waziry, R., Grebely, J., Amin, J., Alavi, M., Hajarizadeh, B., George, J., Matthews, G., Law, M., Dore, G. (2017). Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014). Hepatology Communications, 1(8), 736-747. [More Information]
- Rademaker, M., Gupta, M., Andrews, M., Armour, K., Baker, C., Foley, P., Gebauer, K., George, J., Rubel, D., Sullivan, J. (2017). The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian setting. Australasian Journal of Dermatology, 58(3), 166-170. [More Information]
- Simpson, S., Le Couteur, D., James, D., George, J., Gunton, J., Solon-Biet, S., Raubenheimer, D. (2017). The Geometric Framework for Nutrition as a tool in precision medicine. Nutrition and Healthy Aging, 4(3), 217-226. [More Information]
- Thabet, K., Chan, H., Petta, S., Mangia, A., Berg, T., Boonstra, A., Brouwer, W., Abate, M., Wong, V., Nazmy, M., Liddle, C., George, J., Eslam, M., et al (2017). The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. Hepatology, 65(6), 1840-1850. [More Information]
- John, M., Metwally, M., Mangia, A., Romero-Gomez, M., Berg, T., Sheridan, D., George, J., Eslam, M. (2017). TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C. Gastroenterology, 153(5), 1448-1449. [More Information]
- Read, S., O'Connor, K., Suppiah, V., Ahlenstiel, C., Obeid, S., Cook, K., Cunningham, A., Douglas, M., Hogg, P., Booth, D., George, J., Ahlenstiel, G. (2017). Zinc is a potent and specific inhibitor of IFN-(lambda)3 signaling. Nature Communications, 8, 1-15. [More Information]
- Orriss, I., Arnett, T., George, J., Witham, M. (2016). Allopurinol and oxypurinol promote osteoblast differentiation and increase bone formation. Experimental Cell Research, 342(2), 166-174. [More Information]
- Goland, S., Weinstein, J., Zalik, A., Kuperstein, R., Zilberman, L., Shimoni, S., Arad, M., Ben Gal, T., George, J. (2016). Angiogenic Imbalance and Residual Myocardial Injury in Recovered Peripartum Cardiomyopathy Patients. Circulation. Heart Failure, 9(11). [More Information]
- Zhou, G., Wilson, G., Hebbard, L., Duan, W., Liddle, C., George, J., Qiao, L. (2016). Aptamers: A promising chemical antibody for cancer therapy. Oncotarget, 7(12), 13446-13463. [More Information]
- Basu, U., Goodbrand, J., Mcmurdo, M., Donnan, P., McGilchrist, M., Frost, H., George, J., Witham, M. (2016). Association between allopurinol use and hip fracture in older patients. Bone, 84, 189-193. [More Information]
- Awan, Z., Tay, E., Eyre, N., Wu, L., Beard, M., Boo, I., Drummer, H., George, J., Douglas, M. (2016). Calsyntenin-1 mediates hepatitis C virus replication. Journal of General Virology, 97(8), 1877-1887. [More Information]
- Shimoni, S., Meledin, V., Bar, I., Fabricant, J., Gandelman, G., George, J. (2016). Circulating CD14+ monocytes in patients with aortic stenosis. Journal of Geriatric Cardiology, 13(1), 81-87. [More Information]
- Shimoni, S., Bar, I., Meledin, V., Derazne, E., Gandelman, G., George, J. (2016). Circulating endothelial progenitor cells and clinical outcome in patients with aortic stenosis. PloS One, 11(2). [More Information]
- Shimoni, S., Bar, I., Meledin, V., Gandelman, G., George, J. (2016). Circulating regulatory T cells in patients with aortic valve stenosis: Association with disease progression and aortic valve intervention. International Journal of Cardiology, 218, 181-187. [More Information]
- Bipi, P., Gracious, N., Kumar, S., George, J. (2016). Combined surgical and immunosupressive therapy for encapsulating peritoneal sclerosis. Indian Journal of Nephrology, 26(6), 458-460. [More Information]
- Wallace, B., Siddiqui, M., Palmer, C., George, J. (2016). Common Creatine Kinase gene mutation results in falsely reassuring CK levels in muscle disorders. QJM, 109(6), 413-414. [More Information]
- Eslam, M., Mangia, A., Berg, T., Chan, H., Irving, W., Dore, G., Abate, M., Bugianesi, E., Adams, L., Najim, M., Weltman, M., Rahme, A., Booth, D., Liddle, C., Douglas, M., van der Poorten, D., George, J., White, R., Leung, R., et al (2016). Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology, 64(1), 34-46. [More Information]
- Mahady, S., George, J. (2016). Exercise and diet in the management of nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 65(8), 1172-1182. [More Information]
- Eslam, M., Hashem, A., Romero-Gomez, M., Berg, T., Dore, G., Mangia, A., Chan, H., Irving, W., Sheridan, D., Abate, M., Weltman, M., Kelaeng, K., Ahlenstiel, G., Liddle, C., Douglas, M., Booth, D., George, J., et al (2016). FibroGENE: A gene-based model for staging liver fibrosis. Journal of Hepatology, 64(2), 390-398. [More Information]
- Nielsen, M., Karsdal, M., Kazankov, K., Gronbaek, H., Krag, A., Leeming, D., Schuppan, D., George, J. (2016). Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury. Alimentary Pharmacology and Therapeutics, 44, 1242-1252. [More Information]
- Eslam, M., George, J. (2016). Genetic and epigenetic mechanisms of NASH. Hepatology International, 10(3), 394-406. [More Information]
- Heim, M., Bochud, P., George, J. (2016). Host - hepatitis C viral interactions: The role of genetics. Journal of Hepatology, 65(1 Suppl), S22-S32. [More Information]
- O'Connor, K., Read, S., Wang, X., Schibeci, S., Eslam, M., Ong, A., Weltman, M., Douglas, M., Mazzola, A., Craxi, A., Stewart, G., Liddle, C., George, J., Ahlenstiel, G., Booth, D., et al (2016). IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. Genes and Immunity, 17(6), 328-334. [More Information]
- Katoonizadeh, A., Sharafkhah, M., Ostovaneh, M., Norouzi, A., Khoshbakht, N., Mohamadkhani, A., Eslami, L., Gharravi, A., Shayanrad, A., Khoshnia, M., Esmaili, S., George, J., et al (2016). Immune responses to hepatitis B immunization 10-18 years after primary vaccination: a population-based cohort study. Journal of Viral Hepatitis, 23(10), 805-811. [More Information]
- Jensen, D., Brunda, M., Elston, R., Gane, E., George, J., Glavini, K., Hammond, J., Le Pogam, S., Najera, I., Passe, S., et al (2016). Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. Liver International, 36(4), 505-514. [More Information]
- Williams, K., Sullivan, D., Veillard, A., O'Brien, R., George, J., Jenkins, A., Young, S., Ehnholm, C., Duffield, A., Twigg, S., Keech, A. (2016). Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetic Medicine, 33(3), 356-364. [More Information]
- Sheridan, D., Hajarizadeh, B., Fenwick, F., Matthews, G., Applegate, T., Douglas, M., Neely, D., Askew, B., Dore, G., George, J., et al (2016). Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection. Liver International, 36(12), 1774-1782. [More Information]
- Thabet, K., Asimakopoulos, A., Shojaei, M., Romero-Gomez, M., Mangia, A., Irving, W., Berg, T., Dore, G., Gronbaek, H., Sheridan, D., Weltman, M., White, R., Douglas, M., Liddle, C., van der Poorten, D., George, J., Eslam, M., et al (2016). MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nature Communications, 7, 1-8. [More Information]
- Elder, D., Singh, J., Levin, D., Donnelly, L., Choy, A., George, J., Struthers, A., Doney, A., Lang, C. (2016). Mean HbA
1c and mortality in diabetic individuals with heart failure: A population cohort study. European Journal of Heart Failure, 18(1), 94-102. [More Information] - Vongsuvanh, R., van der Poorten, D., Iseli, T., Strasser, S., McCaughan, G., George, J. (2016). Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma. PloS One, 11(5), 1-12. [More Information]
- Keating, S., Parker, H., Pavey, T., Baker, M., Caterson, I., George, J., Johnson, N. (2016). Objectively Quantified Physical Activity and Sedentary Behavior in Predicting Visceral Adiposity and Liver Fat. Journal of Obesity, 2016, 1-10. [More Information]
- Williams, K., Sullivan, D., Nicholson, G., George, J., Jenkins, A., Januszewski, A., Gebski, V., Manning, P., Tan, Y., Donoghoe, M., Buizen, L., Twigg, S., Keech, A., et al (2016). Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism: Clinical and Experimental, 65(5), 783-793. [More Information]
- Asimakopoulos, A., Mangia, A., Dore, G., Lloyd, A., George, J., Eslam, M. (2016). Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in Europeans. Hepatology, 64(6), 2264-2265. [More Information]
- Eslam, M., George, J. (2016). Targeting IFN-lambda: Therapeutic Implications. Expert Opinion on Therapeutic Targets, 20(12), 1425-1432. [More Information]
- Kazankov, K., Barrera Martinez, F., Moller, H., Rosso, C., Bugianesi, E., David, E., Jouness, R., Esmaili, S., Eslam, M., McLeod, D., George, J., et al (2016). The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. Liver International, 36(10), 1549-1557. [More Information]
- Alavi, M., Law, M., Grebely, J., Amin, J., Hajarizadeh, B., George, J., Dore, G. (2016). Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: a population-based study, 1995-2012. Journal of Hepatology, 65(5), 879-887. [More Information]
- Waziry, R., Grebely, J., Amin, J., Alavi, M., Hajarizadeh, B., George, J., Matthews, G., Law, M., Dore, G. (2016). Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014). Journal of Hepatology, 65(6), 1086-1093. [More Information]
- Dong, Z., Su, L., Esmaili, S., Iseli, T., Ramezani-Moghadam, M., Hu, L., Xu, A., George, J., Wang, J. (2015). Adiponectin attenuates liver fibrosis by inducing nitric oxide production of hepatic stellate cells. Journal of Molecular Medicine, 93(12), 1327-1339. [More Information]
- Ramezani-Moghadam, M., Wang, J., Ho, V., Iseli, T., Alzahrani, B., Xu, A., van der Poorten, D., Qiao, L., George, J., Hebbard, L. (2015). Adiponectin Reduces Hepatic Stellate Cell Migration by Promoting Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Secretion. Journal of Biological Chemistry, 290(9), 5533-5542. [More Information]
- Williams, K., Burns, K., Constantino, M., Shackel, N., Prakoso, E., Wong, J., Wu, T., George, J., McCaughan, G., Twigg, S. (2015). An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes. Journal of Diabetes and Its Complications, 29(8), 1240-1247. [More Information]
- Senthilvelkumar, T., Magimairaj, H., Fletcher, J., Tharion, G., George, J. (2015). Comparison of body weight-supported treadmill training versus body weight-supported overground training in people with incomplete tetraplegia: A pilot randomized trial. Clinical Rehabilitation, 29(1), 42-49. [More Information]
- Dore, G., Lawitz, E., Hezode, C., Shafran, S., Ramji, A., Tatum, H., Taliani, G., Tran, A., Strasser, S., George, J., et al (2015). Daclatasvir plus Peginterferon and Ribavirin is Non-inferior to Peginterferon and Ribavirin Alone, and Reduces Duration of Treatment for HCV Genotype 2 or 3 Infection. Gastroenterology, 148(2), 355-366. [More Information]
- Sun, Y., George, J., Rocha, S. (2015). Dose-dependent effects of allopurinol on human foreskin fibroblast cells and human umbilical vein endothelial cells under hypoxia. PloS One, 10(4). [More Information]
- Wilson, G., Hebbard, L., Duan, W., Qiao, L., George, J. (2015). Editorial: Gene therapy for gastrointestinal and liver cancers: past experience, current status and future perspectives. Current Gene Therapy, 15(2), 93-96. [More Information]
- Wilson, G., Hebbard, L., Duan, W., George, J., Qiao, L. (2015). Editorial: Induced Pluripotent Stem Cells (iPSCs) in the Gastroenterology and Hepatology: from Basic Research to Clinical Applications. Current Stem Cell Research & Therapy, 10(3), 190-192.
- Mahady, S., George, J. (2015). Editorial: triglycerides in chronic liver disease - a marker of disease progression? Alimentary Pharmacology and Therapeutics, 42(2), 239. [More Information]
- Keating, S., Hackett, D., Parker, H., O'Connor, H., Gerofi, J., Salis (nee Sainsbury), A., Baker, M., Chuter, V., Caterson, I., George, J., Johnson, N. (2015). Effect of aerobic exercise training dose on liver fat and visceral adiposity. Journal of Hepatology, 63(1), 174-182. [More Information]
- Heeboll, S., Thomsen, K., Clouston, A., Sundelin, E., Radko, Y., Christensen, L., Ramezani-Moghadam, M., Kreutzfeldt, M., Pedersen, S., Jessen, N., Hebbard, L., George, J., et al (2015). Effect of resveratrol on experimental non-alcoholic steatohepatitis. Pharmacological Research, 95-96, 34-41. [More Information]
- Goudie, A., Elder, D., Deshmukh, H., Szwejkowski, B., Lang, C., George, J. (2015). Effect of warfarin on survival in patients with concomitant left ventricular systolic dysfunction and pulmonary hypertension: A population cohort study. European Journal of Heart Failure, 17(1), 90-97. [More Information]
- Foster, G., Pianko, S., Brown, A., Forton, D., Nahass, R., George, J., Barnes, E., Brainard, D., Massetto, B., Lin, M., et al (2015). Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon-Alfa in Patients with Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients with Cirrhosis and Hepatitis C Virus Genotype 2 Infection. Gastroenterology, 149(6), 1462-1470. [More Information]
- Parker, H., O'Connor, H., Keating, S., Cohn, J., Garg, M., Caterson, I., George, J., Johnson, N. (2015). Efficacy of the Omega-3 Index in predicting non-alcoholic fatty liver disease in overweight and obese adults: a pilot study. British Journal of Nutrition, 114(5), 780-787. [More Information]
- Tse, E., Helbig, K., Van der Hoek, K., McCartney, E., Van der Hoek, M., George, J., Beard, M. (2015). Fatty Acids Induce a Pro-Inflammatory Gene Expression Profile in Huh-7 Cells That Attenuates the Anti-HCV Action of Interferon. Journal of Interferon and Cytokine Research, 35(5), 392-400. [More Information]
- Eslam, M., George, J. (2015). Genome-Wide Association Studies and Hepatitis C: Harvesting the Benefits of the Genomic Revolution. Seminars in Liver Disease, 35(4), 402-420. [More Information]
- Read, S., Tay, E., Shahidi, M., O'Connor, K., Booth, D., George, J., Douglas, M. (2015). Hepatitis C Virus Driven AXL Expression Suppresses the Hepatic Type I Interferon Response. PloS One, 10(8), 1-16. [More Information]
- Scott, C., Cha, K., Rao, R., Liddle, C., George, J., Gunton, J. (2015). Hepatocyte- Specific Deletion of ARNT (Aryl Hydrocarbon Receptor Nuclear Translocator) Results in Altered Fibrotic Gene Expression in the Thioacetamide Model of Liver Injury. PloS One, 10(3), 1-11. [More Information]
- Struthers, A., George, J. (2015). High B-type natriuretic peptide hypertensives at target blood pressure: Potential role of β-blockers to reduce their elevated risk. Hypertension, 66(5), 927-932. [More Information]
- Rueger, S., Bochud, P., Dufour, J., Mullhaupt, B., Semela, D., Helm, M., Moradpour, D., Cerny, A., Malinverni, R., Booth, D., Suppiah, V., George, J., et al (2015). Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut, 64(10), 1605-1615. [More Information]
- Benton, G., DeGray, G., Kleinman, H., George, J., Arnaoutova, I. (2015). In vitro microtumors provide a physiologically predictive tool for breast cancer therapeutic screening. PloS One, 10(4). [More Information]
- Sublette, V., Hopwood, M., George, J., Smith, S., Perry, K., McCaffery, K., Douglas, M. (2015). Instrumental support to facilitate hepatitis C treatment adherence: Working around shortfalls in shared-care. Psychology, Health and Medicine, 20(2), 186-197. [More Information]
- Eslam, M., Hashem, A., Leung, R., Romero-Gomez, M., Berg, T., Dore, G., Chan, H., Irving, W., Sheridan, D., Abate, M., Weltman, M., Douglas, M., Liddle, C., Booth, D., George, J., Ahlenstiel, G., et al (2015). Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nature Communications, 6, 1-10. [More Information]
- Charach, G., Rubalsky, O., Charach, L., Rabinovich, A., Argov, O., Rogowski, O., George, J. (2015). Internal thoracic impedance - A useful method for expedient detection and convenient monitoring of pleural effusion. PloS One, 10(4). [More Information]
- Eslam, M., George, J. (2015). Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy? Hepatology International, 9(1), 5-8. [More Information]
- Buti, M., Fung, S., Gane, E., Afdhal, N., Flisiak, R., Gurel, S., Flaherty, J., Martins, E., Yee, L., Dinh, P., George, J., et al (2015). Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatology International, 9(2), 243-250. [More Information]
- Esmaili, S., George, J. (2015). Ltb4r1 inhibitor: A pivotal insulin sensitizer? Trends in Endocrinology and Metabolism, 26(5), 221-222. [More Information]
- Nielsen, M., Kazankov, K., Leeming, D., Karsdal, M., Krag, A., Barrera Martinez, F., McLeod, D., George, J., Grønbæk, H. (2015). Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients. PloS One, 10(9), 1-12. [More Information]
- Wu, G., Wilson, G., George, J., Qiao, L. (2015). Modulation of Notch Signaling as a Therapeutic Approach for Liver Cancer. Current Gene Therapy, 15(2), 171-181. [More Information]
- Ojha, R., George, J., Chandy, B., Tharion, G., Devasahayam, S. (2015). Neuromodulation by surface electrical stimulation of peripheral nerves for reduction of detrusor overactivity in patients with spinal cord injury: A pilot study. Journal of Spinal Cord Medicine, 38(2), 207-213. [More Information]
- Nguyen, V., George, J. (2015). Nonalcoholic Fatty Liver Disease Management: Dietary and Lifestyle Modifications. Seminars in Liver Disease, 35(3), 318-337. [More Information]
- Wu, G., Wilson, G., Zhou, G., Hebbard, L., George, J., Qiao, L. (2015). Oct4 is a reliable marker of liver tumor propagating cells in hepatocellular carcinoma. Discovery Medicine, 20(110), 219-229.
- Petta, S., Vanni, E., Bugianesi, E., Rosso, C., Cabibi, D., Camma, C., Di Marco, F., Eslam, M., Grimaudo, S., Macaluso, F., McLeod, D., George, J., et al (2015). PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. Alimentary Pharmacology and Therapeutics, 41(10), 939-948. [More Information]
- Nair, S., Sarasamma, S., Gracious, N., George, J., Anish, T., Radhakrishnan, R. (2015). Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level. Experimental and Clinical Transplantation, 13, 197-200. [More Information]
- Kazankov, K., Moller, H., Bibby, B., Vilstrup, H., George, J., Gronbaek, H. (2015). Reply. Hepatology, 61(2), 735-735. [More Information]
- Goland, S., Perelman, S., Asalih, N., Shimoni, S., Walfish, O., Hallak, M., Hagay, Z., George, J., Shotan, A., Blondheim, D. (2015). Shortness of Breath during Pregnancy: Could a Cardiac Factor Be Involved? Clinical Cardiology, 38(10), 598-603. [More Information]
- Mahady, S., Schlub, T., Bero, L., Moher, D., Tovey, D., George, J., Craig, J. (2015). Side effects are incompletely reported among systematic reviews in gastroenterology. Journal of Clinical Epidemiology, 68(2), 144-153. [More Information]
- Reddy, K., Zeuzem, S., Zoulim, F., Weiland, O., Horban, A., Stanciu, C., Villamil, F., Andreone, P., George, J., Dammers, E., et al (2015). Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. The Lancet Infectious Diseases, 15(1), 27-35. [More Information]
- Meledin, V., Gandelman, G., Derazne, E., Kogan, Y., George, J., Shimoni, S. (2015). Stroke volume adjusted to afterload for assessment of cardiac performance in patients with severe aortic stenosis and preserved left ventricular ejection fraction. Cardiology, 130(4), 260-266. [More Information]
- Zhou, G., Wilson, G., George, J., Qiao, L. (2015). Targeting cancer stem cells as a therapeutic approach in liver cancer. Current Gene Therapy, 15(2), 161-170. [More Information]
- Keating, S., George, J., Johnson, N. (2015). The benefits of exercise for patients with non-alcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 9(10), 1247-1250. [More Information]
- Bhala, N., George, J. (2015). The Burden of Non-alcoholic Fatty Liver Disease (NAFLD) in the Asia Pacific Region. Current Hepatology Reports, 14(2), 77-86. [More Information]
- Sublette, V., Smith, S., George, J., McCaffery, K., Douglas, M. (2015). The Hepatitis C treatment experience: Patients' perceptions of the facilitators of and barriers to uptake, adherence and completion. Psychology & Health, 30(8), 987-1004. [More Information]
- Read, S., Tay, E., Shahidi, M., McLauchlan, J., George, J., Douglas, M. (2015). The Mechanism of Interferon Refractoriness During Hepatitis C Virus Infection and Its Reversal with a Peroxisome Proliferator-Activated Receptor [alpha] Agonist. Journal of Interferon and Cytokine Research, 35(6), 486-497. [More Information]
- Duong, H., Dong, Z., Su, L., Boyer, C., George, J., Davis, T., Wang, J. (2015). The Use of Nanoparticles to Deliver Nitric Oxide to Hepatic Stellate Cells for Treating Liver Fibrosis and Portal Hypertension. Small, 11(19), 2291-2304. [More Information]
- Charach, G., Michowitz, Y., Rogowski, O., Charach, L., Argov, O., George, J., Grosskopf, I. (2015). Usefulness of antibodies to oxidized low-density lipoproteins as predictors of morbidity and prognosis in heart failure patients aged ≥65 years. American Journal of Cardiology, 116(9), 1379-1384. [More Information]
- Douglas, M., Esmaili, S., George, J. (2014). A new role for IKK-alpha in Hepatitis C virus induced lipogenesis. Hepatology, 59(5), 2046-2049. [More Information]
- Muir, A., Arora, S., Everson, G., Flisiak, R., George, J., Ghalib, R., Gordon, S., Gray, T., Greenbloom, S., Hassanein, T., et al (2014). A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. Journal of Hepatology, 61(6), 1238-1246. [More Information]
- Bhide, R., Barman, A., Varghese, S., Chatterjee, A., Mammen, S., George, J., Thomas, R. (2014). A rare presentation of subacute progressive ascending myelopathy secondary to cement leakage in percutaneous vertebroplasty. American Journal of Physical Medicine & Rehabilitation, 93(5), 431-436. [More Information]
- Beard, M., Ffrench, R., Gowans, E., Helbig, K., Eyre, N., Douglas, M., Grebely, J., Ahlenstiel, G., Locarnini, S., George, J., et al (2014). A Summary of the 20(th) International Symposium on Hepatitis C Virus and Related Viruses. Gastroenterology, 147(1), e1-e4. [More Information]
- Kraus, S., Naumov, I., Shapira, S., Kazanov, D., Aroch, I., Afek, A., Eisenberg, O., George, J., Arber, N., Finkelstein, A. (2014). Aspirin but not meloxicam attenuates early atherosclerosis in apolipoprotein E knockout mice. IMAJ, 16(4), 233-238.
- Musso, G., Gambino, R., Tabibian, J., Ekstedt, M., Kechagias, S., Hamaguchi, M., Hultcrantz, R., Hagstrom, H., Yoon, S., Charatcharoenwitthaya, P., George, J., Barrera Martinez, F., et al (2014). Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. PLoS Medicine, 11(7), 1-26. [More Information]
- Shimoni, S., Bar, I., Zilberman, L., George, J. (2014). Autoantibodies to oxidized low-density lipoprotein in patients with aortic regurgitation: Association with aortic diameter size. Cardiology, 128(1), 54-61. [More Information]
- George, J., Matucci-Cerinic, M., Bar, I., Shimoni, S. (2014). Circulating autoantibodies to endothelial progenitor cells: Binding characteristics and association with risk factors for atherosclerosis. PloS One, 9(6). [More Information]
- Witham, M., George, J. (2014). Clinical trial design for older people-time for a rethink. QJM, 107(1), 15-16. [More Information]
- Poustchi, H., Katoonizadeh, A., Ostovaneh, M., Moossavi, S., Sharafkhah, M., Esmaili, S., Pourshams, A., Mohamadkhani, A., Besharat, S., Merat, S., George, J., et al (2014). Cohort profile: Golestan Hepatitis B Cohort Study- A Prospective Long Term Study in Northern Iran ​. Middle East Journal of Digestive Diseases, 6(4), 186-194.
- Robotin, M., George, J. (2014). Community-based hepatitis B screening: what works? Hepatology International, 8(4), 478-492. [More Information]
- Robotin, M., Kansil, M., Porwal, M., Penman, A., George, J. (2014). Community-based prevention of hepatitis-B-related liver cancer: Australian insights. Bulletin of the World Health Organization, 92(5), 374-379. [More Information]
- O'Connor, K., George, J., Booth, D., Ahlenstiel, G. (2014). Dendritic cells in hepatitis C virus infection: Key players in the IFNL3-genotype response. World Journal of Gastroenterology, 20(47), 17830-17838. [More Information]
- Flynn, J., Sacks-Davis, R., Higgs, P., Aitken, C., Moneer, S., Suppiah, V., Tracy, L., Ffrench, R., Bowden, S., Drummer, H., George, J., et al (2014). Detection of HCV-Specific IFN-gamma Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users. Hepatitis Monthly, 14(1), 1-14. [More Information]
- Roberts, S., Mitchell, J., Leung, R., Booth, D., Bollipo, S., Ostapowicz, G., Sloss, A., McCaughan, G., Dore, G., Thompson, A., George, J., et al (2014). Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies. Journal of Gastroenterology and Hepatology, 29(1), 179-184. [More Information]
- Heeboll, S., Thomsen, K., Pedersen, S., Vilstrup, H., George, J., Gronbaek, H. (2014). Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World Journal of Hepatology, 6(4), 188-198. [More Information]
- Shahidi, M., Tay, E., Read, S., Ramezani-Moghadam, M., Chayama, K., George, J., Douglas, M. (2014). Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents. Journal of General Virology, 95(11), 2468-2479. [More Information]
- Milner, K., Jenkins, A., Trenell, M., Tid-Ang, J., Samocha-Bonet, D., Weltman, M., Xu, A., George, J., Chisholm, D. (2014). Eradicating hepatitis C virus ameliorates insulin resistance without change in adipose depots. Journal of Viral Hepatitis, 21(5), 325-332. [More Information]
- Sharir, R., Semo, J., Shimoni, S., Ben-Mordechai, T., Landa-Rouben, N., Maysel-Auslender, S., Shaish, A., Entin-Meer, M., Keren, G., George, J. (2014). Experimental myocardial infarction induces altered regulatory T cell hemostasis, and adoptive transfer attenuates subsequent remodeling. PloS One, 9(12). [More Information]
- Thomsen, K., Gronbaek, H., Glavind, E., Hebbard, L., Jessen, N., Clouston, A., George, J., Vilstrup, H. (2014). Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function. American Journal of Physiology: Gastrointestinal and Liver Physiology, 307(3), G295-G301. [More Information]
- O'Connor, K., Parnell, G., Patrick, E., Ahlenstiel, G., Suppiah, V., van der Poorten, D., Read, S., Leung, R., Douglas, M., Yang, J., Stewart, G., Liddle, C., George, J., Booth, D. (2014). Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. Genes and Immunity, 15(2), 88-94. [More Information]
- Read, S., Tay, E., Shahidi, M., George, J., Douglas, M. (2014). Hepatitis C virus infection mediates cholesteryl ester synthesis to facilitate infectious particle production. Journal of General Virology, 95(9), 1900-1910. [More Information]
- George, J., Mackle, G., Manoharan, A., Khan, F., Struthers, A. (2014). High BNP levels in rheumatoid arthritis are related to inflammation but not to left ventricular abnormalities: A prospective case-control study. International Journal of Cardiology, 172(1). [More Information]
- O'Connor, K., Ahlenstiel, G., Suppiah, V., Schibeci, S., Ong, A., Leung, R., van der Poorten, D., Douglas, M., Weltman, M., Stewart, G., Liddle, C., George, J., Booth, D. (2014). IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis. Innate Immunity, 20(6), 598-605. [More Information]
- Eslam, M., Leung, R., Romero-Gomez, M., Mangia, A., Irving, W., Sheridan, D., Spengler, U., Mollison, L., Cheng, W., Bugianesi, E., Douglas, M., Booth, D., George, J., Ahlenstiel, G., et al (2014). IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. Journal of Hepatology, 61(2), 235-241. [More Information]
- Kitson, M., George, J., Dore, G., Leung, R., Button, P., McCaughan, G., Crawford, D., Sievert, W., Weltman, M., Cheng, W., et al (2014). Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection. Journal of Gastroenterology and Hepatology, 29, 1458-1462. [More Information]
- Benton, G., Arnaoutova, I., George, J., Kleinman, H., Koblinski, J. (2014). Matrigel: From discovery and ECM mimicry to assays and models for cancer research. Advanced Drug Delivery Reviews, 79, 3-18. [More Information]
- George, J., Struthers, A., Lang, C. (2014). Modulation of the renin-angiotensin-aldosterone system in heart failure. Current Atherosclerosis Reports, 16(4). [More Information]
- Thomsen, K., Hebbard, L., Glavind, E., Clouston, A., Vilstrup, H., George, J., Grønbæk, H. (2014). Non-alcoholic steatohepatitis weakens the acute phase response to endotoxin in rats. Liver International, 34(10), 1584-1592. [More Information]
- Sen, S., Chacko, J., Karl, S., Mathai, J., Thomas, R., Dastidar, A., Kishore, B., Ninan, P., George, J. (2014). Pediatric bladder augmentation in developing country: Lessons learnt from an experience of 195 cases. Journal International Medical Sciences Academy, 27(2), 79-83.
- Wilson, G., George, J. (2014). Physical and Chemical Insults Induce Inflammation and Gastrointestinal Cancers. Cancer Letters, 345(2), 190-195. [More Information]
- Barrera, F., George, J. (2014). Prothrombotic Factors and Nonalcoholic Fatty Liver Disease: An Additional Link to Cardiovascular Risk? Hepatology, 59(1), 16-18. [More Information]
- Sharir, R., Semo, J., Shaish, A., Landa-Rouben, N., Entin-Meer, M., Keren, G., George, J. (2014). Regulatory T cells influence blood flow recovery in experimental hindlimb ischaemia in an IL-10-dependentmanner. Cardiovascular Research, 103(4), 585-596. [More Information]
- Angulo, P., George, J., Day, C., Vanni, E., Russell, L., De la Cruz, A., Liaquat, H., Mezzabotta, L., Lee, E., Bugianesi, E. (2014). Serum Ferritin Levels Lack Diagnostic Accuracy for Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 12(7), 1163-1169. [More Information]
- Dai, Y., Wilson, G., Huang, B., Peng, M., Teng, G., Zhang, D., Zhang, R., Ebert, M., Chen, J., Wong, B., George, J., Qiao, L., et al (2014). Silencing of Jagged1 inhibits cell growth and invasion in colorectal cancer. Cell Death and Disease, 5, 1-9. [More Information]
- Kazankov, K., Barrera Martinez, F., Møller, H., Bibby, B., Vilstrup, H., George, J., Grønbæk, H. (2014). Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology, 60(2), 521-530. [More Information]
- Tian, A., Wilson, G., Lie, S., Wu, G., Hu, Z., Hebbard, L., Duan, W., George, J., Qiao, L. (2014). Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells. Cancer Letters, 351(2), 232-241. [More Information]
- Semo, J., Sharir, R., Afek, A., Avivi, C., Barshack, I., Maysel-Auslender, S., Krelin, Y., Kain, D., Entin-Meer, M., Keren, G., et al (2014). The 106b∼25 microRNA cluster is essential for neovascularization after hindlimb ischaemia in mice. European Heart Journal, 35(45), 3212-3223. [More Information]
- Volodarsky, I., Shimoni, S., George, J. (2014). The current status of transcutaneous aortic valve implantation. Expert Review of Cardiovascular Therapy, 12(10), 1205-1218. [More Information]
- Grebely, J., Page, K., Sacks-Davis, R., Schim van der Loeff, M., Rice, T., Bruneau, J., Morris, M., Hajarizadeh, B., Amin, J., Cox, A., George, J., et al (2014). The Effects of Female Sex, Viral Genotype, and IL28B Genotype on Spontaneous Clearance of Acute Hepatitis C Virus Infection. Hepatology, 59(1), 109-120. [More Information]
- Saeed, E., Xu, A., George, J. (2014). The multifaceted and controversial immunometabolic actions of adiponectin. Trends in Endocrinology and Metabolism, 25(9), 444-451. [More Information]
- Barrera Martinez, F., George, J. (2014). The Role of Diet and Nutritional Intervention for the Management of Patients with NAFLD. Clinics in Liver Disease, 18(1), 91-112. [More Information]
- George, J., Khan, F., Struthers, A. (2014). The source of BNP in rheumatoid arthritis. International Journal of Cardiology, 174(3), 740. [More Information]
- Mendel, I., Feige, E., Yacov, N., Salem, Y., Levi, I., Propheta-Meiran, O., Shoham, A., Ishai, E., George, J., Harats, D., et al (2014). VB-201, an oxidized phospholipid small molecule, inhibits CD14- and Toll-like receptor-2-dependent innate cell activation and constrains atherosclerosis. Clinical and Experimental Immunology, 175(1), 126-137. [More Information]
- Nair, S., George, J., Kumar, S., Gracious, N., Das, M. (2013). A case of Goodpasture's syndrome complicating pregnancy with dialysis requiring renal failure responding to plasmapheresis and termination of pregnancy. Renal Failure, 35(8), 1173-1175. [More Information]
- Szwejkowski, B., Gandy, S., Rekhraj, S., Houston, J., Lang, C., Morris, A., George, J., Struthers, A. (2013). Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. Journal of the American College of Cardiology, 62(24), 2284-2293. [More Information]
- Beveridge, L., Ramage, L., Mcmurdo, M., George, J., Witham, M. (2013). Allopurinol use is associated with greater functional gains in older rehabilitation patients. Age and Ageing, 42(3), 400-404. [More Information]
- Fischer, J., Bohm, S., Muller, T., Witt, H., Sarrazin, C., Susser, S., Migaud, P., Schott, E., Stewart, G., Brodzinski, A., George, J., et al (2013). Association of IFNL3 rs12979860 and rs8099917 with Biochemical Predictors of Interferon Responsiveness in Chronic Hepatitis C Virus Infection. PloS One, 8(10), 1-11. [More Information]
- Fahrtash, F., Kariyawasam, V., Gray, T., Byth Wilson, K., George, J., Douglas, M. (2013). Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B. World Journal of Gastroenterology, 19(5), 721-726. [More Information]
- Suppiah, V., Armstrong, N., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Dore, G., Irving, W., Stewart, G., George, J., Booth, D., Ahlenstiel, G., et al (2013). CCR5-Delta32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. Genes and Immunity, 14(5), 286-290. [More Information]
- Shimoni, S., Bar, I., Zilberman, L., Goland, S., Edri, O., Gandelman, G., Afek, A., Shamiss, A., George, J. (2013). Circulating progenitor and apoptotic progenitor cells in patients with aortic regurgitation. Circulation Journal, 77(3), 764-771. [More Information]
- Carulli, L., Maurantonio, M., Hebbard, L., Baldelli, E., Loria, P., George, J. (2013). Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD. Current Pharmaceutical Design, 19(29), 5280-5296. [More Information]
- Kim, M., Lee, K., Iseli, T., Hoy, A., George, J., Grewal, T., Roufogalis, B. (2013). Compound K modulates fatty acid-induced lipid droplet formation and expression of proteins involved in lipid metabolism in hepatocytes. Liver International, 33(10), 1583-1593. [More Information]
- Hu, L., George, J., Wang, J. (2013). Current concepts on the role of nitric oxide in portal hypertension. World Journal of Gastroenterology, 19(11), 1707-1717. [More Information]
- Foster, G., Zeuzem, S., Pianko, S., Sarin, S., Piratvisuth, T., Shah, S., Andreone, P., Sood, A., Chuang, W., Lee, C., George, J., et al (2013). Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. Journal of Viral Hepatitis, 20(4), e115-e123. [More Information]
- Petta, S., Rosso, C., Leung, R., Abate, M., Booth, D., Solomone, F., Gambino, R., Rizzetto, M., Caviglia, P., Smedile, A., George, J., et al (2013). Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients with Genotype 1 Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 11(3), 311-317. [More Information]
- Wilson, G., Hu, Z., Duan, W., Tian, A., Wang, X., McCleod, D., Lam, V., George, J., Qiao, L. (2013). Efficacy of Using Cancer Stem Cell Markers in Isolating and Characterising Liver Cancer Stem Cells. Stem Cells and Development, 22(19), 2655-2664. [More Information]
- George, J., George, R., Dixit, R., Gupta, R., Gupta, N. (2013). Fat embolism syndrome. Lung India, 30(1), 47-53. [More Information]
- Robotin, M., Patton, Y., George, J. (2013). Getting it right: The impact of a continuing medical education program on hepatitis B knowledge of Australian primary care providers. International Journal of General Medicine, 6, 115-122. [More Information]
- Barman, A., Bhide, R., Viswanathan, A., George, J., Thomas, R., Tharion, G. (2013). Gorham's disease of the spine. NeuroRehabilitation, 33(1), 121-126. [More Information]
- van der Poorten, D., Samer, C., Ramezani-Moghadam, M., Coulter, S., Kacevska, M., Schrijnders, D., Wu, L., McLeod, D., Bugianesi, E., Komuta, M., Liddle, C., Hebbard, L., George, J., et al (2013). Hepatic Fat Loss in Advanced Nonalcoholic Steatohepatitis: Are Alterations in Serum Adiponectin the Cause? Hepatology, 57(6), 2180-2188. [More Information]
- Sacks-Davis, R., Atiken, C., Higgs, P., Spelman, T., Pedrana, A., Bowden, S., Bharadwaj, M., Nivarthi, U., Suppiah, V., George, J., et al (2013). High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: A prospective cohort study. PloS One, 8(11), 1-12. [More Information]
- Rekhraj, S., Gandy, S., Szwejkowski, B., Nadir, M., Noman, A., Houston, J., Lang, C., George, J., Struthers, A. (2013). High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. Journal of the American College of Cardiology, 61(9), 926-932. [More Information]
- Gelinas, J., Fabre, T., Willems, P., Leung, R., George, J., Willems, B., Bruneau, J., Shoukry, N. (2013). IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test. Immunogenetics, 65(6), 397-403. [More Information]
- Fischer, J., Bohm, S., George, J., Sarrazin, C., Berg, T. (2013). Impact of cohort size and host factors on combined analysis of interleukin 28B rs12979860 and rs8099917 in hepatitis c virus infection. Hepatology, 57(1), 416-417. [More Information]
- Feige, E., Yacov, N., Salem, Y., Levi, I., Mendel, I., Propheta-Meiran, O., Shoham, A., Hait-Darshan, R., Polonsky, O., George, J., et al (2013). Inhibition of monocyte chemotaxis by VB-201, a small molecule lecinoxoid, hinders atherosclerosis development in ApoE-/- mice. Atherosclerosis, 229(2), 430-439. [More Information]
- Eslam, M., Booth, D., George, J., Ahlenstiel, G. (2013). Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection. World Journal of Gastroenterology, 19(41), 7055-7061. [More Information]
- Anderson, W., Lipworth, B., Rekhraj, S., Struthers, A., George, J. (2013). Left ventricular hypertrophy in COPD without hypoxemia: The elephant in the room? Chest, 143(1), 91-97. [More Information]
- Booth, D., George, J. (2013). Loss of function of the new interferon IFN-λ4 may confer protection from hepatitis C. Nature Genetics, 45(2), 119-120. [More Information]
- Schwartzenberg, S., Meledin, V., Zilberman, L., Goland, S., George, J., Shimoni, S. (2013). Low circulating monocyte count is associated with severe aortic valve stenosis. IMAJ, 15(9), 568-572.
- Charach, G., Rabinovich, A., Ori, A., Weksler, D., Sheps, D., Charach, L., Weintraub, M., George, J. (2013). Low levels of low-density lipoprotein cholesterol: A negative predictor of survival in elderly patients with advanced heart failure. Cardiology, 127(1), 45-50. [More Information]
- Barrera Martinez, F., George, J. (2013). Non-alcoholic fatty liver disease: more than just ectopic fat accumulation. Drug Discovery Today: Disease Mechanisms, 10(1-2), e47-e54. [More Information]
- Hashemi, S., van der Poorten, D., Barrera Martinez, F., Bandara, P., Lux, O., Kench, J., George, J. (2013). Oxidative stress is closely associated with insulin resistance in genotypes 1 and 3 chronic hepatitis C. Hepatology International, 7(2), 516-523. [More Information]
- Grebely, J., Feld, J., Applegate, T., Matthews, G., Hellard, M., Sherker, A., Petoumenos, K., Zang, G., Shaw, I., Yeung, B., George, J., et al (2013). Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology, 57(6), 2124-2134. [More Information]
- Sublette, V., Douglas, M., McCaffery, K., George, J., Nicholson Perry, K. (2013). Psychological, lifestyle and social predictors of hepatitis c treatment response: a systematic review. Liver International, 33(6), 894-903. [More Information]
- Dong, Z., Su, L., Brymora, J., Bird, C., Xie, Q., George, J., Wang, J. (2013). Resistin mediates the hepatic stellate cell phenotype. World Journal of Gastroenterology, 19(28), 4475-4485. [More Information]
- Angulo, P., Bugianesi, E., Bjornsson, E., Charatcharoenwitthaya, P., Mills, P., Barrera Martinez, F., Haflidadottir, S., Day, C., George, J. (2013). Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology, 145(4), 782-789. [More Information]
- Mahady, S., George, J. (2013). The Future Liver of the Asia Pacific: Fatter and Firmer from More Fructose and Fortune? Journal of Clinical and Experimental Hepatology, 3(2), 106-113. [More Information]
- Poustchi, H., Eslami, M., Ostovaneh, M., Modabbernia, A., Saeedian, F., Taslimi, S., George, J., Malekzadeh, R., Zamani, F. (2013). Transient elastography in hepatitis C virus-infected patients with beta-thalassemia for assessment of fibrosis. Hepatology Research, 43(12), 1276-1283. [More Information]
- Wilson, G., Tian, A., Hebbard, L., Duan, W., George, J., Li, X., Qiao, L. (2013). Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro. Cancer Letters, 341(2), 224-230. [More Information]
- Vongsuvanh, R., George, J., Qiao, L., van der Poorten, D. (2013). Visceral adiposity in gastrointestinal and hepatic carcinogenesis. Cancer Letters, 330(1), 1-10. [More Information]
- Kitson, M., Dore, G., George, J., Button, P., McCaughan, G., Crawford, D., Sievert, W., Weltman, M., Cheng, W., Roberts, S. (2013). Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. Journal of Hepatology, 58(3), 467-472. [More Information]
- Nguyen, V., George, J., van der Poorten, D. (2012). A maxillary mass in a HBV-cirrhotic patient. Liver International, 32(6), 988-988. [More Information]
- Rahman, W., Huang, P., Belov, L., Chrisp, J., Christopherson, R., Stapelberg, P., Warner, F., George, J., Bowen, D., Strasser, S., Koorey, D., Sharland, A., McCaughan, G., Shackel, N. (2012). Analysis of human liver disease using a cluster of differentiation (CD) antibody microarray. Liver International, 32(10), 1527-1534. [More Information]
- Fischer, J., Bohm, S., Scholz, M., Muller, T., Witt, H., George, J., Sarrazin, C., Susser, S., Schott, E., Suppiah, V., Booth, D., Stewart, G., et al (2012). Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology, 55(6), 1700-1710. [More Information]
- Raftopoulos, S., George, J., Bourliere, M., Rossi, E., de Boer, W., Jeffrey, G., Bulsara, M., Speers, D., MacQuillan, G., Ching, H., McLeod, D., et al (2012). Comparison of noninvasive models of fibrosis in chronic hepatitis B. Hepatology International, 6(2), 457-467. [More Information]
- Robotin, M., Patton, Y., Kansil, M., Penman, A., George, J. (2012). Cost of treating chronic hepatitis B: Comparison of current treatment guidelines. World Journal of Gastroenterology, 18(42), 6106-6113. [More Information]
- Johnson, N., van Overbeek, D., Chapman, P., Thompson, M., Sachinwalla, T., George, J. (2012). Effect of prolonged exercise and pre-exercise dietary manipulation on hepatic triglycerides in trained men. European Journal of Applied Physiology, 112(5), 1817-1825. [More Information]
- Keating, S., Hackett, D., George, J., Johnson, N. (2012). Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Hepatology, 57(1), 157-166. [More Information]
- Johnson, N., Keating, S., George, J. (2012). Exercise and the Liver: Implications for Therapy in Fatty Liver Disorders. Seminars in Liver Disease, 32(1), 65-79. [More Information]
- Patin, E., Kutalik, Z., Guergnon, J., Bibert, S., Nalpas, B., Jouanguy, E., Munteanu, M., Bousquet, L., Argiro, L., Halfon, P., Suppiah, V., Stewart, G., Booth, D., George, J., et al (2012). Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection. Gastroenterology, 143(5), 1244-1252. [More Information]
- Gidding, H., Law, M., Amin, J., Ostapowicz, G., Weltman, M., Macdonald, G., Sasadeusz, J., Haber, P., George, J., Dore, G. (2012). Hepatitis C treatment outcomes in Australian clinics. Medical Journal of Australia, 196(10), 633-637. [More Information]
- Mahady, S., George, J. (2012). Management of nonalcoholic steatohepatitis: an evidence-based approach. Clinics in Liver Disease, 16(3), 631-645. [More Information]
- Parker, H., Johnson, N., Burdon, C., Cohn, J., O'Connor, H., George, J. (2012). Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Hepatology, 56(4), 944-951. [More Information]
- Booth, D., Ahlenstiel, G., George, J. (2012). Pharmacogenomics of hepatitis C infections: personalizing therapy. Genome Medicine, 4(12), 1-10. [More Information]
- Mahady, S., Wong, G., Craig, J., George, J. (2012). Pioglitazone and Vitamin E for Nonalcoholic Steatohepatitis: A Cost Utility Analysis. Hepatology, 56(6), 2172-2179. [More Information]
- Pianko, S., Zeuzem, S., Chuang, W., Foster, G., Sarin, S., Flisiak, R., Lee, C., Andreone, P., Piratvisuth, T., Shah, S., George, J., et al (2012). Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. Journal of Viral Hepatitis, 19(9), 623-634. [More Information]
- Poutschi, H., George, J. (2012). Reply. Hepatology, 55(6), 2039-2040. [More Information]
- Parker, H., Johnson, N., George, J. (2012). Reply to: "The optimal dose of omega-3 supplementation for non-alcoholic fatty liver disease". Journal of Hepatology, 57(2), 469-470. [More Information]
- Thein, H., Walter, S., Gidding, H., Amin, J., Law, M., George, J., Dore, G. (2012). Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort. Hepatology Research, 42(12), 1175-1186. [More Information]
- Grebely, J., Hellard, M., Applegate, T., Petoumenos, K., Yeung, B., Feld, J., Rawlinson, W., Lloyd, A., George, J., Kaldor, J., et al (2012). Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. AIDS, 26(13), 1653-1661. [More Information]
- Vongsuvanh, R., George, J., McLeod, D., van der Poorten, D. (2012). Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 57(2), 392-398. [More Information]
- Ahlenstiel, G., Booth, D., George, J. (2012). Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms? Antiviral Therapy, 17(6 Pt B), 1163-1170. [More Information]
- Hebbard, L., George, J. (2011). Animal models of nonalcoholic fatty liver disease. Nature Reviews. Gastroenterology & Hepatology, 8(1), 35-44. [More Information]
- Ahlenstiel, G., Booth, D., George, J. (2011). Clinical significance of IL28B gene variation in hepatitis C virus infection. Hot Topics in viral Hepatitis, (20), 17-24. [More Information]
- Adams, L., George, J., Bugianesi, E., Rossi, E., de Boer, W., van der Poorten, D., Ching, H., Bulsara, M., Jeffrey, G. (2011). Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology, 26(10), 1536-1543. [More Information]
- Poustchi, H., Farrell, G., Strasser, S., Lee, A., McCaughan, G., George, J. (2011). Feasibility of conducting a randomised control trial for liver cancer screening: Is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology, 54(6), 1998-2004. [More Information]
- Poustchi, H., George, J., Esmaili, S., Esna-Ashari, F., Ardalan, G., Sepanlou, G., Alavian, S. (2011). Gender differences in healthy ranges for serum alanine aminotransferase levels in adolescence. PloS One, 6(6), e21178-1-e21178-7. [More Information]
- Smith, K., Suppiah, V., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Matthews, G., Irving, W., Ahlenstiel, G., Stewart, G., George, J., Booth, D., et al (2011). Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Medicine, 3(8), 57-1-57-13. [More Information]
- Suppiah, V., Gaudieri, S., Armstrong, N., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Dore, G., Ahlenstiel, G., Stewart, G., George, J., Booth, D., et al (2011). IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study. PLoS Medicine, 8(9), e1001092-1-e1001092-8. [More Information]
- Liu, Y., Brymora, J., Zhang, H., Smith, B., Ramezani-Moghadam, M., George, J., Wang, J. (2011). Leptin and Acetaldehyde Synergistically Promotes aSMA Expression in Hepatic Stellate Cells by an Interleukin 6-Dependent Mechanism. Alcoholism: Clinical and Experimental Research, 35(5), 921-928. [More Information]
- Park, G., Wiseman, E., George, J., Katelaris, P., Seow, F., Fung, C., Ngu, M. (2011). Non-invasive Estimation of Liver Fibrosis in Non-alcoholic Fatty Liver Disease Using the (13) C-Caffeine Breath Test. Journal of Gastroenterology and Hepatology, 26(9), 1411-1416. [More Information]
- Patel, K., Jhaveri, R., George, J., Qiang, G., Kenedi, C., Brown, K., Cates, C., Zekry, A., Tillmann, H., Elliott, L., et al (2011). Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C. Journal of Viral Hepatitis, 18(5), 331-337. [More Information]
- Pattullo, V., Douglas, M., George, J. (2011). Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis? Expert Review of Gastroenterology and Hepatology, 5(2), 265-277. [More Information]
- Gidding, H., Law, M., Amin, J., Macdonald, G., Sasadeusz, J., Jones, T., Strasser, S., George, J., Dore, G. (2011). Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Medical Journal of Australia, 194(8), 398-402. [More Information]
- Walter, S., Thein, H., Gidding, H., Amin, J., Law, M., George, J., Dore, G. (2011). Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. Journal of Gastroenterology and Hepatology, 26(12), 1757-1764. [More Information]
- Jacobson, I., McHutchison, J., Dusheiko, G., Di Bisceglie, A., Reddy, K., Bzowej, N., Marcellin, P., Muir, A., Ferenci, P., Flisiak, R., George, J., et al (2011). Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection. New England Journal of Medicine, 364(25), 2405-2416. [More Information]
- Bhala, N., Angulo, P., van der Poorten, D., Lee, E., Hui, J., Saracco, G., Adams, L., Charatcharoenwitthaya, P., Topping, J., Bugianesi, E., George, J., et al (2011). The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study. Hepatology, 54(4), 1208-1216. [More Information]
- Mahady, S., Webster, A., Walker, S., Sanyal, A., George, J. (2011). The role of thiazolidinediones in non-alcoholic steatohepatitis - A systematic review and meta analysis. Journal of Hepatology, 55(6), 1383-1390. [More Information]
- Thein, H., Walter, S., Gidding, H., Amin, J., Law, M., George, J., Dore, G. (2011). Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992-2007. Journal of Viral Hepatitis, 18(7), e232-e241. [More Information]
- Walter, S., Thein, H., Amin, J., Gidding, H., Ward, K., Law, M., George, J., Dore, G. (2011). Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. Journal of Hepatology, 54(5), 879-886. [More Information]
- Johnson, N., George, J. (2010). An Active Part in Treating Liver Disease. Exercise In Medical Conditions: Exercise And Non-Alcoholic Fatty Liver Disease. SportEx Health, 25, 18-20.
- Milner, K., van der Poorten, D., Trenell, M., Jenkins, A., Xu, A., Smythe, G., Dore, G., Zekry, A., Weltman, M., Fragomeli, V., George, J., et al (2010). Chronic Hepatitis C is Associated with Peripheral rather than Hepatic Insulin Resistance. Gastroenterology, 138(3), 932-941. [More Information]
- Johnson, N., George, J. (2010). Fitness Versus Fatness: Moving Beyond Weight Loss in Nonalcoholic Fatty Liver Disease. Hepatology, 52(1), 370-381. [More Information]
- van der Poorten, D., Shahidi, M., Tay, E., Sesha, J., Tran, K., McLeod, D., Milliken, J., Ho, V., Hebbard, L., Douglas, M., George, J. (2010). Hepatitis C Virus Induces the Cannabinoid Receptor 1. PloS One, 5(9), 1-10. [More Information]
- Mahady, S., George, J. (2010). How to Treat: Hepatitis C infection. Australian Doctor, , 1-6.
- Ahlenstiel, G., Booth, D., George, J. (2010). IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. Journal of Gastroenterology and Hepatology, 45(9), 903-910. [More Information]
- Bhala, N., Usherwood, T., George, J. (2010). Nichtalkoholische Fettlebererkrankung [Non-alcoholic fatty liver]. Praxis, 99(3), 187-189. [More Information]
- Grebely, J., Petoumenos, K., Hellard, M., Matthews, G., Suppiah, V., Applegate, T., Yeung, B., Marks, P., Rawlinson, W., Lloyd, A., Booth, D., George, J., et al (2010). Potential Role for Interleukin-28B Genotype in Treatment Decision-Making in Recent Hepatitis C Virus Infection. Hepatology, 52(4), 1216-1224. [More Information]
- Patterson, S., George, J., Strasser, S., Lee, A., Sievert, W., Nicoll, A., Desmond, P., Roberts, S., Locarnini, S., Bowden, S., et al (2010). Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut, 60(2), 247-254. [More Information]
- Hebbard, L., George, J. (2010). The chicken or the egg: adipocytes and hepatic insulin resistance. Hepatology, 51(3), 1076-1079. [More Information]
- Robotin, M., Kansil, M., George, J., Howard, K., Tipper, S., Levy, M., Phung, N., Penman, A. (2010). Using a population-based approach to prevent hepatocellular cancer in New South Wales, Australia: effects on health services utilisation. BMC Health Services Research, 10, 215-224. [More Information]
- Milner, K., van der Poorten, D., Xu, A., Bugianesi, E., Kench, J., Lam, K., Chisholm, D., George, J. (2009). Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology, 49(6), 1926-1934. [More Information]
- Smith, B., George, J. (2009). Adipocyte-hepatocyte crosstalk and the pathogenesis of nonalcoholic fatty liver disease. Hepatology, 49(5), 1765-1767. [More Information]
- Johnson, N., Sachinwalla, T., Walton, D., Smith, K., Armstrong, A., Thompson, M., George, J. (2009). Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology, 50(4), 1105-1112. [More Information]
- Robotin, M., Kansil, M., Howard, K., George, J., Tipper, S., Dore, G., Levy, M., Penman, A. (2009). Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. Journal of Hepatology, 50(5), 990-998. [More Information]
- Booth, M., Dobbins, T., Aitken, R., Denney-Wilson, E., Hardy, L., Okely, A., George, J., Sullivan, D., Cowell, C. (2009). Costs of managing conditions associated with obesity among Australian teenagers. Journal of Paediatrics and Child Health, 45(7-8), 448-456. [More Information]
- Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M., Bassendine, M., Spengler, U., Dore, G., Powell, E., Stewart, G., Booth, D., George, J., et al (2009). IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature Genetics, 41(10), 1100-1104. [More Information]
- Johnson, N., St George, A., George, J. (2009). Impact of lifestyle modification on patients with chronic liver disease. Hot Topics in viral Hepatitis, 5(14), 17-22. [More Information]
- St George, A., Bauman, A., Johnston, A., Farrell, G., Chey, T., George, J. (2009). Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology, 50(1), 68-76. [More Information]
- Wang, J., Leclercq, I., Brymora, J., Xu, N., Ramezani-Moghadam, M., London, R., Brigstock, D., George, J. (2009). Kupffer Cells Mediate Leptin-Induced Liver Fibrosis. Gastroenterology, 137(2), 713-723. [More Information]
- Douglas, M., George, J. (2009). Molecular mechanisms of insulin resistance in chronic hepatitis C. World Journal of Gastroenterology, 15(35). [More Information]
- Bhala, N., Usherwood, T., George, J. (2009). Non-alcoholic fatty liver disease. BMJ: British Medical Journal, 339(b2474), 513-514. [More Information]
- George, J., Robotin, M. (2009). Overview: Hepatocellular carcinoma - the future starts now. Cancer Forum, 33(2), 83-87.
- Phung, T., Pera, N., Farrell, G., Leclercq, I., Hou, J., George, J. (2009). Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. International Journal of Molecular Medicine, 24, 171-180. [More Information]
- Milner, K., Chisholm, D., George, J. (2009). The many faces of hepatitis C: liver disease and type 2 diabetes. Hepatology, 50(3), 668-670. [More Information]
- Van Hazel, G., Pavlakis, N., Goldstein, D., Olver, I., Tapner, M., Price, D., Bower, G., Briggs, G., Rossleigh, M., Taylor, D., George, J. (2009). Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy. Journal of Clinical Oncology, 27(25), 4089-4095. [More Information]
- Poustchi, H., Mohamadkhani, A., Bowden, S., Montazeri, G., Ayres, A., Revill, P., Farrell, G., Locarnini, S., George, J., Malekzadeh, R. (2008). Clinical significance of precore and core promoter mutations in genotype D hepatitis B-related chronic liver disease. Journal of Viral Hepatitis, 15(10), 753-760. [More Information]
- van der Poorten, D., George, J. (2008). Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. Clinics in Liver Disease, 12(4), 805-824. [More Information]
- St George, A., Bauman, A., Johnston, A., Farrell, G., Chey, T., George, J. (2008). Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. Hepatology, 24(3), 399-407. [More Information]
- Cua, I., Hui, J., Kench, J., George, J. (2008). Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology, 48(3), 723-731. [More Information]
- Poustchi, H., Negro, F., Hui, J., Cua, I., Brandt, L., Kench, J., George, J. (2008). Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. Journal of Hepatology, 48(1), 28-34. [More Information]
- Cua, I., George, J. (2008). Insulin resistance, adipocytokines and HCV infection: A missing link? Hepatology, 47, 760-761.
- George, J., Liddle, C. (2008). Nonalcoholic fatty liver disease: Pathogenesis and potential for nuclear receptors as therapeutic targets. Molecular Pharmaceutics, 5(1), 49-59. [More Information]
- van der Poorten, D., George, J. (2008). Nonalcoholic steatohepatitis is frequently acompanied by metabolic diseases: Reply to the Editor. Hepatology, 48(5), 1729. [More Information]
- Johnson, N., Walton, D., Sachinwalla, T., Thompson, C., Smith, K., Ruell, P., Stannard, S., George, J. (2008). Noninvasive assessment of hepatic lipid composition: advancing understanding and management of fatty liver disorders. Hepatology, 47, 1513-1523. [More Information]
- van der Poorten, D., Kenny, D., George, J. (2008). Prevalence of and risk factors for hepatitis C in Aboriginal and non-Aboriginal adolescent offenders. Medical Journal of Australia, 188(10), 610-614. [More Information]
- Robotin, M., George, J., Supramaniam, R., Sitas, F., Penman, A. (2008). Preventing primary liver cancer: how well are we faring towards a national hepatitis B strategy? Medical Journal of Australia, 188(6), 363-365. [More Information]
- Johnson, N., Sachinwalla, T., George, J. (2008). Reply: In Vitro Proton Magnetic Resonance Spectroscopy of Liver Tissue Informs In Vivo Hepatic Proton Magnetic Resonance Spectroscopy Studies. Hepatology, 48(3), 1016-1017. [More Information]
- Wang, J., Brymora, J., George, J. (2008). Roles of adipokines in liver injury and fibrosis. Expert Review of Gastroenterology and Hepatology, 2(1), 47-57. [More Information]
- George, J., Denney-Wilson, E., Okely, A., Hardy, L., Aitken, R. (2008). The population distributions, upper normal limits and correlations between liver tests among Australian adolescents. Journal of Paediatrics and Child Health, 44(10), 579-585. [More Information]
- Booth, M., George, J., Denney-Wilson, E., Okely, A., Hardy, L., Aitken, R., Dobbins, T. (2008). The population prevalence of adverse concentrations and associations with adiposity of liver tests among Australian adolescents. Journal of Paediatrics and Child Health, 44(12), 686-691. [More Information]
- Yan, K., Guirgis, M., Dinh, T., George, J., Dev, A., Lee, A., Zekry, A. (2008). Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World Journal of Gastroenterology, 14(21), 3416-3420. [More Information]
- van der Poorten, D., Milner, K., Hui, J., Hodge, A., Trenell, M., Kench, J., London, R., Peduto, A., Chisholm, D., George, J. (2008). Visceral fat: A key mediator of steatohepatitis in metabolic liver disease. Hepatology, 48(2), 449-457. [More Information]
- van der Poorten, D., Kenny, D., George, J. (2007). A new upper limit for alanine aminotransferase and risk factors for raised alt and hepatitis C in adolescents: a study of 439 male adolescent offenders on community orders. Journal of Gastroenterology and Hepatology, 22(Supplement 3), A344-A344.
- Angulo, P., George, J., Marchesini, G., Bugianesi, E., Farrell, G., Day, C. (2007). Author's reply: Non-invasive markers of advanced histology in nonalcoholic fatty liver disease. Gastroenterology, 133(4), 1377-1378.
- van der Poorten, D., George, J. (2007). Current and novel therapies for the treatment of nonalcoholic steatohepatitis. Hepatology International, 1(3), 343-354. [More Information]
- Cua, I., Hui, J., Bandara, P., Kench, J., Farrell, G., McCaughan, G., George, J. (2007). Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology, 46(1), 66-73. [More Information]
- van der Poorten, D., Kenny, D., Butler, T., George, J. (2007). Liver disease in adolescents: A cohort study of high-risk individuals. Hepatology, 46(6), 1750-1758. [More Information]
- Razali, K., Thein, H., Bell, J., Cooper-Stanbury, M., Dolan, K., Dore, G., George, J., Kaldore, J., Karvelas, M., Li, J., Weltman, M., et al (2007). Modelling the hepatitis C virus epidemic in Australia. Drug and Alcohol Dependence, 91(39509), 228-235. [More Information]
- London, R., George, J. (2007). Pathogenesis of NASH: Animal Models. Clinics in Liver Disease, 11(1), 55-74. [More Information]
- Cua, I., George, J. (2007). Reply. Hepatology, 46(6), 2051. [More Information]
- Angulo, P., Hui, J., Marchesini, G., Bugianesi, E., George, J., Farrell, G., Enders, F., Saksena, S., Burt, A., Bida, J., Kench, J., et al (2007). The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 45(4), 846-854. [More Information]
- George, J. (2006). Angiopoietin-like proteins: Another player in the metabolic field. Journal of Hepatology, 44(4), 832-834. [More Information]
- Bugianesi, E., Marchesini, G., Gentilcore, E., Cua, I., Vanni, E., Rizzetto, M., George, J. (2006). Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology, 44(6), 1648-1655. [More Information]
- Salmond, S., George, J., Strasser, S., Batey, R. (2006). Hep573 study of complementary medicine for chronic hepatitis C. Journal Of Clinical Virology, 36(Supplement 2), S134-S135.
- Chitturi, S., George, J. (2006). Hepatitis C and overweight. Hot Topics in viral Hepatitis, 2, 15-21.
- Cua, I., George, J. (2006). Interpretation of abnormal liver tests in patients with diabetes. Diabetes Management Journal, 14, 30-31.
- Cua, I., George, J. (2006). Interpretation of abnormal liver tests in patients with diabetes. Diabetes Management Journal, 14, 30.
- Cua, I., Hui, J., Bandara, P., Kench, J., McCaughan, G., George, J. (2006). Is insulin resistance and liver injury in chronic hepatitis C associated with virus-specific alteration in the levels of serum adipocytokines? Journal of Gastroenterology and Hepatology, 21, A22-A22.
- St George, A., Johnston, A., Bauman, A., Iverson, D., Tapsell, L., McCaughan, G., Strasser, S., McGrath, L., Green, J., Farrell, G., George, J. (2006). Lifestyle intervention in early liver disease: metabolic changes at 3 months. Journal of Gastroenterology and Hepatology, 21(Suppl. 4), A315.
- Cua, I., Kwan, V., Henriquez, M., Kench, J., George, J. (2006). Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis. Gut, 55(10), 1521-1522. [More Information]
- Leandro, G., Mangia, A., Hui, J., Fabris, P., Rubbia-Brandt, L., Colloredo, G., Adinolfi, L., Asselah, T., Jonsson, J., Smedile, A., George, J., et al (2006). Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology, 130(6), 1636-1642. [More Information]
- Wang, J., Batey, R., George, J. (2006). Role of ethanol in the regulation of hepatic stellate cell function. World Journal of Gastroenterology, 12(43), 6926-6932. [More Information]
- Poustchi, H., George, J., Farrell, G. (2006). The efficacy of a liver cancer screening program on cancer detection and patient survival. Journal of Gastroenterology and Hepatology, 21, A52-A52.
- Helbig, K., George, J., Beard, M. (2005). A novel I-TAC promoter polymorphic variant is functional in the presence of replicating HCV in vitro. Journal Of Clinical Virology, 32(2), 137-143. [More Information]
- Bandara, P., George, J., McCaughan, G., Naidoo, D., Lux, O., Salonikas, C., Kench, J., Byth Wilson, K., Farrell, G. (2005). Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C. Liver International, 25(3), 518-526. [More Information]
- Perry, J., Poustchi, H., George, J., Farrell, G., McCaughan, G., Strasser, S. (2005). Current approaches to the diagnosis and management of hepatocellular carcinoma. Clinical and Experimental Medicine, 5(1), 1-13. [More Information]
- Adams, L., Bulsara, M., Rossi, E., DeBoer, B., Speers, D., George, J., Kench, J., Farrell, G., McCaughan, G., Jeffrey, G. (2005). Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clinical Chemistry, 51(10), 1867-1873. [More Information]
- Kumar, U., Farrell, G., Kench, J., George, J. (2005). Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. Journal of Gastroenterology and Hepatology, 20(9), 1395-1400. [More Information]
- Dela Pena, A., Leclercq, I., Field, J., George, J., Jones, B., Farrell, G. (2005). NF-kappa B activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology, 129(5), 1663-1674. [More Information]
- Cua, I., George, J. (2005). Non-alcoholic fatty liver disease. British Journal of Hospital Medicine, 66(2), 106-111. [More Information]
- Hui, J., George, J. (2005). Reply: Adiponectin – Tipping the scales from NAFLD to NASH. Gastroenterology, 128(2), 513-513. [More Information]
- Hui, J., George, J. (2005). Reply: Reduced plasma adiponectin: central obesity as an underestimated causative risk factor. Hepatology, 41, 401-402. [More Information]
- Hui, J., Hodge, A., Farrell, G., Kench, J., Kriketos, A., George, J. (2004). Beyond Insulin Resistance In Nash: Tnf-Alpha Or Adiponectin? Hepatology, 40(1), 46-54. [More Information]
- Coverdale, S., Khan, M., Byth Wilson, K., Lin, R., Weltman, M., George, J., Samarasinghe, D., Liddle, C., Farrell, G., Kench, J., Crewe, E. (2004). Effects Of Interferon Treatment Response On Liver Complications Of Chronic Hepatitis C: 9-Year Follow-Up Study. American Journal of Gastroenterology, 99(4), 636-644. [More Information]
- McCaughan, G., George, J. (2004). Fibrosis Progression In Chronic Hepatitis C Virus Infection. Gut, 53(3), 318-321. [More Information]
- Hui, J., Farrell, G., Kench, J., George, J. (2004). High sensitivity C-reactive protein values do not reliably predict the severity of histological change in NAFLD. Hepatology, 39(5), 1458-1459. [More Information]
- Sud, A., Hui, J., Farrell, G., Bandara, P., Kench, J., Fung, C., Lin, R., Samarasinghe, D., Liddle, C., McCaughan, G., George, J. (2004). Improved Prediction Of Fibrosis In Chronic Hepatitis C Using Measures Of Insulin Resistance In A Probability Index. Hepatology, 39(5), 1239-1247. [More Information]
- Kwan, V., George, J. (2004). Liver Disease Due To Parenteral And Enteral Nutrition. Clinics in Liver Disease, 8(4), 893-913, ix-x.
- Chitturi, S., Farrell, G., George, J. (2004). Non-Alcoholic Steatohepatitis In The Asia-Pacific Region: Future Shock? Journal of Gastroenterology and Hepatology, 19(4), 368-374. [More Information]
- Zeuzem, S., Diago, M., Gane, E., Reddy, K., Pockros, P., Prati, D., Shiffman, M., Farci, P., Gitlin, N., O'Brien, C., George, J., et al (2004). Peginterferon Alfa-2a (40 Kilodaltons) and Ribavirin in Patients With Chronic Hepatitis C and Normal Aminotransferase Levels. Gastroenterology, 127(6), 1724-1732. [More Information]
- Shao, R., Shi, Z., Gotwals, P., Koteliansky, V., George, J., Rockey, D. (2003). Cell and molecular regulation of endothelin-1 production during hepatic wound healing. Molecular Biology of the Cell, 14(6), 2327-2341. [More Information]
- Coverdale, S., Samarasinghe, D., Lin, R., Kench, J., Byth Wilson, K., Khan, M., Crewe, E., Liddle, C., George, J., Farrell, G. (2003). Changes in Antipyrine Clearance and Platelet Count, but Not Conventional Liver Tests, Correlate With Fibrotic Change in Chronic Hepatitis C: Value for Predicting Fibrotic Progression. American Journal of Gastroenterology, 98(6), 1384-1390. [More Information]
- Kumar, D., Wallington-Beddoe, C., George, J., Lin, R., Samarasinghe, D., Liddle, C., Farrell, G. (2003). Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hapatitis c in a clinic setting. Medical Journal of Australia, 178(6), 267-271.
- Hui, J., Sud, A., Farrell, G., Bandara, P., Byth Wilson, K., Kench, J., McCaughan, G., George, J. (2003). Insulin resistance is associated with chronic Hepatitis C and virus infection fibrosis progression. Gastroenterology, 125(6), 1695-1704. [More Information]
- Chitturi, S., George, J. (2003). Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Current Gastroenterology, 5(1), 18-25. [More Information]
- George, J. (2003). Invited Book Review – Hepatitis C: An Australian perspective. Eds. N Crofts, G Dore and S Locarnini. Internal Medicine Journal, 33(1), 64-64.
- George, J., Pera, N., Phung, T., Leclercq, I., Hou, J., Farrell, G. (2003). Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. Journal of Hepatology, 39(5), 756-764. [More Information]
- Hui, J., Kench, J., Chitturi, S., Sud, A., Farrell, G., Blyth, K., Hall, P., Khan, M., George, J. (2003). Long term outcomes of cirrhosis in nonalcoholic steatohepatitis compares with hepatitis c. Hepatology, 38(2), 420-427. [More Information]
- Perry, J., Strasser, S., George, J., Farrell, G., McCaughan, G. (2003). Pharmacotherapy of hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 4(12), 2175-2185. [More Information]
- Chitturi, S., Farrell, G., George, J. (2003). Reply: Iron and HFE mutations in nonalcoholic steatohepatitis: Innocent bystanders or accessories to the crime? Gastroenterology, 125(2), 616-616.
- Lee, D., Chitturi, S., Kench, J., George, J., Fuller, S., Bradstock, K., Lin, R., Wong, K., Young, N. (2003). Transjugular liver biopsy effecting changes in clinical management. Journal of Medical Imaging and Radiation Oncology, 47(2), 117-120. [More Information]
- Hui, J., George, J., Liddle, C., Lin, R., Samarasinghe, D., Crewe, E., Farrell, G. (2002). Changes in Serum Albumin During Treatment of Chronic Hepatitis B With Lamivudine: Effects of Response and Emergence of Drug Resistance. American Journal of Gastroenterology, 97(4), 1003-1009. [More Information]
- Teoh, N., George, J. (2002). Evaluating patients who have abnormal liver tests. Medicine Today, 3(10), 58-67.
- Chitturi, S., George, J., Ranjitkumar, S., Kench, J., Benson, W. (2002). Exchange Transfusion for Severe Intrahepatic Cholestasis Associated With Sickle Cell Disease. Journal of Clinical Gastroenterology, 35(4), 362-363. [More Information]
- Alonso, C., George, J., Pesce, C., Bissell, D., Kornblihtt, A. (2002). Fibronectin transcription in liver cells: promoter occupation and function in sinusoidal endothelial cells and hepatocytes. Biochemical and Biophysical Research Communications, 295(5), 1077-1084. [More Information]
- Hui, J., Kench, J., Farrell, G., Lin, R., Samarasinghe, D., Liddle, C., Byth, K., George, J. (2002). Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. Journal of Gastroenterology and Hepatology, 17(8), 873-881. [More Information]
- Chitturi, S., Le, V., Kench, J., Loh, C., George, J. (2002). Gliclazide-Induced Acute Hepatitis with Hypersensitivity Features. Digestive Diseases and Sciences, 47(5), 1107-1110. [More Information]
- Hui, J., Farrell, G., Lin, R., Samarasinghe, D., Liddle, C., George, J., Kench, J., Byth, K. (2002). Hepatic Steatosis in Chronic Hepatitis C Infection. Journal of Gastroenterology and Hepatology, 17(8), 873-881.
- Kumar, S., Farrell, G., Fung, C., George, J. (2002). Hepatitis C Virus Genotype 3 is Cytopathic to Hepatocytes: Reversal of Hepatic Steatosis after Sustained Therapeutic Response. Hepatology, 36(5), 1266-1272. [More Information]
- Chitturi, S., George, J. (2002). Hepatotoxicity of Commonly Used Drugs: nonsteroidal Anti-Inflammatory Drugs, Antihypertensives, Antidiabetic Agents, Anticonvulsants, Lipid-Lowering Agents, Psychotropic Drugs. Seminars in Liver Disease, 22(2), 169-183. [More Information]
- Chitturi, S., Weltman, M., Farrell, G., McDonald, D., Liddle, C., Samarasinghe, D., Lin, R., Abeygunasekera, S., George, J. (2002). HFE Mutations, Hepatic Iron, and Fibrosis: Ethnic-Specification Association of NASH with C282Y but not with Fibrotic Severity. Hepatology, 36(1), 142-149. [More Information]
- Chitturi, S., Abeygunasekera, S., Farrell, G., Holmes-Walker, J., Hui, J., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., Weltman, M., George, J. (2002). NASH and Insulin Resistance: Insulin Hypersecretion and Specific Association with the Insulin Resistance Syndrome. Hepatology, 35(2), 373-379. [More Information]
- Chitturi, S., Farrell, G., Frost, L., Kriketos, A., Lin, R., Liddle, C., Samarasinghe, D., George, J. (2002). Serum Leptin in NASH Correlates with Hepatic Steatosis but not Fibrosis: A Manifestation of Lipotoxicity? Hepatology, 36(2), 403-409. [More Information]
- Wong, V., Fu, A., George, J., Cheung, N. (2002). Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clinical Endocrinology, 56(6), 793-798. [More Information]
- Chitturi, S., Hui, J., Salisbury, E., Mitchell, D., George, J. (2001). Abdominal pain in an intrauterine contraceptive devise user. Postgraduate Medical Journal, 77, 602-610.
- Chitturi, S., Abeygunasekera, S., Fung, C., Samarasinghe, D., Lin, R., McDonald, D., Weltman, M., Farrell, G., George, J. (2001). Haemochromatosis gene mutations, hepatic iron content and nonalcoholic steatohepatitis. Hepatology, 19, 1768-1778.
- George, J., Hui, J., Farrell, G., Lin, R., Samarasinghe, D., Kench, J. (2001). Predictors for steatosis and fibrosis in chronic hepatitis C. Journal of Hepatology, 34, 153-153.
- Farrell, G., Liddle, C., Samarasinghe, D., Lin, R., George, J., Chitturi, S., Frost, L. (2001). Serum Leptin: An independent predictor of hepatic steatosis but not fibrotic severity in nonalcoholic steatohepatitis. Hepatology, 34, 752-752.
- Pera, N., Phung, H., Leclercq, I., Farrell, G., George, J. (2001). This role of oxidative stress in the evolution of hepatic fibrogenesis in a rodent model of nonalcoholic steatohepatitis. Hepatology, 34, 1132-1132.
- Bissell,, D., Roulot, D., George, J. (2001). Transforming growth factor B and the liver. Hepatology, 34(5), 859-867.
- Phung, T., Farrell, G., Robertson, G., George, J. (2001). Vitamin E but not glutathione precursors ameliorates hepatic fibrosis in experimental NASH. Journal of Gastroenterology and Hepatology, 16.
- Phung, T., Farrell, G., Robertson, G., George, J. (2001). Vitamin E but not glutathione precursors inhibits hepatic fibrosis in experimental NASH exhibiting oxidative stress and mitochondrial abnormalities. Hepatology, 34, 756-756.
Conferences
- Parker, H., O'Connor, H., Cohn, J., Garg, M., Johnson, N., Caterson, I., George, J. (2015). Effect of combined fish oil plus coenzyme Q10 supplementation on Omega-3 Index and cardiovascular risk markers in overweight men. Joint Annual Scientific Meeting of the Nutrition Society of New Zealand and the Nutrition Society of Australia, New Zealand: Nutrition Society of Australia and Nutrition Society of New Zealand.
- Parker, H., O'Connor, H., Keating, S., Cohn, J., Garg, M., Caterson, I., George, J., Johnson, N. (2014). Efficacy of the Omega-3 Index in predicting NAFLD in overweight and obese adults: a pilot study. 2014 Australian and New Zealand Obesity Society Annual Scientific Meeting, Sydney, Australia: Australian and New Zealand Obesity Society.
- Parker, H., O'Connor, H., Keating, S., Cohn, J., Garg, M., Caterson, I., George, J., Johnson, N. (2014). Omega-3 Index and liver fat: an unexpected relationship. Nutrition Society of Australia 2014 Annual Scientific Meeting, Australia.
- Parker, H., Keating, S., O'Connor, H., Cohn, J., Caterson, I., George, J., Johnson, N. (2012). Can reported short-term dietary intake predict fatty liver? Nutrition Society of Australia 2012 Annual Scientific Meeting, Not-Known.
- Parker, H., Burdon, C., O'Connor, H., George, J., Cohn, J., Johnson, N. (2011). Omega-3 fatty acid supplementation for non-alcoholic fatty liver disease in humans: a systematic review and meta- analysis. International Conference on the Science of Nutrition in Medicine and Healthcare 2011, Sydney, Australia: The Science of Nutrition in Medicine and Healthcare.
- Farrell, G., Phung, T., Ip, E., Dela Pena, A., Robertson, G., Pera, N., George, J., Leclercq, I. (2002). Sources of oxidant stress in fatty liver disorders. Interactive mechanisms, and relevance to fibrosing steatohepatitis. AASLD Single Topic Conference NASH – Nonalcoholic Steatohepatitis.
- Phung, T., Farrell, G., Robertson, G., George, J. (2001). Antioxidant therapy with vitamin E ameliorates hepatic fibrosis in MCDD-associated NASH. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
- Leclercq, I., George, J., Farrell, G., Robertson, G., Field, J. (2001). Leptin is an essential mediator of hepatic fibrogenesis and liver regeneration in chronic CCl4-induced liver injury. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
- Pera, N., Phung, H., Leclercq, I., Farrell, G., George, J. (2001). Oxidative stress and the evolution of hepatic fibrogenesis in a rodent model of nonalcoholic steatohepatitis. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
- Coverdale, S., Samarasinghe, D., Lin, R., Liddle, C., George, J., Farrell, G., Kench, J., Byth, K., Khan, M., Crewe, E. (2001). Prediction of histological progression in chronic hepatitis C. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
- Pera, N., Phung, H., Leclercq, I., Farrell, G., George, J. (2001). The role of oxidative stress in the evolution of hepatic fibrogenesis in a rodent model of nonalcoholic steatohepatitis. The American Association for the Study of Liver Diseases 52nd Annual Meeting, : World Scientific Publishing.
Patents
- Booth, D., Ahlenstiel, G., George, J., O'Connor, K., Eslam, M. (2021). A method to predict rate of fibrosis in liver diseases. Patent No. 10,939,868.
Magazine / Newspaper Articles
- Singal, D., George, J. (2002). Chronic hepatitis C. Australian Doctor.
2024
- Pan, Z., Alharthi, J., Bayoumi, A., George, J., Eslam, M. (2024). A Cell Specific Effect of MBOAT7 MAFLD-risk Variant on Immune Cells. Frontiers in Bioscience - Landmark, 29(4), 148. [More Information]
- Zhang, H., Crespo, J., Grønbæk, H., Yang, W., Eslam, M., Wong, R., Machado, M., Yu, M., Ghanem, O., Okanoue, T., George, J., et al (2024). A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease. Hepatology International. [More Information]
- Feng, G., Schattenberg, J., Labenz, C., Mahadeva, S., Chan, W., Chi, X., Delamarre, A., De Ledinghen, V., Petta, S., Bugianesi, E., George, J., et al (2024). acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study. Clinical Gastroenterology and Hepatology. [More Information]
- Clark, P., Sinclair, M., George, J., Sievert, W., MacQuillan, G., Tse, E., Nicoll, A., Wade, A., Cheng, W., Roberts, S., et al (2024). Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study (OPERA-C). Drug and Alcohol Review. [More Information]
- Zhang, L., Turan, S., Alisi, A., Weiss, R., Faienza, M., Ashraf, A., Sundaram, S., Srivastava, A., De Bruyne, R., Kang, Y., Baur, L., George, J., et al (2024). An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease. Med, 5(7), 797-815.e2. [More Information]
- Kouvari, M., Mantzoros, C., Valenzuela-Vallejo, L., Guatibonza-Garcia, V., Verrastro, O., Axarloglou, E., Mylonakis, S., George, J., Papatheodoridis, G., Mingrone, G. (2024). Apolipoprotein C-III in association with metabolic-dysfunction associated steatotic liver disease: A large, multicenter study. Clinical Nutrition, 43(12), 101-108. [More Information]
- Kim, D., Choi, Y., Lee, J., Choi, H., Yoon, K., Yim, S., Park, C., Kim, D., Lee, H., Choi, W., George, J., et al (2024). Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation. Hepatology International. [More Information]
- Yuan, H., Targher, G., Tian, N., Li, G., Zhang, X., George, J., Zhou, M., Wang, F., Zheng, M., Liu, W., et al (2024). Associations between cuprotosis-related genes and the spectrum of metabolic dysfunction-associated fatty liver disease: An exploratory study. Diabetes, Obesity and Metabolism. [More Information]
- Tang, Y., Jiang, X., Zhu, C., Audsley, J., Tangkijvanich, P., Avihingsanon, A., Song, S., Liu, S., Lewin, S., George, J., Douglas, M., et al (2024). Circulating capsid-antibody-complexes (CACs) drive intrahepatic complement deposition and inform subclinical liver inflammation in chronic hepatitis B. Antiviral Research, 231, 106017. [More Information]
- Nash, E., Chitturi, S., Flores, J., Braund, A., Bonnichsen, M., Riordan, S., Humphris, J., Duong, T., Mckenzie, C., Liu, K., Strasser, S., George, J., et al (2024). Drug-induced liver injury from selective androgen receptor modulators, anabolic-androgenic steroids and bodybuilding supplements in Australia. Alimentary Pharmacology and Therapeutics, 59(8), 953-961. [More Information]
- Pan, Z., Bayoumi, A., Metwally, M., George, J., Eslam, M. (2024). Exportin 4 DNA promoter methylation in liver fibrosis. PloS One, 19(2024-05-05 00:00:00). [More Information]
- Bajaj, J., Topazian, M., Torre, A., Xie, Q., George, J., Kamath, P., Choudhury, A., Kumaran, V., Wong, F., Seto, W., et al (2024). Geographic disparities in access to liver transplant for advanced cirrhosis: Time to ring the alarm!. American Journal Of Transplantation. [More Information]
- Cao, Z., Seto, W., Desalegn, H., Alvares-da-Silva, M., Bush, B., Thacker, L., Xie, Q., Bajaj, J., Wong, F., Choudhury, A., George, J., et al (2024). Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium. The Lancet Gastroenterology & Hepatology. [More Information]
- Tu, T., Eslam, M., Berg, T., Chan, H., George, J., Douglas, M., Ajoyan, H., Nur Umami, R., Veeraraghavan, V., Boldbaatar, D., et al (2024). Inhibition of Cellular Factor TM6SF2 Suppresses Secretion Pathways of Hepatitis B, Hepatitis C, and Hepatitis D Viruses. The Journal of Infectious Diseases, 230(4), 970-981. [More Information]
- Tomic, D., Salim, A., George, J., Magliano, D., Shaw, J. (2024). Liver disease mortality and hospitalisations among people with type 2 diabetes mellitus: A population-based study. Liver International, 44(2), 508-517. [More Information]
- Eslam, M., George, J. (2024). MAFLD: from a disease framework to patient care. Hepatology International. [More Information]
- Howell, J., De Santis, T., Muller, K., Nguyen, B., Olynyk, J., Shackel, N., Valery, P., Wigg, A., George, J., Roberts, S., et al (2024). Overcoming disparities in hepatocellular carcinoma outcomes in First Nations Australians: a strategic plan for action. Medical Journal of Australia. [More Information]
- Pennisi, G., Enea, M., Romero-Gomez, M., Bugianesi, E., Wai-Sun Wong, V., Fracanzani, A., de Lédinghen, V., George, J., Berzigotti, A., Viganò, M., et al (2024). Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria. Hepatology, 79(4), 912-925. [More Information]
- Armandi, A., Ampuero, J., Pennisi, G., Aller, R., Tiniakos, D., Burt, A., David, E., Vecchio, F., Maggioni, M., Cabibi, D., Eslam, M., George, J., et al (2024). Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease. Gut, , 330815. [More Information]
- Tang, L., Jiang, P., Wang, C., Chen, Q., Byrne, C., Targher, G., Eslam, M., George, J., Wong, V., Zheng, M., et al (2024). Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort. Liver International. [More Information]
- Perananthan, V., George, J. (2024). Severe liver injury following use of RAD-140, a selective androgen receptor modulator, for body building. Australian Prescriber, 47(1), 26-28. [More Information]
- Genovese, F., Fahy, W., Wain, L., Vestbo, J., Nanthakumar, C., Shaker, S., Hoyer, N., Leeming, D., George, J., Trebicka, J., et al (2024). The fibroblast hormone Endotrophin is a biomarker of mortality in chronic diseases. Matrix Biology, 132, 1-9. [More Information]
- Kalo, E., Müller, L., Kloeckner, R., George, J., Thimme, R., Bettinger, D., Ahlenstiel, G., Sturm, L., Schultheiss, M., Moore, O., et al (2024). The Freiburg Index of Post-TIPS Survival accurately predicts mortality in patients with acute decompensation of cirrhosis. Liver International. [More Information]
- Zeng, X., George, J., Newberry, C., Zheng, J., George, E., Spearman, C., Kontogianni, M., Ristic-Medic, D., Peres, W., Depboylu, G., et al (2024). The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus. Metabolism: Clinical and Experimental, 161, 156028. [More Information]
- Kouvari, M., Valenzuela-Vallejo, L., Axarloglou, E., Verrastro, O., Papatheodoridis, G., Mingrone, G., George, J., Mantzoros, C. (2024). Thyroid function, adipokines and mitokines in metabolic dysfunction-associated steatohepatitis: A multi-centre biopsy-based observational study. Liver International. [More Information]
- Le, H., Fajardo Lubian, A., Bowring, B., Van Der Poorten, D., Iredell, J., George, J., Venturini, C., Ahlenstiel, G., Read, S. (2024). Using a human colonoid-derived monolayer to study bacteriophage translocation. Gut Microbes, 16(1), 2331520. [More Information]
- Kurup, R., Kalo, E., Read, S., Ma, W., George, J., Ahlenstiel, G. (2024). Validation and Comparison of Non-Invasive Tests for the Exclusion of High-Risk Varices in Compensated Advanced Chronic Liver Disease. Livers, 4(2), 182-192. [More Information]
2023
- Kalo, E., Baig, A., Gregg, E., George, J., Read, S., Ma, W., Ahlenstiel, G. (2023). A novel, nurse-led ‘one stop’ clinic for patients with liver cirrhosis results in fewer liver-related unplanned readmissions and improved survival. BMC Gastroenterology, 23(1). [More Information]
- Fischer, J., Long, S., Koukoulioti, E., Müller, T., Fueloep, B., Heyne, R., Eslam, M., George, J., Finkelmeier, F., Waidmann, O., et al (2023). Association of Common Polymorphisms in the Interleukin-1 Beta Gene with Hepatocellular Carcinoma in Caucasian Patients with Chronic Hepatitis B. Pathogens, 12(1). [More Information]
- Ramírez-Mejía, M., Jiménez-Gutiérrez, C., Eslam, M., George, J., Méndez-Sánchez, N. (2023). Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification? Hepatology International. [More Information]
- Clark, P., Sinclair, M., George, J., Bollipo, S., McGarity, B., Sievert, W., MacQuillan, G., Tse, E., Nicoll, A., Wade, A., Levy, M., et al (2023). Broadening and strengthening the health providers caring for patients with chronic hepatitis C may improve continuity of care. Journal of Gastroenterology and Hepatology. [More Information]
- Valenzuela-Vallejo, L., Papatheodoridis, G., Mingrone, G., George, J., Mantzoros, C., Chrysafi, P., Kouvari, M., Guatibonza-Garcia, V., Mylonakis, S., Katsarou, A., Eslam, M., et al (2023). Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study. Metabolism: Clinical and Experimental, 148, 155694. [More Information]
- Roder, D., Banham, D., George, J., Rushton, S., O’Brien, T. (2023). Demographic, health, and prognostic characteristics of Australians with liver cancer: a cohort study of linked data in New South Wales for informing cancer control. BMC Public Health, 23(1). [More Information]
- Rauff, B., Ramezani-Moghadam, M., Tay, E., George, J., Douglas, M. (2023). Development of an in vitro model to study hepatitis C virus-induced fibrosis. Future Virology, 18(12), 757-766. [More Information]
- Lu, H., George, J., Eslam, M., Villanueva, A., Bolondi, L., Reeves, H., McCain, M., Chambers, E., Ward, C., Sartika, D., et al (2023). Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease. Liver Cancer, 12(1), 19-31. [More Information]
- Chai, T., Byth Wilson, K., George, J., Pasupathy, D., Cheung, N. (2023). Elevated Hepatic Steatosis Index is Associated with the Development of Adverse Maternal, but Not Adverse Neonatal, Outcomes: A Retrospective Cohort Study. International Journal of Women's Health, 15, 589-598. [More Information]
- Kalo, E., George, J., Read, S., Majumdar, A., Ahlenstiel, G. (2023). Evolution of risk prediction models for post-operative mortality in patients with cirrhosis. Hepatology International. [More Information]
- Keating, S., Sabag, A., Hallsworth, K., Hickman, I., MacDonald, G., Stine, J., George, J., Johnson, N. (2023). Exercise in the Management of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Position Statement from Exercise and Sport Science Australia. Sports Medicine, 53(12), 2347-2371. [More Information]
- Valerio, H., Grebely, J., Matthews, G., Dore, G., Alavi, M., Marshall, A., Hajarizadeh, B., Amin, J., Law, M., Tillakeratne, S., George, J., et al (2023). Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia: A population-based study. Drug and Alcohol Review. [More Information]
- Wai-Sun Wong, V., Anstee, Q., Nitze, L., Geerts, A., George, J., Nolasco, V., Kjær, M., Ladelund, S., Newsome, P., Ratziu, V. (2023). FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial. EClinicalMedicine, 66. [More Information]
- Bajaj, J., Choudhury, A., Xie, Q., Kamath, P., Topazian, M., Hayes, P., Torre, A., Desalegn, H., Idilman, R., Cao, Z., George, J., et al (2023). Global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium. The Lancet Gastroenterology & Hepatology, 8(7), 611-622. [More Information]
- Zhang, H., Rios, R., Boursier, J., Anty, R., Chan, W., George, J., Yilmaz, Y., Wong, V., Fan, J., Dufour, J., et al (2023). Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-Alcoholic steatohepatitis risk diagnosis: An international registry study. Chinese Medical Journal, 136(3), 341-350. [More Information]
- Jia, X., Song, E., Liu, Y., Chen, J., Wan, P., Hu, Y., Ye, D., Chakrabarti, S., Mahajan, H., George, J., et al (2023). Identification and multicentric validation of soluble CDCP1 as a robust serological biomarker for risk stratification of NASH in obese Chinese. Cell Reports Medicine, 4(11). [More Information]
- Currenti, J., Mishra, A., Wallace, M., George, J., Sharma, A. (2023). Immunosuppressive mechanisms of oncofetal reprogramming in the tumor microenvironment: implications in immunotherapy response. Biochemical Society Transactions, 51(2), 597-612. [More Information]
- Gofton, C., Clark-Dickson, M., George, J. (2023). Lean Metabolic-Associated Fatty Liver Disease. Endocrinology and Metabolism Clinics of North America. [More Information]
- Kouvari, M., Valenzuela-Vallejo, L., Guatibonza-Garcia, V., Polyzos, S., Deng, Y., Kokkorakis, M., Agraz, M., Mylonakis, S., Katsarou, A., Verrastro, O., Eslam, M., George, J., et al (2023). Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study. Metabolism: Clinical and Experimental, 147. [More Information]
- Clark, P., Valery, P., Strasser, S., Weltman, M., Thompson, A., Levy, M., Leggett, B., Zekry, A., Rong, J., George, J., et al (2023). Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort. Digestive Diseases and Sciences, 68(1), 291-303. [More Information]
- Alharthi, J., Pan, Z., Gloss, B., McLeod, D., Weltman, M., George, J., Eslam, M. (2023). Loss of metabolic adaptation in lean MAFLD is driven by endotoxemia leading to epigenetic reprogramming. Metabolism: Clinical and Experimental, 144. [More Information]
- Gofton, C., Upendran, Y., Zheng, M., George, J. (2023). MAFLD: How is it different from NAFLD? Clinical and Molecular Hepatology, 29, S17-S31. [More Information]
- Tang, L., Li, G., Eslam, M., Zhu, P., Chen, S., Leung, H., Huang, O., Wong, G., Zhou, Y., Karsdal, M., George, J., et al (2023). N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD. Hepatology International, 17(1), 190-201. [More Information]
- Fernandez, M., Pal, S., Arrese, M., Arab, J., George, J., Mendez-Sanchez, N. (2023). Nonalcoholic Fatty Liver Disease in Latin America and Australia. Clinics in Liver Disease, 27(2), 301-315. [More Information]
- Abomughaid, M., Tay, E., Pickford, R., Malladi, C., Read, S., Coorssen, J., Gloss, B., George, J., Douglas, M. (2023). PEMT Mediates Hepatitis C Virus-Induced Steatosis, Explains Genotype-Specific Phenotypes and Supports Virus Replication. International Journal of Molecular Sciences, 24(10). [More Information]
- El-Khobar, K., Tay, E., Diefenbach, E., Gloss, B., George, J., Douglas, M. (2023). Polo-like kinase-1 mediates hepatitis C virus-induced cell migration, a drug target for liver cancer. Life Science Alliance, 6(11). [More Information]
- Ramandi, A., George, J., Merat, S., Jafari, E., Sharafkhah, M., Radmard, A., Nateghi Baygi, A., Delavari, A., Mohammadi, Z., Poustchi, H., et al (2023). Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial. Hepatology International, 17(4), 882-888. [More Information]
- Calzadilla-Bertot, L., Jeffrey, G., Wang, Z., Huang, Y., Garas, G., Wallace, M., De Boer, B., George, J., Eslam, M., Phu, A., et al (2023). Predicting liver-related events in NAFLD: A predictive model. Hepatology, 78(4), 1240-1251. [More Information]
- Fischer, J., van Bömmel, F., Koukoulioti, E., Müller, T., Heyne, R., Eslam, M., George, J., Finkelmeier, F., Waidmann, O., Berg, T. (2023). Sex-differences in the association of interleukin-10 and interleukin-12 variants with the progression of hepatitis B virus infection in Caucasians. Hepatology Research, 53(12), 1156-1168. [More Information]
- Yeoh, Y., Hajarizadeh, B., Dore, G., Lockart, I., Danta, M., Flynn, C., Blackmore, C., Levy, M., George, J., Alavi, M. (2023). Temporal change in aetiology and clinical characteristics of hepatocellular carcinoma in a large cohort of patients in New South Wales, Australia. Internal Medicine Journal. [More Information]
- Kouvari, M., Mylonakis, S., Katsarou, A., Valenzuela-Vallejo, L., Guatibonza-Garcia, V., Kokkorakis, M., Verrastro, O., Angelini, G., Markakis, G., Eslam, M., George, J., et al (2023). The first external validation of the Dallas steatosis index in biopsy-proven Non-alcoholic fatty liver Disease: A multicenter study. Diabetes Research and Clinical Practice, 203. [More Information]
- Canivet, C., Lange, N., Blanchet, O., Moal, V., Ibrahim Kamal Jouness, R., Roux, M., Chan, W., Sturm, N., Eslam, M., Bugianesi, E., George, J., et al (2023). Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients. Clinical Gastroenterology and Hepatology, 21(12), 3097-3106.e10. [More Information]
- Janko, N., Majeed, A., Clements, W., Fink, M., Lubel, J., Goodwin, M., Nicoll, A., Strasser, S., Sood, S., Bollipo, S., George, J., et al (2023). Wide variation in pre-procedural blood product transfusion practices in cirrhosis: a national multidisciplinary survey. Hepatology Communications, 7(5). [More Information]
2022
- Younossi, Z., Ong, J., Takahashi, H., Yilmaz, Y., Eguc`hi, Y., El Kassas, M., Buti, M., Diago, M., Zheng, M., Fan, J., George, J., et al (2022). A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 20(6), e1456-e1468. [More Information]
- Alharthi, J., Bayoumi, A., Thabet, K., Pan, Z., Gloss, B., Latchoumanin, O., Lundberg, M., Twine, N., McLeod, D., Alenizi, S., Liddle, C., George, J., Eslam, M., et al (2022). A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes. Nature Communications, 13(1). [More Information]
- Lazarus, J., Anstee, Q., Arab, J., Batterham, R., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M., Francque, S., George, J., et al (2022). Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews. Gastroenterology & Hepatology, 19(1), 60-78. [More Information]
- Tang, L., Ma, H., Eslam, M., Wong, G., Zhu, P., Chen, S., Leeming, D., Karsdal, M., Li, G., Huang, O., George, J., et al (2022). Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. Metabolism: Clinical and Experimental, 128, 154958. [More Information]
- Zhou, K., Huo, X., Nguyen, R., Bae, D., Han, S., Zhang, Z., Duan, W., Yuen, L., Lam, V., George, J., Qiao, L. (2022). Aptamer-mediated doxorubicin delivery reduces HCC burden in 3D organoids model. Journal of Controlled Release, 341, 341-350. [More Information]
- Younes, R., Govaere, O., Petta, S., Miele, L., Tiniakos, D., Burt, A., David, E., Vecchio, F., Maggioni, M., Cabibi, D., Eslam, M., George, J., et al (2022). Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach? Gut, 71(2), 382-390. [More Information]
- Coupland, H., Day, C., Haber, P., Pritchard-Jones, J., McKee, K., George, J., McCaughan, G. (2022). Client resistance to hepatitis C treatment initiation in opioid agonist treatment clinics in Sydney, Australia: A qualitative study. Drug and Alcohol Review, 41(3), 706-714. [More Information]
- Younossi, Z., Yilmaz, Y., Yu, M., Wai-Sun Wong, V., Fernandez, M., Isakov, V., Duseja, A., Mendez-Sanchez, N., Eguchi, Y., Bugianesi, E., George, J., et al (2022). Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. Clinical Gastroenterology and Hepatology, 20(10), 2296-2306000000. [More Information]
- Jefferies, M., Rashid, H., Graham, R., Read, S., Banik, G., Lam, T., Njiomegnie, G., Eslam, M., Zhao, X., Ahmed, N., Douglas, M., George, J. (2022). COVID-19 Impact on Australian Patients with Substance Use Disorders: Emergency Department Admissions in Western Sydney before Vaccine Roll Out. Vaccines, 10(6). [More Information]
- Gofton, C., Agar, M., George, J. (2022). Early Implementation of Palliative and Supportive Care in Hepatocellular Carcinoma. Seminars in Liver Disease, 42(4), 514-530. [More Information]
- Willumsen, N., Jensen, C., Green, G., Nissen, N., Neely, J., Nelson, D., Pedersen, R., Frederiksen, P., Chen, I., Boisen, M., Eslam, M., George, J., et al (2022). Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types. Cellular and Molecular Life Sciences, 79(4), 204. [More Information]
- Bae, D., George, J., Qiao, L. (2022). From MAFLD to hepatocellular carcinoma and everything in between. Chinese Medical Journal, 135(5), 547-556. [More Information]
- Mendez-Sanchez, N., Bugianesi, E., Gish, R., Lammert, F., Tilg, H., Nguyen, M., Sarin, S., Fabrellas, N., Zelber-Sagi, S., Fan, J., George, J., et al (2022). Global multi-stakeholder endorsement of the MAFLD definition. The Lancet Gastroenterology & Hepatology, 7(5), 388-390. [More Information]
- Clark, P., Valery, P., Ward, J., Strasser, S., Weltman, M., Thompson, A., Levy, M., Leggett, B., Zekry, A., Rong, J., et al (2022). Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up. BMC Gastroenterology, 22(1). [More Information]
- Cassidy, S., Kroeger, C., Wang, T., Mitra, S., Liu, C., Ribeiro, R., Dai, A., Lau, J., Huang, R., Masedunkas, A., Jose, S., Liu, N., McGrady, M., Lo, S., George, J., Cistulli, P., Khor, L., Kozor, R., Ugander, M., Wilcox, I., Hunyor, I., Fontana, L., et al (2022). Impact of an intensive lifestyle program on low attenuation plaque and myocardial perfusion in coronary heart disease: A randomised clinical trial protocol. Nutrition and Healthy Aging, 7(1-2), 9-22. [More Information]
- Fukunaga, S., Nakano, D., Tsutsumi, T., Kawaguchi, T., Eslam, M., Yoshinaga, S., Abe, H., Nouno, R., Joh, S., Mitsuyama, K., George, J., et al (2022). Lean/normal-weight metabolic dysfunction-associated fatty liver disease is a risk factor for reflux esophagitis. Hepatology Research, 52(8), 699-711. [More Information]
- George, J., Kawaguchi, T. (2022). Liver fat and a perturbed metabolic milieu: a consilience of factors driving liver cancer development. Hepatology International, 16(4), 733-736. [More Information]
- Kawaguchi, T., Tsutsumi, T., Nakano, D., Eslam, M., George, J., Torimura, T. (2022). MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. Clinical and Molecular Hepatology, 28(2), 150-163. [More Information]
- Sarin, S., Eslam, M., Fan, J., Lin, H., George, J., Omata, M. (2022). MAFLD, patient-centred care, and APASL. Hepatology International, 16(5), 1032-1034. [More Information]
- Eslam, M., El-Serag, H., Francque, S., Sarin, S., Wei, L., Bugianesi, E., George, J. (2022). Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nature Reviews. Gastroenterology and Hepatology, 19(10), 638-651. [More Information]
- Speliotes, E., George, J. (2022). Metabolic and genetic contributions to NAFLD: Really distinct and homogeneous? Journal of Hepatology, 76(3), 498-500. [More Information]
- Zhou, X., Cai, J., Targher, G., Byrne, C., Shapiro, M., Sung, K., Somers, V., Chahal, C., George, J., Chen, L., et al (2022). Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovascular Diabetology, 21(1). [More Information]
- Tu, T., Zehnder, B., Wettengel, J., Zhang, H., Coulter, S., Ho, V., Douglas, M., Protzer, U., George, J., Urban, S. (2022). Mitosis of hepatitis B virus-infected cells in vitro results in uninfected daughter cells. JHEP Reports, 4(9). [More Information]
- Maharaj, A., Lubel, J., Lam, E., Clark, P., Duncan, O., George, J., Jeffrey, G., Lipton, L., Liu, H., McCaughan, G., Tu, T., et al (2022). Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus. Hepatology Communications, 6(11), 3260-3271. [More Information]
- Chan, M., Huo, Y., Trieu, N., Mitchelle, A., George, J., He, E., Lee, A., Chang, J., Yang, J. (2022). Noncontrast MRI for Hepatocellular Carcinoma Detection: A Systematic Review and Meta-analysis – A Potential Surveillance Tool? Clinical Gastroenterology and Hepatology, 20(1), 44-5.60E+03. [More Information]
- George, J., Zhou, G., Qiao, L. (2022). Response to the letter by Dr. Renba Liang. Cancer Letters, 540, 215650. [More Information]
- Chen, H., van Reyk, D., Oliveira, A., Chan, Y., Town, S., Rayner, B., Pollock, C., Saad, S., George, J., Padula, M., Oliver, B. (2022). Sex-dependent responses to maternal exposure to PM2.5 in the offspring. Antioxidants, 11(11). [More Information]
- Zhou, K., Nguyen, R., Qiao, L., George, J. (2022). Single cell RNA-seq analysis identifies a noncoding RNA mediating resistance to sorafenib treatment in HCC. Molecular Cancer, 21(1), 6. [More Information]
- Sabag, A., Barr, L., Armour, M., Armstong, A., Baker, C., Twigg, S., Chang, D., Hackett, D., Keating, S., George, J., Johnson, N. (2022). The Effect of High-intensity Interval Training vs Moderate-intensity Continuous Training on Liver Fat: A Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 107(3), 862-881. [More Information]
- Al-Omary, A., Blyth, K., Weltman, M., George, J., Eslam, M. (2022). The importance and impact of recognizing metabolic dysfunction-associated fatty liver disease in patients with chronic hepatitis C. Journal of Digestive Diseases, 23(1), 33-43. [More Information]
- Chai, T., Deng, D., Byth Wilson, K., George, J., Pasupathy, D., Cheung, N. (2022). The prevalence of metabolic dysfunction–associated fatty liver disease and its association on adverse pregnancy outcomes in women with gestational diabetes mellitus. Diabetes Research and Clinical Practice, 191. [More Information]
- Saleh, S., George, J., Kott, K., Meikle, P., Figtree, G. (2022). The Translation and Commercialisation of Biomarkers for Cardiovascular Disease—A Review. Frontiers in Cardovascular Medicine, 9. [More Information]
- Tshori, S., Livschitz, S., Volodarsky, I., Goland, S., Shimoni, S., Fabrikant, J., George, J. (2022). Transthyretin Cardiac Amyloidosis Scintigraphy Using Planar D-SPECT on Dedicated Cardiac CZT Camera. Journal of Nuclear Cardiology, 29(4), 1995-2000. [More Information]
- Shah, S., Alavi, M., Hajarizadeh, B., Matthews, G., Martinello, M., Danta, M., Amin, J., Law, M., George, J., Valerio, H., et al (2022). Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales. JHEP Reports, 4(10). [More Information]
- Khadija, H., Gandelman, G., Ayyad, O., Poles, L., Jonas, M., Paz, O., George, J., Blatt, A. (2022). Trends in Transfemoral Aortic Valve Implantation Related Thrombocytopenia. Journal of Clinical Medicine, 11(3). [More Information]
- Heinze, K., Nazeran, T., Lee, S., Krämer, P., Cairns, E., Chiu, D., Leung, S., Kang, E., Meagher, N., Kennedy, C., Boros, J., Sharma, R., Brand, A., George, J., et al (2022). Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. Journal of Pathology, 256(4), 388-401. [More Information]
2021
- Eslam, M., Wong, G., Hashem, A., Chan, H., Nielsen, M., Leeming, D., Chan, A., Chen, Y., Duffin, K., Karsdal, M., George, J., et al (2021). A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. American Journal of Gastroenterology, 116(5), 984-993. [More Information]
- Calzadilla-Bertot, L., Vilar-Gomez, E., Wong, V., Romero-Gomez, M., Aller-de la Fuente, R., Wong, G., Castellanos, M., Eslam, M., Desai, A., Jeffrey, G., George, J., et al (2021). ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. Hepatology, 73(6), 2238-2250. [More Information]
- Lockart, I., Hajarizadeh, B., Buckley, N., Davison, S., Prakoso, E., Levy, M., George, J., Dore, G., Danta, M. (2021). All-cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy. Journal of Gastroenterology and Hepatology, 36(12), 3515-3523. [More Information]
- Zhou, G., Bae, D., Nguyen, R., Huo, X., Han, S., Zhang, Z., Hebbard, L., Duan, W., Eslam, M., Liddle, C., Qiao, L., George, J., et al (2021). An aptamer-based drug delivery agent (CD133-apt-Dox) selectively and effectively kills liver cancer stem-like cells. Cancer Letters, 501, 124-132. [More Information]
- Deng, D., George, J., Pasupathy, D., Cheung, N. (2021). Antenatal FibroScan® assessment for metabolic-associated fatty liver in pregnant women at risk of gestational diabetes from a multiethnic population: a pilot study. Internal Medicine Journal. [More Information]
- Gao, F., Zheng, K., Yan, H., Sun, Q., Pan, K., Wang, T., Chen, Y., Targher, G., Byrne, C., George, J., et al (2021). Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019. Frontiers in Endocrinology, 12, 604100. [More Information]
- Liu, W., Eslam, M., Zheng, K., Ma, H., Rios, R., Lv, M., Li, G., Tang, L., Zhu, P., Wang, X., George, J., et al (2021). Associations of hydroxysteroid 17-beta dehydrogenase 13 variants with liver histology in chinese patients with metabolic-associated fatty liver disease. Journal of Clinical and Translational Hepatology, 9(2), 194-202. [More Information]
- Khadija, H., Gandelman, G., Ayyad, O., Poles, L., Jonas, M., Paz, O., Goland, S., Shimoni, S., Meledin, V., George, J., et al (2021). Comparative analysis of the kinetic behavior of systemic inflammatory markers in patients with depressed versus preserved left ventricular function undergoing transcatheter aortic valve implantation. Journal of Clinical Medicine, 10(18). [More Information]
- Metwally, M., Bayoumi, A., Khan, A., Adams, L., Aller, R., García-Monzón, C., Arias-Loste, M., Bugianesi, E., Miele, L., Anna, A., Latchoumanin, O., Han, S., Alenizi, S., El Sharkawy, R., Elattar, A., Liddle, C., George, J., Eslam, M., et al (2021). Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. EBioMedicine, 70, 103521. [More Information]
- Esmaili, S., Langfelder, P., Belgard, T., Vitale, D., Azardaryany, M., Alipour Talesh, G., Ramezani-Moghadam, M., Ho, V., Dvorkin, D., Dervish, S., Liddle, C., George, J., et al (2021). Core liver homeostatic co-expression networks are preserved but respond to perturbations in an organism- and disease-specific manner. Cell Systems, 12(5), 432-4.45E+09. [More Information]
- Kjær, M., George, J., Kazankov, K., Grønbæk, H. (2021). Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy? Expert Review of Gastroenterology and Hepatology, 15(1), 51-64. [More Information]
- Liu, C., Chu, D., Kalantar-Zadeh, K., George, J., Young, H., Liu, G. (2021). Cytokines: From Clinical Significance to Quantification. Advanced Science, 8(15), 2004433-1-2004433-29. [More Information]
- Eslam, M., Alkhouri, N., Vajro, P., Baumann, U., Weiss, R., Socha, P., Marcus, C., Lee, W., Kelly, D., Porta, G., Baur, L., George, J., et al (2021). Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. The Lancet Gastroenterology & Hepatology, 6(10), 864-873. [More Information]
- Nguyen, R., Bae, D., Qiao, L., George, J. (2021). Developing liver organoids from induced pluripotent stem cells (iPSCs): An alternative source of organoid generation for liver cancer research. Cancer Letters, 508, 13-17. [More Information]
- Khadija, H., Gandelman, G., Ayyad, O., Jaber, M., Poles, L., Jonas, M., Paz, O., Abu Sbaih, F., Sella, G., Shimoni, S., et al (2021). Differential systemic inflammatory responses after TAVI: The role of self versus balloon expandable devices. PloS One, 16(10 October). [More Information]
- Devarbhavi, H., Aithal, G., Treeprasertsuk, S., Takikawa, H., Mao, Y., Shasthry, S., Hamid, S., Tan, S., Philips, C., George, J., et al (2021). Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatology International, 15(2), 258-282. [More Information]
- Kuscuoglu, D., Bewersdorf, L., Wenzel, K., Gross, A., Kobazi Ensari, G., Luo, Y., Kilic, K., Hittatiya, K., Golob-Schwarzl, N., Leube, R., George, J., Metwally, M., Eslam, M., et al (2021). Dual proteotoxic stress accelerates liver injury via activation of p62-Nrf2. Journal of Pathology, 254(1), 80-91. [More Information]
- Rittig, N., Aagaard, N., Villadsen, G., Sandahl, T., Jessen, N., Grønbæk, H., George, J. (2021). Editorial: metformin for portal hypertension—old dog, new tricks? Authors' reply. Alimentary Pharmacology and Therapeutics, 54(3), 347. [More Information]
- Papaluca, T., Roberts, S., Strasser, S., Stuart, K., Farrell, G., MacQuillan, G., Dore, G., Wade, A., George, J., Hazeldine, S., et al (2021). Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients with Difficult to Cure Characteristics. Clinical Infectious Diseases, 73(9), E3288-E3295. [More Information]
- Fassler, M., Rappaport, M., Cuño, C., George, J. (2021). Engagement of TREM2 by a novel monoclonal antibody induces activation of microglia and improves cognitive function in Alzheimer’s disease models. Journal of Neuroinflammation, 18(1). [More Information]
- Wijaya, R., Read, S., Schibeci, S., Han, S., Azardaryany, M., van der Poorten, D., Lin, R., Yuen, L., Lam, V., Douglas, M., George, J., Ahlenstiel, G. (2021). Expansion of dysfunctional CD56-CD16+ NK cells in chronic hepatitis B patients. Liver International, 41(5), 969-981. [More Information]
- Wijaya, R., Read, S., Truong, N., Han, S., Chen, D., Shahidipour, H., Fewings, N., Schibeci, S., Azardaryany, M., Parnell, G., Booth, D., van der Poorten, D., Lin, R., George, J., Douglas, M., Ahlenstiel, G. (2021). HBV vaccination and HBV infection induces HBV-specific natural killer cell memory. Gut, 70(2), 357-369. [More Information]
- Robotin, M., Wallace, J., Gallego, G., George, J. (2021). Hepatitis b and liver cancer: Community awareness, knowledge and beliefs of middle eastern migrants in sydney, australia. International Journal of Environmental Research and Public Health, 18(16), 8534-1-8534-11. [More Information]
- Wijaya, R., Read, S., Selvamani, S., Schibeci, S., Azardaryany, M., Ong, A., van der Poorten, D., Lin, R., Douglas, M., George, J., Ahlenstiel, G. (2021). Hepatitis C Virus (HCV) Eradication With Interferon-Free Direct-Acting Antiviral-Based Therapy Results in KLRG1+ HCV-Specific Memory Natural Killer Cells. The Journal of Infectious Diseases, 223(7), 1183-1195. [More Information]
- Lockart, I., Hajarizadeh, B., Alavi, M., Davison, S., Prakoso, E., Levy, M., George, J., Dore, G., Danta, M. (2021). Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival. Journal of Viral Hepatitis, 28(5), 710-718. [More Information]
- Valerio, H., Alavi, M., Law, M., Tillakeratne, S., Amin, J., Janjua, N., Krajden, M., George, J., Matthews, G., Hajarizadeh, B., et al (2021). High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. Journal of Hepatology, 74(2), 293-302. [More Information]
- Shek, D., Read, S., Nagrial, A., Carlino, M., Gao, B., George, J., Ahlenstiel, G. (2021). Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates. The Oncologist, 26(7), e1216-e1225. [More Information]
- Eslam, M., Ahmed, A., Després, J., Jha, V., Halford, J., Wei Chieh, J., Harris, D., Nangaku, M., Colagiuri, S., Targher, G., George, J., et al (2021). Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. The Lancet Gastroenterology & Hepatology, 6(9), 743-753. [More Information]
- Read, S., Gloss, B., Liddle, C., George, J., Ahlenstiel, G. (2021). Interferon-λ3 Exacerbates the Inflammatory Response to Microbial Ligands: Implications for SARS-CoV-2 Pathogenesis. Journal of Inflammation Research, 14, 1257-1270. [More Information]
- Gantzel, R., Kjær, M., Laursen, T., Kazankov, K., George, J., Møller, H., Grønbæk, H. (2021). Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis. Frontiers in Medicine, 7, 615599. [More Information]
- George, J., Gish, R., Geier, A. (2021). MAFLD and Cardiovascular Events: What Does the Evidence Show? Clinical Gastroenterology and Hepatology, 19(10), 2025-2028. [More Information]
- Tsutsumi, T., Eslam, M., Kawaguchi, T., Yamamura, S., Kawaguchi, A., Nakano, D., Koseki, M., Yoshinaga, S., Takahashi, H., Anzai, K., George, J., et al (2021). MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach. Hepatology Research, 51(11), 1115-1128. [More Information]
- Eslam, M., George, J. (2021). MAFLD: A game changer redefining fatty liver disease for adults and children. Journal of Hepatology, 74(4), 992-994. [More Information]
- Eslam, M., George, J. (2021). MAFLD: A holistic view to redefining fatty liver disease. Journal of Hepatology, 74(4), 983-985. [More Information]
- Eslam, M., George, J. (2021). MAFLD: Now is the time to capitalize on the momentum. Journal of Hepatology, 74(5), 1262-1263. [More Information]
- Gao, F., Zheng, K., Wang, X., Yan, H., Sun, Q., Pan, K., Wang, T., Chen, Y., George, J., Zheng, M. (2021). Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. Journal of Gastroenterology and Hepatology, 36(1), 204-207. [More Information]
- Booth, D., Ahlenstiel, G., George, J., O'Connor, K., Eslam, M. (2021). A method to predict rate of fibrosis in liver diseases. Patent No. 10,939,868.
- Bayoumi, A., Elsayed, A., Han, S., Petta, S., Adams, L., Aller, R., Khan, A., García-Monzón, C., Arias-Loste, M., Miele, L., Latchoumanin, O., Alenizi, S., Metwally, M., Qiao, L., Liddle, C., George, J., Eslam, M., et al (2021). Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. Advanced Science, 8(11), 2004168. [More Information]
- Teodorovich, N., Jonas, M., Haberman, D., Khadija, H., Ayyad, O., Gandelman, G., Poles, L., George, J., Blatt, A. (2021). Natural anti-endothelial cell antibodies in patients undergoing coronary angiography. IMAJ, 23(10), 657-661.
- Curran, F., Bhalraam, U., Mohan, M., Singh, J., Anker, S., Dickstein, K., Doney, A., Filippatos, G., George, J., Metra, M., et al (2021). Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction. ESC Heart Failure, 8(4), 3168-3179. [More Information]
- Fukunaga, S., Nakano, D., Kawaguchi, T., Eslam, M., Ouchi, A., Nagata, T., Kuroki, H., Kawata, H., Abe, H., Nouno, R., George, J., et al (2021). Non-obese mafld is associated with colorectal adenoma in health check examinees: A multicenter retrospective study. International Journal of Molecular Sciences, 22(11), 5462. [More Information]
- Grimaudo, S., Dongiovanni, P., Pihlajamäki, J., Eslam, M., Yki-Järvinen, H., Pipitone, R., Baselli, G., Cammà, C., Di Marco, V., Enea, M., George, J., et al (2021). NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. Liver International, 41(11), 2712-2719. [More Information]
- Valerio, H., Alavi, M., Law, M., McManus, H., Tillakeratne, S., Bajis, S., Martinello, M., Matthews, G., Amin, J., Janjua, N., George, J., et al (2021). Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study. Clinical Infectious Diseases, 73(11), 2037-2044. [More Information]
- Bishay, R., Tonks, K., George, J., Samocha-Bonet, D., Meyerowitz-Katz, G., Chisholm, D., James, D., Greenfield, J. (2021). Plasma Bile Acids More Closely Align With Insulin Resistance, Visceral and Hepatic Adiposity Than Total Adiposity. Journal of Clinical Endocrinology and Metabolism, 106(3), e1131-e1139. [More Information]
- Wu, C., Smet, M., Heath, S., Curnow, J., Lin, M., George, J., Alahakoon, T. (2021). Pregnancy complicated by refractory severe hypercholanaemia from sodium taurocholate co-transporting polypeptide deficiency. The Journal of Obstetrics and Gynaecology Research, 47(2), 822-826. [More Information]
- Rittig, N., Aagaard, N., Villadsen, G., Sandahl, T., Jessen, N., Grønbæk, H., George, J. (2021). Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension. Alimentary Pharmacology and Therapeutics, 54(3), 320-328. [More Information]
- Calzadilla-Bertot, L., Vilar-Gomez, E., George, J., Adams, L. (2021). REPLY. Hepatology, 74(1), 531-532. [More Information]
- Bae, S., Nguyen, R., Qiao, L., George, J. (2021). Role of the constitutive androstane receptor (CAR) in human liver cancer. Biochimica et Biophysica Acta-Reviews on Cancer, 1875 (2), 188516. [More Information]
- Shimoni, O., Korenfeld, R., Goland, S., Meledin, V., Haberman, D., George, J., Shimoni, S. (2021). Subclinical myocardial dysfunction in patients recovered from covid-19 disease: Correlation with exercise capacity. Biology, 10(11). [More Information]
- Chai, T., Rajaratnam, R., Deng, D., George, J., Pasupathy, D., Cheung, N. (2021). The prevalence of gestational diabetes mellitus in women diagnosed with non-alcoholic fatty liver disease during pregnancy: A systematic review and meta-analysis. Journal of Diabetes and Its Complications, 35(9), 107991. [More Information]
- Deng, D., George, J., Pasupathy, D., Cheung, N. (2021). The prevalence of metabolic associated fatty liver detected by FibroScan(R) in women with gestational diabetes in a multiethnic population. Diabetes Research and Clinical Practice, 174, 108757. [More Information]
- Vilar-Gomez, E., Calzadilla-Bertot, L., Wong, V., Castellanos, M., Aller-de la Fuente, R., Eslam, M., Wong, G., George, J., Romero-Gomez, M., Adams, L. (2021). Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis–Related, Child–Pugh A Cirrhosis. Clinical Gastroenterology and Hepatology, 19(1), 136-145.e6. [More Information]
- Gofton, C., George, J. (2021). Updates in fatty liver disease: Pathophysiology, diagnosis and management. Australian Journal of General Practice, 50(10), 702-707. [More Information]
- Liu, Y., Veeraraghavan, V., Pinkerton, M., Fu, J., Douglas, M., George, J., Tu, T. (2021). Viral Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Occurrence and Recurrence. Frontiers in Microbiology, 12, 665201. [More Information]
- Goland, S., Volodarsky, I., Fabricant, Y., Livschitz, S., Tshori, S., Cuciuc, V., Zilberman, L., Fugenfirov, I., Meledin, V., Shimoni, S., et al (2021). Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction. PloS One, 16(7 July). [More Information]
- Eslam, M., Ratziu, V., George, J. (2021). Yet more evidence that MAFLD is more than a name change. Journal of Hepatology, 74(4), 977-979. [More Information]
2020
- Eslam, M., Newsome, P., Sarin, S., Anstee, Q., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J., Schattenberg, J., George, J., et al (2020). A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology, 73(1), 202-209. [More Information]
- Tu, T., Zehnder, B., Qu, B., Ni, Y., Main, N., Allweiss, L., Dandri, M., Shackel, N., George, J., Urban, S. (2020). A novel method to precisely quantify hepatitis B virus covalently closed circular (ccc)DNA formation and maintenance. Antiviral Research, 181, 104865. [More Information]
- George, J., Rappaport, M., Shimoni, S., Goland, S., Voldarsky, I., Fabricant, Y., Edri, O., Cuciuc, V., Lifshitz, S., Tshori, S., et al (2020). A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model. European Heart Journal, 41(12), 1260-1270. [More Information]
- Dewdney, B., Roberts, A., Qiao, L., George, J., Hebbard, L. (2020). A Sweet Connection? Fructose's Role in Hepatocellular Carcinoma. Biomolecules, 10(4), 496. [More Information]
- Nguyen, R., Bae, D., Zhou, G., Read, S., Ahlenstiel, G., George, J., Qiao, L. (2020). Application of organoids in translational research of human diseases with a particular focus on gastrointestinal cancers. Biochimica Et Biophysica Acta-Reviews On Cancer, 1873 (2), 1-12. [More Information]
- Karsdal, M., Daniels, S., Holm Nielsen, S., Bager, C., Rasmussen, D., Loomba, R., Surabattula, R., Villesen, I., Luo, Y., Shevell, D., George, J., et al (2020). Collagen biology and non-invasive biomarkers of liver fibrosis. Liver International, 40(4), 736-750. [More Information]
- Gao, F., Zheng, K., Gu, J., George, J., Zheng, M. (2020). COVID-19 and liver transplantation: Lessons learned from three reported cases. Transplant Infectious Disease, 22(4), e13335. [More Information]
- Zhand, S., Jazi, M., Mohammadi, S., Rasekhi, R., Rostamian, G., Kalani, M., Rostamian, A., George, J., Douglas, M. (2020). Covid-19: The immune responses and clinical therapy candidates. International Journal of Molecular Sciences, 21(15), 1-34. [More Information]
- Jensen, C., Nielsen, S., Eslam, M., Genovese, F., Nielsen, M., Vongsuvanh, R., Uchila, R., van der Poorten, D., George, J., Karsdal, M., et al (2020). Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma – A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients. Journal of Hepatocellular Carcinoma, 7, 301-313. [More Information]
- Targher, G., Mantovani, A., Byrne, C., Wang, X., Yan, H., Sun, Q., Pan, K., Zheng, K., Chen, Y., Eslam, M., George, J., et al (2020). Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19. Diabetes and Metabolism, 46(6), 505-507. [More Information]
- Li, G., Chan, Y., Wang, B., Saad, S., George, J., Oliver, B., Chen, H. (2020). E-cigarettes damage the liver and alter nutrient metabolism in pregnant mice and their offspring. Annals of the New York Academy of Sciences, 1475 (1), 64-77. [More Information]
- Roberts, S., Strasser, S., Nicoll, A., Kemp, W., Majeed, A., Mitchell, J., Stuart, K., Gow, P., Sood, S., MacQuillan, G., George, J., et al (2020). Efficacy and safety profile of calcineurin inhibitor salvage therapy in autoimmune hepatitis. Scandinavian Journal of Gastroenterology, 55(11), 1309-1317. [More Information]
- Huang, J., Zheng, K., George, J., Gao, H., Wei, R., Yan, H., Zheng, M. (2020). Fatal outcome in a liver transplant recipient with COVID-19. American Journal Of Transplantation, 20(7), 1907-1910. [More Information]
- Zheng, K., Fan, J., Shi, J., Wong, V., Eslam, M., George, J., Zheng, M. (2020). From NAFLD to MAFLD: a "redefining" moment for fatty liver disease. Chinese Medical Journal, 133(19), 2271-2273. [More Information]
- Eslam, M., George, J. (2020). Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nature Reviews. Gastroenterology and Hepatology, 17(1), 40-52. [More Information]
- Bayoumi, A., Jalil, I., Metwally, M., Adams, L., Aller, R., García-Monzón, C., Arias-Loste, M., Miele, L., Petta, S., Craxì, A., Qiao, L., Liddle, C., George, J., Eslam, M., et al (2020). Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease. PloS One, 15, e0243590. [More Information]
- Njiomegnie, G., Read, S., Fewings, N., George, J., McKay, F., Ahlenstiel, G. (2020). Immunomodulation of the Natural Killer Cell Phenotype and Response during HCV Infection. Journal of Clinical Medicine, 9(4), 1-19. [More Information]
- Douglas, M., Tay, E., Wang, D., Ong, A., Wilson, C., Phu, A., Kok, J., Dwyer, D., Bull, R., Lloyd, A., George, J., et al (2020). Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance. Hepatology Communications, 4(6), 904-915. [More Information]
- Chen, F., Esmaili, S., Rogers, G., Bugianesi, E., Petta, S., Marchesini, G., Bayoumi, A., Metwally, M., Azardaryany, M., Coulter, S., Liddle, C., George, J., Eslam, M., et al (2020). Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. Hepatology, 71(4), 1213-1227. [More Information]
- Zheng, K., Gao, F., Wang, X., Sun, Q., Pan, K., Wang, T., Ma, H., Chen, Y., Liu, W., George, J., et al (2020). Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism: Clinical and Experimental, 108, 154244. [More Information]
- Sarin, S., Kumar, M., Eslam, M., George, J., Al Mahtab, M., Akbar, S., Jia, J., Tian, Q., Aggarwal, R., Muljono, D., et al (2020). Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology & Hepatology, 5(2), 167-228. [More Information]
- Schneider, C., Hamesch, K., Gross, A., Mandorfer, M., Moeller, L., Pereira, V., Pons, M., Kuca, P., Reichert, M., Benini, F., Eslam, M., George, J., et al (2020). Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi*Z Variant of AAT (Pi*MZ vs Pi*ZZ genotype) and Noncarriers. Gastroenterology, 159(2), 534-5.48. [More Information]
- Laursen, T., Sandahl, T., Kazankov, K., George, J., Gronbaek, H. (2020). Liver-related effects of chronic hepatitis C antiviral treatment. World Journal of Gastroenterology, 26(22), 2931-2947. [More Information]
- Alharthi, J., Latchoumanin, O., George, J., Eslam, M. (2020). Macrophages in metabolic associated fatty liver disease. World Journal of Gastroenterology, 26(16), 1861-1878. [More Information]
- Yamamura, S., Eslam, M., Kawaguchi, T., Tsutsumi, T., Nakano, D., Yoshinaga, S., Takahashi, H., Anzai, K., George, J., Torimura, T. (2020). MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver International, 40(12), 3018-3030. [More Information]
- Eslam, M., Sanyal, A., George, J. (2020). MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 158(7), 1999-2014. [More Information]
- Zhou, Y., Zheng, K., Wang, X., Sun, Q., Pan, K., Wang, T., Ma, H., Chen, Y., George, J., Zheng, M. (2020). Metabolic-associated fatty liver disease is associated with severity of COVID-19. Liver International, 40(9), 2160-2163. [More Information]
- Eslam, M., Chen, F., George, J. (2020). NAFLD in Lean Asians. Clinical Liver Disease, 16(6), 240-243. [More Information]
- Adams, L., Roberts, S., Strasser, S., Mahady, S., Powell, E., Estes, C., Razavi, H., George, J. (2020). Nonalcoholic fatty liver disease burden: Australia, 2019–2030. Journal of Gastroenterology and Hepatology, 35(9), 1628-1635. [More Information]
- Huang, J., Wang, X., Zheng, K., Liu, W., Chen, J., George, J., Zheng, M. (2020). Obesity hypoventilation syndrome and severe COVID-19. Metabolism: Clinical and Experimental, 108, 154249. [More Information]
- Gao, F., Zheng, K., Wang, X., Sun, Q., Pan, K., Wang, T., Chen, Y., Targher, G., Byrne, C., George, J., et al (2020). Obesity Is a Risk Factor for Greater COVID-19 Severity. Diabetes Care, 43(7), E72-E74. [More Information]
- Targher, G., Mantovani, A., Wang, X., Yan, H., Sun, Q., Pan, K., Byrne, C., Zheng, K., Chen, Y., Eslam, M., George, J., et al (2020). Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes and Metabolism, 46(4), 335-337. [More Information]
- Eslam, M., George, J. (2020). Reply to: Correspondence on “A new definition for metabolic associated fatty liver disease: an international expert consensus statement”: MAFLD: Moving from a concept to practice. Journal of Hepatology, 73(5), 1268-1269. [More Information]
- Eslam, M., George, J. (2020). Reply to: correspondence regarding “A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement”: Bringing evidence to the NAFLD-MAFLD debate. Journal of Hepatology, 73(6), 1575. [More Information]
- Targher, G., Mantovani, A., Byrne, C., Wang, X., Yan, H., Sun, Q., Pan, K., Zheng, K., Chen, Y., Eslam, M., George, J., et al (2020). Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut, 69(8), 1545-1547. [More Information]
- Eslam, M., Sarin, S., Wong, V., Fan, J., Kawaguchi, T., Ahn, S., Zheng, M., Shiha, G., Yilmaz, Y., Gani, R., George, J., et al (2020). The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatology International, 14(6), 889-919. [More Information]
- Sabag, A., Way, K., Sultana, R., Keating, S., Gerofi, J., Chuter, V., Byrne, N., Baker, M., George, J., Caterson, I., Twigg, S., Johnson, N. (2020). The Effect of a Novel Low-Volume Aerobic Exercise Intervention on Liver Fat in Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care, 43(10), 2371-2378. [More Information]
- Dewdney, B., Alanazy, M., Gillman, R., Walker, S., Wankell, M., Qiao, L., George, J., Roberts, A., Hebbard, L. (2020). The effects of fructose and metabolic inhibition on hepatocellular carcinoma. Scientific Reports, 10(1), 16769. [More Information]
- Bayoumi, A., Gronbaek, H., George, J., Eslam, M. (2020). The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease. Trends in Genetics, 36(6), 429-441. [More Information]
- Haberman, D., Chernin, G., Meledin, V., Zikry, M., Shuvy, M., Gandelman, G., Goland, S., George, J., Shimoni, S. (2020). Urea level is an independent predictor of mortality in patients with severe aortic valve stenosis. PloS One, 15(3). [More Information]
- Méndez-Sánchez, N., Valencia-Rodríguez, A., Qi, X., Yoshida, E., Romero-Gomez, M., George, J., Eslam, M., Abenavoli, L., Xie, W., Teschke, R., et al (2020). What has the COVID-19 pandemic taught us so far? Addressing the problem from a hepatologist’s perspective. Journal of Clinical and Translational Hepatology, 8(2), 24. [More Information]
- Zheng, K., Eslam, M., George, J., Zheng, M. (2020). When a new definition overhauls perceptions of MAFLD related cirrhosis care. Hepatobiliary Surgery and Nutrition, 9(6), 801-804. [More Information]
- Zhou, Y., Zheng, K., Wang, X., Yan, H., Sun, Q., Pan, K., Wang, T., Ma, H., Chen, Y., George, J., et al (2020). Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis. Journal of Hepatology, 73(3), 719-721. [More Information]
2019
- Li, G., Chan, Y., Sukjamnong, S., Anwer, A., Vindin, H., Padula, M., Zakarya, R., George, J., Oliver, B., Saad, S., et al (2019). A Mitochondrial Specific Antioxidant Reverses Metabolic Dysfunction and Fatty Liver Induced by Maternal Cigarette Smoke in Mice. Nutrients, 11(7), 1-14. [More Information]
- Metwally, M., Bayoumi, A., Romero-Gomez, M., Thabet, K., John, M., Adams, L., Huo, X., Aller, R., Garcia-Monzon, C., Arias-Loste, M., Liddle, C., Qiao, L., George, J., Eslam, M., et al (2019). A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3 ' UTR. Journal of Hepatology, 70(3), 494-500. [More Information]
- El Sharkawy, R., Bayoumi, A., Metwally, M., Mangia, A., Berg, T., Romero-Gomez, M., Abate, M., Irving, W., Sheridan, D., Dore, G., Latchoumanin, O., Thabet, K., Najim, M., Douglas, M., Liddle, C., Qiao, L., George, J., Eslam, M., et al (2019). A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms. Scientific Reports, 9(1), 1-10. [More Information]
- Daniels, S., Leeming, D., Eslam, M., Hashem, A., Nielsen, M., Krag, A., Karsdal, M., Grove, J., Neil Guha, I., Kawaguchi, T., George, J., et al (2019). ADAPT: An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology, 69(3), 1075-1086. [More Information]
- Shah, N., Ventura-Cots, M., Abraldes, J., Alboraie, M., Alfadhli, A., Argemi, J., Badia-Aranda, E., Arús-Soler, E., Barritt, S., et al, George, J., Siow, W. (2019). Alcohol-related Liver Disease is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide. Clinical Gastroenterology and Hepatology, 17(11), 2320-2329. [More Information]
- Hu, L., Su, L., Dong, Z., Wu, Y., Lv, Y., George, J., Wang, J. (2019). AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model. Journal of Molecular Medicine, 97(3), 423-434. [More Information]
- Nicoll, A., Roberts, S., Lim, R., Mitchell, J., Weltman, M., George, J., Wigg, A., Stuart, K., Gow, P., MacQuillan, G., Strasser, S., et al (2019). Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels. Alimentary Pharmacology and Therapeutics, 49(10), 1314-1322. [More Information]
- Strasser, S., Thompson, A., Roberts, S., George, J. (2019). Clinical Cases in Hepatitis: Towards improving liver disease management in Australia. Journal of Gastroenterology and Hepatology, 34, 5-15. [More Information]
- Thomas, E., George, J., Sruthi, D., Vineetha, N., Gracious, N. (2019). Clinical course of dengue fever and its impact on renal function in renal transplant recipients and patients with chronic kidney disease. Nephrology, 24(5), 564-568. [More Information]
- Rosso, C., Kazankov, K., Younes, R., Esmaili, S., Marietti, M., Sacco, M., Carli, F., Gaggini, M., Salomone, F., Møller, H., George, J., et al (2019). Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. Journal of Hepatology, 71(5), 1012-1021. [More Information]
- Alavi, M., Law, M., Valerio, H., Grebely, J., Amin, J., Hajarizadeh, B., Selvey, C., George, J., Dore, G. (2019). Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. Journal of Hepatology, 71(2), 281-288. [More Information]
- Semo, J., Chernin, G., Jonas, M., Shimoni, S., George, J. (2019). Deletion of the Mir-106b~ 25 MicroRNA cluster attenuates atherosclerosis in Apolipoprotein e knockout mice. Lipids in Health and Disease, 18(1). [More Information]
- Parker, H., Cohn, J., O'Connor, H., Garg, M., Caterson, I., George, J., Johnson, N. (2019). Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial. Nutrients, 11(2), 1-15. [More Information]
- Younossi, Z., Stepanova, M., Ong, J., Yilmaz, Y., Duseja, A., Eguchi, Y., Kassas, M., Castellanos-Fernandez, M., George, J., Jacobson, I., et al (2019). Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients with Nonalcoholic and Alcohol-Related Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 17(8), 1625-1633. [More Information]
- Wei, L., Jia, J., Wang, F., Niu, J., Zhao, X., Mu, S., Liang, L., Wang, Z., Hwang, P., George, J., et al (2019). Efficacy and safety of elbasvir/grazoprevir in participants with HCV genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: final results from the randomized C-CORAL study. Journal of Gastroenterology and Hepatology, 34(1), 12-21. [More Information]
- Eslam, M., George, J. (2019). Genetic Insights for Drug Development in NAFLD. Trends In Pharmacological Sciences, 40(7), 506-516. [More Information]
- Younossi, Z., Tacke, F., Arrese, M., Sharma, B., Mostafa, I., Bugianesi, E., Wong, V., Yilmaz, Y., George, J., Fan, J., et al (2019). Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. Hepatology, 69(6), 2672-2682. [More Information]
- Douglas, M., Tay, E., Eden, J., George, J. (2019). Hepatitis C Virus Genotype 8 - successful treatment with sofosbuvir/velpatasvir. The Journal of Infectious Diseases, 220(4), 720-722. [More Information]
- Metwally, M., Thabet, K., Bayoumi, A., Nikpour, M., Stevens, W., Sahhar, J., Zochling, J., Roddy, J., Tymms, K., Strickland, G., Liddle, C., Manolios, N., George, J., Eslam, M., et al (2019). IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis. Scientific Reports, 9(1), 1-5. [More Information]
- Eslam, M., Ahlenstiel, G., George, J. (2019). Interferon Lambda and Liver Fibrosis. Journal of Interferon and Cytokine Research, 39(10), 627-635. [More Information]
- Wijaya, R., Read, S., Schibeci, S., Eslam, M., Azardaryany, M., El-Khobar, K., van der Poorten, D., Lin, R., Yuen, L., Lam, V., George, J., Douglas, M., Ahlenstiel, G. (2019). KLRG1+ natural killer cells exert a novel antifibrotic function in chronic hepatitis B. Journal of Hepatology, 71(2), 252-264. [More Information]
- Read, S., Wijaya, R., Ramezani-Moghadam, M., Tay, E., Schibeci, S., Liddle, C., Lam, V., Yuen, L., Douglas, M., Booth, D., George, J., Ahlenstiel, G. (2019). Macrophage Coordination of the Interferon Lambda Immune Response. Frontiers in Immunology, 10, 1-16. [More Information]
- Scott, C., Stokes, R., Cha, K., Clouston, A., Eslam, M., Metwally, M., Swarbrick, M., George, J., Gunton, J. (2019). Myeloid cell deletion of Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) induces non-alcoholic steatohepatitis. PloS One, 14(12), 1-20. [More Information]
- Younossi, Z., Stepanova, M., Ong, J., Jacobson, I., Bugianesi, E., Duseja, A., Eguchi, Y., Wong, V., Negro, F., Yilmaz, Y., George, J., et al (2019). Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clinical Gastroenterology and Hepatology, 17(4), 748-755. [More Information]
- Ong, A., Tay, E., Dwyer, D., George, J., Douglas, M. (2019). Pre-treatment antiviral resistance in Australians with chronic hepatitis C: prevalence of NS3 and NS5A resistance data in the state of New South Wales. Antiviral Therapy, 24(4), 281-290. [More Information]
- Eslam, M., George, J. (2019). Refining the role of epicardial adipose tissue in non-alcoholic fatty liver disease. Hepatology International, 13(6), 662-664. [More Information]
- John, M., Kim, K., Bae, S., Qiao, L., George, J. (2019). Role of BMP-9 in human liver disease. Gut, 68(11), 2097-2100. [More Information]
- Walker, S., Wankell, M., Ho, V., White, R., Deo, N., Devine, C., Dewdney, B., Bhathal, P., Govaere, O., Roskams, T., Qiao, L., George, J., Hebbard, L. (2019). Targeting mTOR and Src restricts hepatocellular carcinoma growth in a novel murine liver cancer model. PloS One, 14(2), 1-16. [More Information]
- Levy-Neuman, S., Meledin, V., Gandelman, G., Goland, S., Zilberman, L., Edri, O., Shneider, N., Abaeh, N., Bdolah-Abram, T., George, J., et al (2019). The Association Between Longitudinal Strain at Rest and Stress and Outcome in Asymptomatic Patients With Moderate and Severe Aortic Stenosis. Journal of the American Society of Echocardiography, 32(6), 722-729. [More Information]
- Wong, M., Huang, J., George, J., Huang, J., Leung, C., Eslam, M., Chan, H., Ng, S. (2019). The changing epidemiology of liver diseases in the Asia-Pacific region. Nature Reviews. Gastroenterology and Hepatology, 16(1), 57-73. [More Information]
- Møhlenberg, M., Terczynska-Dyla, E., Thomsen, K., George, J., Eslam, M., Gronbaek, H., Hartmann, R. (2019). The role of IFN in the development of NAFLD and NASH. Cytokine, 124, 1-6. [More Information]
- Kazankov, K., Jorgensen, S., Thomsen, K., Moller, H., Vilstrup, H., George, J., Schuppan, D., Gronbaek, H. (2019). The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nature Reviews. Gastroenterology and Hepatology, 16(3), 145-159. [More Information]
- Gupta, S., Read, S., Shackel, N., Hebbard, L., George, J., Ahlenstiel, G. (2019). The Role of Micronutrients in the Infection and Subsequent Response to Hepatitis C Virus. Cells, 8(6), 1-20. [More Information]
- Eslam, M., Sanyal, A., George, J. (2019). Toward More Accurate Nomenclature for Fatty Liver Diseases. Gastroenterology, 157(3), 590-593. [More Information]
- D'Avigdor, W., Budzinska, M., Lee, M., Lam, R., Kench, J., Stapelberg, M., McLennan, S., Farrell, G., George, J., McCaughan, G., Shackel, N., et al (2019). Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected Liver. Scientific Reports, 9(1), 1-12. [More Information]
2018
- Kawaguchi, T., Tokushige, K., Hyogo, H., Aikata, H., Nakajima, T., Ono, M., Kawanaka, M., Sawada, K., Imajo, K., Honda, K., George, J., et al (2018). A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. Scientific Reports, 8(1), 1-13. [More Information]
- Kabir, T., Ganda, C., Brown, R., Beveridge, D., Richardson, K., Chaturvedi, V., Candy, P., Epis, M., Wintle, L., Kalinowski, F., George, J., et al (2018). A miR-7/GAS6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. Hepatology, 67(1), 216-231. [More Information]
- El Sharkawy, R., Thabet, K., Lampertico, P., Petta, S., Mangia, A., Berg, T., Metwally, M., Bayoumi, A., Douglas, M., Khan, A., et al (2018). A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 48(5), 564-573. [More Information]
- Zhou, G., Latchoumanin, O., Hebbard, L., Duan, W., Liddle, C., George, J., Qiao, L. (2018). Aptamers as targeting ligands and therapeutic molecules for overcoming drug resistance in cancers. Advanced Drug Delivery Reviews, 134, 107-121. [More Information]
- Younossi, Z., Loomba, R., Rinella, M., Bugianesi, E., Marchesini, G., Neuschwander-Tetri, B., Serfaty, L., Negro, F., George, J., et al (2018). Current and Future Therapeutic Regimens for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology, 68(1), 361-371. [More Information]
- Younossi, Z., Loomba, R., Anstee, Q., Rinella, M., Bugianesi, E., Marchesini, G., Neuschwander-Tetri, B., Serfaty, L., Negro, F., Caldwell, S., George, J., et al (2018). Diagnostic Modalities for Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis and Associated Fibrosis. Hepatology, 68(1), 349-360. [More Information]
- El Sharkawy, R., George, J., Eslam, M. (2018). Editorial: STAT-4 polymorphism - a tool to personalise clinical practice in chronic HBV infection Authors' reply. Alimentary Pharmacology and Therapeutics, 48(7), 769-770. [More Information]
- Eslam, M., George, J. (2018). Editorial: weight change, liver histology and the metabolic effects of obeticholic acid in NASH. Alimentary Pharmacology and Therapeutics, 47(7), 1038-1039. [More Information]
- Roberts, S., Lim, R., Strasser, S., Nicoll, A., Gazzola, A., Mitchell, J., Siow, W., Khoo, T., Hamarneh, Z., Weltman, M., George, J., et al (2018). Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy. Clinical Gastroenterology and Hepatology, 16(2), 268-277. [More Information]
- George, J., Burnevich, E., Sheen, I., Heo, J., Van Kinh, N., Tanwandee, T., Cheng, P., Kim, D., Tak, W., Kizhlo, S., et al (2018). Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection. Hepatology Communications, 2(5), 595-606. [More Information]
- Furer, V., Hazan, E., Mor, A., Segal, M., Katav, A., Aloush, V., Elkayam, O., George, J., Ablin, J. (2018). Elevated Levels of Eotaxin-2 in Serum of Fibromyalgia Patients. Pain Research and Management, 2018. [More Information]
- Vilar-Gomez, E., Calzadilla-Bertot, L., Wong, V., Castellanos, M., de la Fuente, R., Metwally, M., Eslam, M., Gonzalez-Fabian, L., Alvarez-Quinones Sanz, M., Conde-Martin, A., George, J., et al (2018). Fibrosis Severity as a Determinant of Cause-specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease. Gastroenterology, 155(2), 443-457.e17. [More Information]
- Younossi, Z., Anstee, Q., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., Bugianesi, E. (2018). Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature Reviews. Gastroenterology and Hepatology, 15(1), 11-20. [More Information]
- Katoonizadeh, A., Motamed-Gorji, N., Sharafkhah, M., Ostovaneh, M., Esmaili, S., Eslami, L., Gharravi, A., Khoshnia, M., Shayanrad, A., Katouli, F., George, J., et al (2018). Intra-familial Transmission of Chronic Hepatitis B Infection: A Large Population-Based Cohort Study in Northern Iran. Archives of Iranian Medicine, 21(10), 436-442.
- Goland, S., Fugenfirov, I., Volodarsky, I., Aronson, H., Zilberman, L., Shimoni, S., George, J. (2018). Left ventricular reverse remodeling in recent onset idiopathic dilated cardiomyopathy using contemporary echo techniques. IMAJ, 20(12), 749-753.
- Sublette, V., Smith, S., George, J., McCaffery, K., Douglas, M. (2018). Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals' perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion. Journal of Health Psychology, 23(13), 1720-1731. [More Information]
- Alavi, M., Grebely, J., Hajarizadeh, B., Amin, J., Larney, S., Law, M., George, J., Degenhardt, L., Dore, G. (2018). Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012. BMC Infectious Diseases, 18(1), 215. [More Information]
- George, J., Anstee, Q., Ratziu, V., Sanyal, A. (2018). NAFLD: The evolving landscape. Journal of Hepatology, 68(2), 227-229. [More Information]
- Mahady, S., George, J. (2018). Predicting the future burden of NAFLD and NASH. Journal of Hepatology, 69(4), 774-775. [More Information]
- Laursen, T., Siggard, C., Kazankov, K., Sandahl, T., Moller, H., Ong, A., Douglas, M., George, J., Tarp, B., Kristensen, L., et al (2018). Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology. Scandinavian Journal of Gastroenterology, 53(8), 986-993. [More Information]
- McCaughan, G., Thwaites, P., Roberts, S., Strasser, S., Mitchell, J., Morales, B., Mason, S., Gow, P., Wigg, A., George, J., et al (2018). Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15). Alimentary Pharmacology and Therapeutics, 47(3), 401-411. [More Information]
- Laursen, T., Wong, G., Kazankov, K., Sandahl, T., Moller, H., Hamilton-Dutoit, S., George, J., Chan, H., Gronbaek, H. (2018). Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. Journal of Gastroenterology and Hepatology, 33(2), 484-491. [More Information]
- Read, S., Parnell, G., Booth, D., Douglas, M., George, J., Ahlenstiel, G. (2018). The antiviral role of zinc and metallothioneins in hepatitis C infection. Journal of Viral Hepatitis, 25(5), 491-501. [More Information]
- Alavi, M., Janjua, N., Chong, M., Grebely, J., Aspinall, E., Innes, H., Valerio, H., Hajarizadeh, B., Hayes, P., Krajden, M., George, J., et al (2018). The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: an international study. Journal of Hepatology, 68(3), 393-401. [More Information]
- Simpson, S., Raubenheimer, D., Cogger, V., Macia, L., Solon-Biet, S., Le Couteur, D., George, J. (2018). The nutritional geometry of liver disease including non-alcoholic fatty liver disease (NAFLD). Journal of Hepatology, 68(2), 316-325. [More Information]
- Alzahrani, B., Iseli, T., Ramezani-Moghadam, M., Ho, V., Wankell, M., Sun, E., Qiao, L., George, J., Hebbard, L. (2018). The role of AdipoR1 and AdipoR2 in liver fibrosis. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1864 (3), 700-708. [More Information]
- Zeuzem, S., Serfaty, L., Vierling, J., Cheng, W., George, J., Sperl, J., Strasser, S., Kumada, H., Hwang, P., Robertson, M., et al (2018). The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. Journal of Gastroenterology, 53(5), 679-688. [More Information]
- Alavi, M., Janjua, N., Chong, M., Grebely, J., Aspinall, E., Innes, H., Valerio, H., Hajarizadeh, B., Hayes, P., Krajden, M., George, J., et al (2018). Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: an international comparison. Journal of Viral Hepatitis, 25(5), 473-481. [More Information]
- Robotin, M., Masgoret, X., Porwal, M., Goldsbury, D., Khoo, C., George, J. (2018). Using a chronic hepatitis B Registry to support population-level liver cancer prevention in Sydney, Australia. Clinical Epidemiology, 10, 41-49. [More Information]
- Sheppard-Law, S., Zablotska-Manos, I., Kermeen, M., Holdaway, S., Lee, A., George, J., Zekry, A., Maher, L. (2018). Utilisation of hepatocellular carcinoma screening in Australians at risk of hepatitis B virus-related carcinoma and prescribed anti-viral therapy. Journal of Clinical Nursing, 27(13-14), 2673-2683. [More Information]
2017
- Siddiqui, M., Maroteau, C., Veluchamy, A., Tornio, A., Tavendale, R., Carr, F., Abelega, N., Carr, D., Bloch, K., Hallberg, P., et al (2017). A common missense variant of LILRB5 is associated with statin intolerance and myalgia. European Heart Journal, 38(48), 3569-3575. [More Information]
- Gauthiez, E., Habfast-Robertson, I., Rueger, S., Kutalik, Z., Aubert, V., Berg, T., Cerny, A., Gorgievski, M., George, J., Heim, M., et al (2017). A systematic review and meta-analysis of HCV clearance. Liver International, 37(10), 1431-1445. [More Information]
- Baatarkhuu, O., Lee, H., George, J., Munkh-Orshikh, D., Enkhtuvshin, B., Ariunaa, S., Eslam, M., Ahn, S., Han, K., Kim, D. (2017). Acute hepatitis A, B and C but not D is still prevalent in Mongolia: a time trend analysis. Clinical and Molecular Hepatology, 23(2), 147-153. [More Information]
- Obeid, S., Wankell, M., Charrez, B., Sternberg, J., Kreuter, R., Esmaili, S., Ramezani-Moghadam, M., Devine, C., Read, S., Bhathal, P., Ahlenstiel, G., Qiao, L., George, J., Hebbard, L., et al (2017). Adiponectin confers protection from acute colitis and restricts a B cell immune response. Journal of Biological Chemistry, 292(16), 6569-6582. [More Information]
- Hashida, R., Kawaguchi, T., Bekki, M., Omoto, M., Matsuse, H., Nago, T., Takano, Y., Ueno, T., Koga, H., George, J., et al (2017). Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. Journal of Hepatology, 66(1), 142-152. [More Information]
- Zhou, G., Latchoumanin, O., Bagdesar, M., Hebbard, L., Duan, W., Liddle, C., George, J., Qiao, L. (2017). Aptamer-based therapeutic approaches to target cancer stem cells. Theranostics, 7(16), 3948-3961. [More Information]
- Siddiqui, M., Veluchamy, A., Maroteau, C., Tavendale, R., Carr, F., Pearson, E., Colhoun, H., Morris, A., George, J., Doney, A., et al (2017). CKM Glu83Gly Is Associated with Blunted Creatine Kinase Variation, but Not with Myalgia. Circulation Cardiovascular Genetics, 10(4). [More Information]
- Mahady, S., Macaskill, P., Craig, J., Wong, G., Chu, W., Chan, H., George, J., Wong, V. (2017). Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis. Clinical Gastroenterology and Hepatology, 15(9), 1453-1460. [More Information]
- Huo, X., Han, S., Wu, G., Latchoumanin, O., Zhou, G., Qiao, L., George, J., Hebbard, L. (2017). Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: Implications for tumorigenesis, disease progression, and liver cancer stem cells. Molecular Cancer, 16(1), 1-10. [More Information]
- Keating, S., Hackett, D., Parker, H., Way, K., O'Connor, H., Salis (nee Sainsbury), A., Baker, M., Chuter, V., Caterson, I., George, J., Johnson, N. (2017). Effect of resistance training on liver fat and visceral adiposity in adults with obesity: A randomized controlled trial. Hepatology Research, 47(7), 622-631. [More Information]
- Rødgaard-Hansen, S., St George, A., Kazankov, K., Bauman, A., George, J., Grønbæk, H., Møller, H. (2017). Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease. Scandinavian Journal of Clinical and Laboratory Investigation, 77(7), 498-504. [More Information]
- Mahady, S., Wong, G., Turner, R., Mitchell, P., Macaskill, P., Craig, J., George, J. (2017). Elevated Liver Enzymes and Mortality in Older Individuals: A Prospective Cohort Study. Journal of Clinical Gastroenterology, 51(5), 439-445. [More Information]
- Sabag, A., Way, K., Keating, S., Sultana, R., O'Connor, H., Baker, M., Chuter, V., George, J., Johnson, N. (2017). Exercise and ectopic fat in type 2 diabetes: a systematic review and meta-analysis. Diabetes and Metabolism, 43(3), 195-210. [More Information]
- Sheppard-Law, S., Zablotska-Manos, I., Kermeen, M., Holdaway, S., Lee, A., Zekry, A., Dore, G., George, J., Maher, L. (2017). Factors associated with HBV virological breakthrough. Antiviral Therapy, 22(1), 53-60. [More Information]
- Sheppard-Law, S., Zablotska-Manos, I., Kermeen, M., Holdaway, S., Lee, A., Zekry, A., Dore, G., George, J., Maher, L. (2017). Factors associated with non-adherence to HBV antiviral therapy. Antiviral Therapy, 22(1), 53-60. [More Information]
- Lim, L., Thompson, A., Patterson, S., George, J., Strasser, S., Lee, A., Sievert, W., Nicoll, A., Desmond, P., Roberts, S., et al (2017). Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy. Liver International, 37(6), 827-835. [More Information]
- Scott, C., Cha, K., Ngai, J., Jiang, C., Cheng, K., Stokes, R., Ho, K., George, J., Gonzalez, F., Gunton, J. (2017). Hepatic Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) regulates metabolism in mice. PloS One, 12(11), 1-14. [More Information]
- Waziry, R., Hajarizadeh, B., Grebely, J., Amin, J., Law, M., Danta, M., George, J., Dore, G. (2017). Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. Journal of Hepatology, 67(6), 1204-1212. [More Information]
- Eslam, M., McLeod, D., Kelaeng, K., Mangia, A., Berg, T., Thabet, K., Irving, W., Dore, G., Sheridan, D., Gronbaek, H., Booth, D., Weltman, M., Douglas, M., Liddle, C., George, J., et al (2017). IFN-(lambda)3, not IFN-(lambda)4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nature Genetics, 49(5), 795-800. [More Information]
- Bipi, P., George, J., Gomathy, S., Gracious, N., Kumar, S., Mohandas, M. (2017). Lactate levels and risk of lactic acidosis with metformin in diabetic kidney disease patients. Saudi Journal of Kidney Diseases and Transplantation, 28(6), 1356-1361. [More Information]
- Sublette, V., Smith, S., George, J., McCaffery, K., Douglas, M. (2017). Listening to both sides: A qualitative comparison between patients with hepatitis C and their healthcare professionals' perceptions of the facilitators and barriers to hepatitis C treatment adherence and completion. Journal of Health Psychology, 22(10), 1300-1311. [More Information]
- Robotin, M., Porwal, M., Hopwood, M., Nguyen, D., Sze, M., Treloar, C., George, J. (2017). Listening to the consumer voice: developing multilingual cancer information resources for people affected by liver cancer. Health Expectations, 20(1), 171-182. [More Information]
- Petta, S., Eslam, M., Valenti, L., Bugianesi, E., Barbara, M., Camma, C., Porzio, M., Rosso, C., Fargion, S., George, J., et al (2017). Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. Liver International, 37(9), 1389-1396. [More Information]
- Keating, S., Parker, H., Hickman, I., Gomersall, S., Wallen, M., Coombes, J., Macdonald, G., George, J., Johnson, N. (2017). NAFLD in clinical practice: Can simple blood and anthropometric markers be used to detect change in liver fat measured by 1H-MRS? Liver International, 37(12), 1907-1915. [More Information]
- Wu, G., Wilson, G., George, J., Liddle, C., Hebbard, L., Qiao, L. (2017). Overcoming treatment resistance in cancer: Current understanding and tactics. Cancer Letters, 387, 69-76. [More Information]
- Rankin, S., Elder, D., Ogston, S., George, J., Lang, C., Choy, A. (2017). Population-level incidence and monitoring of adverse drug reactions with long-term amiodarone therapy. Cardiovascular Therapeutics, 35(3). [More Information]
- Mahady, S., Gale, J., Macaskill, P., Craig, J., George, J. (2017). Prevalence of elevated alanine transaminase in Australia and its relationship to metabolic risk factors: A cross-sectional study of 9,447 people. Journal of Gastroenterology and Hepatology, 32(1), 169-176. [More Information]
- Lubel, J., Strasser, S., Stuart, K., Dore, G., Thompson, A., Pianko, S., Bollipo, S., Mitchell, J., Fragomeli, V., Jones, T., George, J., et al (2017). Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 – final results of the REV1TAL study. Antiviral Therapy, 22(8), 699-710. [More Information]
- Han, S., Latchoumanin, O., Wu, G., Zhou, G., Hebbard, L., George, J., Qiao, L. (2017). Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors. Cancer Letters, 390, 188-200. [More Information]
- Gane, E., DeJesus, E., Janczewska, E., George, J., Diago, M., Da Silva, M., Reesink, H., Nikitin, I., Hinrichsen, H., Bourgeois, S., et al (2017). Simeprevir with peginterferon (alpha)-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: An open-label, rollover study. BMC Infectious Diseases, 17(1), 1-13. [More Information]
- Waziry, R., Grebely, J., Amin, J., Alavi, M., Hajarizadeh, B., George, J., Matthews, G., Law, M., Dore, G. (2017). Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014). Hepatology Communications, 1(8), 736-747. [More Information]
- Rademaker, M., Gupta, M., Andrews, M., Armour, K., Baker, C., Foley, P., Gebauer, K., George, J., Rubel, D., Sullivan, J. (2017). The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian setting. Australasian Journal of Dermatology, 58(3), 166-170. [More Information]
- Simpson, S., Le Couteur, D., James, D., George, J., Gunton, J., Solon-Biet, S., Raubenheimer, D. (2017). The Geometric Framework for Nutrition as a tool in precision medicine. Nutrition and Healthy Aging, 4(3), 217-226. [More Information]
- Thabet, K., Chan, H., Petta, S., Mangia, A., Berg, T., Boonstra, A., Brouwer, W., Abate, M., Wong, V., Nazmy, M., Liddle, C., George, J., Eslam, M., et al (2017). The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. Hepatology, 65(6), 1840-1850. [More Information]
- John, M., Metwally, M., Mangia, A., Romero-Gomez, M., Berg, T., Sheridan, D., George, J., Eslam, M. (2017). TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C. Gastroenterology, 153(5), 1448-1449. [More Information]
- Read, S., O'Connor, K., Suppiah, V., Ahlenstiel, C., Obeid, S., Cook, K., Cunningham, A., Douglas, M., Hogg, P., Booth, D., George, J., Ahlenstiel, G. (2017). Zinc is a potent and specific inhibitor of IFN-(lambda)3 signaling. Nature Communications, 8, 1-15. [More Information]
2016
- Orriss, I., Arnett, T., George, J., Witham, M. (2016). Allopurinol and oxypurinol promote osteoblast differentiation and increase bone formation. Experimental Cell Research, 342(2), 166-174. [More Information]
- Goland, S., Weinstein, J., Zalik, A., Kuperstein, R., Zilberman, L., Shimoni, S., Arad, M., Ben Gal, T., George, J. (2016). Angiogenic Imbalance and Residual Myocardial Injury in Recovered Peripartum Cardiomyopathy Patients. Circulation. Heart Failure, 9(11). [More Information]
- Zhou, G., Wilson, G., Hebbard, L., Duan, W., Liddle, C., George, J., Qiao, L. (2016). Aptamers: A promising chemical antibody for cancer therapy. Oncotarget, 7(12), 13446-13463. [More Information]
- Basu, U., Goodbrand, J., Mcmurdo, M., Donnan, P., McGilchrist, M., Frost, H., George, J., Witham, M. (2016). Association between allopurinol use and hip fracture in older patients. Bone, 84, 189-193. [More Information]
- Awan, Z., Tay, E., Eyre, N., Wu, L., Beard, M., Boo, I., Drummer, H., George, J., Douglas, M. (2016). Calsyntenin-1 mediates hepatitis C virus replication. Journal of General Virology, 97(8), 1877-1887. [More Information]
- Shimoni, S., Meledin, V., Bar, I., Fabricant, J., Gandelman, G., George, J. (2016). Circulating CD14+ monocytes in patients with aortic stenosis. Journal of Geriatric Cardiology, 13(1), 81-87. [More Information]
- Shimoni, S., Bar, I., Meledin, V., Derazne, E., Gandelman, G., George, J. (2016). Circulating endothelial progenitor cells and clinical outcome in patients with aortic stenosis. PloS One, 11(2). [More Information]
- Shimoni, S., Bar, I., Meledin, V., Gandelman, G., George, J. (2016). Circulating regulatory T cells in patients with aortic valve stenosis: Association with disease progression and aortic valve intervention. International Journal of Cardiology, 218, 181-187. [More Information]
- Bipi, P., Gracious, N., Kumar, S., George, J. (2016). Combined surgical and immunosupressive therapy for encapsulating peritoneal sclerosis. Indian Journal of Nephrology, 26(6), 458-460. [More Information]
- Wallace, B., Siddiqui, M., Palmer, C., George, J. (2016). Common Creatine Kinase gene mutation results in falsely reassuring CK levels in muscle disorders. QJM, 109(6), 413-414. [More Information]
- Eslam, M., Mangia, A., Berg, T., Chan, H., Irving, W., Dore, G., Abate, M., Bugianesi, E., Adams, L., Najim, M., Weltman, M., Rahme, A., Booth, D., Liddle, C., Douglas, M., van der Poorten, D., George, J., White, R., Leung, R., et al (2016). Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology, 64(1), 34-46. [More Information]
- Mahady, S., George, J. (2016). Exercise and diet in the management of nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 65(8), 1172-1182. [More Information]
- Eslam, M., Hashem, A., Romero-Gomez, M., Berg, T., Dore, G., Mangia, A., Chan, H., Irving, W., Sheridan, D., Abate, M., Weltman, M., Kelaeng, K., Ahlenstiel, G., Liddle, C., Douglas, M., Booth, D., George, J., et al (2016). FibroGENE: A gene-based model for staging liver fibrosis. Journal of Hepatology, 64(2), 390-398. [More Information]
- Nielsen, M., Karsdal, M., Kazankov, K., Gronbaek, H., Krag, A., Leeming, D., Schuppan, D., George, J. (2016). Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury. Alimentary Pharmacology and Therapeutics, 44, 1242-1252. [More Information]
- Eslam, M., George, J. (2016). Genetic and epigenetic mechanisms of NASH. Hepatology International, 10(3), 394-406. [More Information]
- Heim, M., Bochud, P., George, J. (2016). Host - hepatitis C viral interactions: The role of genetics. Journal of Hepatology, 65(1 Suppl), S22-S32. [More Information]
- O'Connor, K., Read, S., Wang, X., Schibeci, S., Eslam, M., Ong, A., Weltman, M., Douglas, M., Mazzola, A., Craxi, A., Stewart, G., Liddle, C., George, J., Ahlenstiel, G., Booth, D., et al (2016). IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. Genes and Immunity, 17(6), 328-334. [More Information]
- Katoonizadeh, A., Sharafkhah, M., Ostovaneh, M., Norouzi, A., Khoshbakht, N., Mohamadkhani, A., Eslami, L., Gharravi, A., Shayanrad, A., Khoshnia, M., Esmaili, S., George, J., et al (2016). Immune responses to hepatitis B immunization 10-18 years after primary vaccination: a population-based cohort study. Journal of Viral Hepatitis, 23(10), 805-811. [More Information]
- Jensen, D., Brunda, M., Elston, R., Gane, E., George, J., Glavini, K., Hammond, J., Le Pogam, S., Najera, I., Passe, S., et al (2016). Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. Liver International, 36(4), 505-514. [More Information]
- Williams, K., Sullivan, D., Veillard, A., O'Brien, R., George, J., Jenkins, A., Young, S., Ehnholm, C., Duffield, A., Twigg, S., Keech, A. (2016). Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetic Medicine, 33(3), 356-364. [More Information]
- Sheridan, D., Hajarizadeh, B., Fenwick, F., Matthews, G., Applegate, T., Douglas, M., Neely, D., Askew, B., Dore, G., George, J., et al (2016). Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection. Liver International, 36(12), 1774-1782. [More Information]
- Thabet, K., Asimakopoulos, A., Shojaei, M., Romero-Gomez, M., Mangia, A., Irving, W., Berg, T., Dore, G., Gronbaek, H., Sheridan, D., Weltman, M., White, R., Douglas, M., Liddle, C., van der Poorten, D., George, J., Eslam, M., et al (2016). MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nature Communications, 7, 1-8. [More Information]
- Elder, D., Singh, J., Levin, D., Donnelly, L., Choy, A., George, J., Struthers, A., Doney, A., Lang, C. (2016). Mean HbA
1c and mortality in diabetic individuals with heart failure: A population cohort study. European Journal of Heart Failure, 18(1), 94-102. [More Information] - Vongsuvanh, R., van der Poorten, D., Iseli, T., Strasser, S., McCaughan, G., George, J. (2016). Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma. PloS One, 11(5), 1-12. [More Information]
- Keating, S., Parker, H., Pavey, T., Baker, M., Caterson, I., George, J., Johnson, N. (2016). Objectively Quantified Physical Activity and Sedentary Behavior in Predicting Visceral Adiposity and Liver Fat. Journal of Obesity, 2016, 1-10. [More Information]
- Williams, K., Sullivan, D., Nicholson, G., George, J., Jenkins, A., Januszewski, A., Gebski, V., Manning, P., Tan, Y., Donoghoe, M., Buizen, L., Twigg, S., Keech, A., et al (2016). Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism: Clinical and Experimental, 65(5), 783-793. [More Information]
- Asimakopoulos, A., Mangia, A., Dore, G., Lloyd, A., George, J., Eslam, M. (2016). Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in Europeans. Hepatology, 64(6), 2264-2265. [More Information]
- Eslam, M., George, J. (2016). Targeting IFN-lambda: Therapeutic Implications. Expert Opinion on Therapeutic Targets, 20(12), 1425-1432. [More Information]
- Kazankov, K., Barrera Martinez, F., Moller, H., Rosso, C., Bugianesi, E., David, E., Jouness, R., Esmaili, S., Eslam, M., McLeod, D., George, J., et al (2016). The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. Liver International, 36(10), 1549-1557. [More Information]
- Alavi, M., Law, M., Grebely, J., Amin, J., Hajarizadeh, B., George, J., Dore, G. (2016). Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: a population-based study, 1995-2012. Journal of Hepatology, 65(5), 879-887. [More Information]
- Waziry, R., Grebely, J., Amin, J., Alavi, M., Hajarizadeh, B., George, J., Matthews, G., Law, M., Dore, G. (2016). Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014). Journal of Hepatology, 65(6), 1086-1093. [More Information]
2015
- Dong, Z., Su, L., Esmaili, S., Iseli, T., Ramezani-Moghadam, M., Hu, L., Xu, A., George, J., Wang, J. (2015). Adiponectin attenuates liver fibrosis by inducing nitric oxide production of hepatic stellate cells. Journal of Molecular Medicine, 93(12), 1327-1339. [More Information]
- Ramezani-Moghadam, M., Wang, J., Ho, V., Iseli, T., Alzahrani, B., Xu, A., van der Poorten, D., Qiao, L., George, J., Hebbard, L. (2015). Adiponectin Reduces Hepatic Stellate Cell Migration by Promoting Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Secretion. Journal of Biological Chemistry, 290(9), 5533-5542. [More Information]
- Williams, K., Burns, K., Constantino, M., Shackel, N., Prakoso, E., Wong, J., Wu, T., George, J., McCaughan, G., Twigg, S. (2015). An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes. Journal of Diabetes and Its Complications, 29(8), 1240-1247. [More Information]
- Senthilvelkumar, T., Magimairaj, H., Fletcher, J., Tharion, G., George, J. (2015). Comparison of body weight-supported treadmill training versus body weight-supported overground training in people with incomplete tetraplegia: A pilot randomized trial. Clinical Rehabilitation, 29(1), 42-49. [More Information]
- Dore, G., Lawitz, E., Hezode, C., Shafran, S., Ramji, A., Tatum, H., Taliani, G., Tran, A., Strasser, S., George, J., et al (2015). Daclatasvir plus Peginterferon and Ribavirin is Non-inferior to Peginterferon and Ribavirin Alone, and Reduces Duration of Treatment for HCV Genotype 2 or 3 Infection. Gastroenterology, 148(2), 355-366. [More Information]
- Sun, Y., George, J., Rocha, S. (2015). Dose-dependent effects of allopurinol on human foreskin fibroblast cells and human umbilical vein endothelial cells under hypoxia. PloS One, 10(4). [More Information]
- Wilson, G., Hebbard, L., Duan, W., Qiao, L., George, J. (2015). Editorial: Gene therapy for gastrointestinal and liver cancers: past experience, current status and future perspectives. Current Gene Therapy, 15(2), 93-96. [More Information]
- Wilson, G., Hebbard, L., Duan, W., George, J., Qiao, L. (2015). Editorial: Induced Pluripotent Stem Cells (iPSCs) in the Gastroenterology and Hepatology: from Basic Research to Clinical Applications. Current Stem Cell Research & Therapy, 10(3), 190-192.
- Mahady, S., George, J. (2015). Editorial: triglycerides in chronic liver disease - a marker of disease progression? Alimentary Pharmacology and Therapeutics, 42(2), 239. [More Information]
- Keating, S., Hackett, D., Parker, H., O'Connor, H., Gerofi, J., Salis (nee Sainsbury), A., Baker, M., Chuter, V., Caterson, I., George, J., Johnson, N. (2015). Effect of aerobic exercise training dose on liver fat and visceral adiposity. Journal of Hepatology, 63(1), 174-182. [More Information]
- Parker, H., O'Connor, H., Cohn, J., Garg, M., Johnson, N., Caterson, I., George, J. (2015). Effect of combined fish oil plus coenzyme Q10 supplementation on Omega-3 Index and cardiovascular risk markers in overweight men. Joint Annual Scientific Meeting of the Nutrition Society of New Zealand and the Nutrition Society of Australia, New Zealand: Nutrition Society of Australia and Nutrition Society of New Zealand.
- Heeboll, S., Thomsen, K., Clouston, A., Sundelin, E., Radko, Y., Christensen, L., Ramezani-Moghadam, M., Kreutzfeldt, M., Pedersen, S., Jessen, N., Hebbard, L., George, J., et al (2015). Effect of resveratrol on experimental non-alcoholic steatohepatitis. Pharmacological Research, 95-96, 34-41. [More Information]
- Goudie, A., Elder, D., Deshmukh, H., Szwejkowski, B., Lang, C., George, J. (2015). Effect of warfarin on survival in patients with concomitant left ventricular systolic dysfunction and pulmonary hypertension: A population cohort study. European Journal of Heart Failure, 17(1), 90-97. [More Information]
- Foster, G., Pianko, S., Brown, A., Forton, D., Nahass, R., George, J., Barnes, E., Brainard, D., Massetto, B., Lin, M., et al (2015). Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon-Alfa in Patients with Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients with Cirrhosis and Hepatitis C Virus Genotype 2 Infection. Gastroenterology, 149(6), 1462-1470. [More Information]
- Parker, H., O'Connor, H., Keating, S., Cohn, J., Garg, M., Caterson, I., George, J., Johnson, N. (2015). Efficacy of the Omega-3 Index in predicting non-alcoholic fatty liver disease in overweight and obese adults: a pilot study. British Journal of Nutrition, 114(5), 780-787. [More Information]
- Tse, E., Helbig, K., Van der Hoek, K., McCartney, E., Van der Hoek, M., George, J., Beard, M. (2015). Fatty Acids Induce a Pro-Inflammatory Gene Expression Profile in Huh-7 Cells That Attenuates the Anti-HCV Action of Interferon. Journal of Interferon and Cytokine Research, 35(5), 392-400. [More Information]
- Eslam, M., George, J. (2015). Genome-Wide Association Studies and Hepatitis C: Harvesting the Benefits of the Genomic Revolution. Seminars in Liver Disease, 35(4), 402-420. [More Information]
- Read, S., Tay, E., Shahidi, M., O'Connor, K., Booth, D., George, J., Douglas, M. (2015). Hepatitis C Virus Driven AXL Expression Suppresses the Hepatic Type I Interferon Response. PloS One, 10(8), 1-16. [More Information]
- Scott, C., Cha, K., Rao, R., Liddle, C., George, J., Gunton, J. (2015). Hepatocyte- Specific Deletion of ARNT (Aryl Hydrocarbon Receptor Nuclear Translocator) Results in Altered Fibrotic Gene Expression in the Thioacetamide Model of Liver Injury. PloS One, 10(3), 1-11. [More Information]
- Struthers, A., George, J. (2015). High B-type natriuretic peptide hypertensives at target blood pressure: Potential role of β-blockers to reduce their elevated risk. Hypertension, 66(5), 927-932. [More Information]
- Rueger, S., Bochud, P., Dufour, J., Mullhaupt, B., Semela, D., Helm, M., Moradpour, D., Cerny, A., Malinverni, R., Booth, D., Suppiah, V., George, J., et al (2015). Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut, 64(10), 1605-1615. [More Information]
- Benton, G., DeGray, G., Kleinman, H., George, J., Arnaoutova, I. (2015). In vitro microtumors provide a physiologically predictive tool for breast cancer therapeutic screening. PloS One, 10(4). [More Information]
- Sublette, V., Hopwood, M., George, J., Smith, S., Perry, K., McCaffery, K., Douglas, M. (2015). Instrumental support to facilitate hepatitis C treatment adherence: Working around shortfalls in shared-care. Psychology, Health and Medicine, 20(2), 186-197. [More Information]
- Eslam, M., Hashem, A., Leung, R., Romero-Gomez, M., Berg, T., Dore, G., Chan, H., Irving, W., Sheridan, D., Abate, M., Weltman, M., Douglas, M., Liddle, C., Booth, D., George, J., Ahlenstiel, G., et al (2015). Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nature Communications, 6, 1-10. [More Information]
- Charach, G., Rubalsky, O., Charach, L., Rabinovich, A., Argov, O., Rogowski, O., George, J. (2015). Internal thoracic impedance - A useful method for expedient detection and convenient monitoring of pleural effusion. PloS One, 10(4). [More Information]
- Eslam, M., George, J. (2015). Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy? Hepatology International, 9(1), 5-8. [More Information]
- Buti, M., Fung, S., Gane, E., Afdhal, N., Flisiak, R., Gurel, S., Flaherty, J., Martins, E., Yee, L., Dinh, P., George, J., et al (2015). Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatology International, 9(2), 243-250. [More Information]
- Esmaili, S., George, J. (2015). Ltb4r1 inhibitor: A pivotal insulin sensitizer? Trends in Endocrinology and Metabolism, 26(5), 221-222. [More Information]
- Nielsen, M., Kazankov, K., Leeming, D., Karsdal, M., Krag, A., Barrera Martinez, F., McLeod, D., George, J., Grønbæk, H. (2015). Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients. PloS One, 10(9), 1-12. [More Information]
- Wu, G., Wilson, G., George, J., Qiao, L. (2015). Modulation of Notch Signaling as a Therapeutic Approach for Liver Cancer. Current Gene Therapy, 15(2), 171-181. [More Information]
- Ojha, R., George, J., Chandy, B., Tharion, G., Devasahayam, S. (2015). Neuromodulation by surface electrical stimulation of peripheral nerves for reduction of detrusor overactivity in patients with spinal cord injury: A pilot study. Journal of Spinal Cord Medicine, 38(2), 207-213. [More Information]
- Nguyen, V., George, J. (2015). Nonalcoholic Fatty Liver Disease Management: Dietary and Lifestyle Modifications. Seminars in Liver Disease, 35(3), 318-337. [More Information]
- Wu, G., Wilson, G., Zhou, G., Hebbard, L., George, J., Qiao, L. (2015). Oct4 is a reliable marker of liver tumor propagating cells in hepatocellular carcinoma. Discovery Medicine, 20(110), 219-229.
- Petta, S., Vanni, E., Bugianesi, E., Rosso, C., Cabibi, D., Camma, C., Di Marco, F., Eslam, M., Grimaudo, S., Macaluso, F., McLeod, D., George, J., et al (2015). PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. Alimentary Pharmacology and Therapeutics, 41(10), 939-948. [More Information]
- Nair, S., Sarasamma, S., Gracious, N., George, J., Anish, T., Radhakrishnan, R. (2015). Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level. Experimental and Clinical Transplantation, 13, 197-200. [More Information]
- Kazankov, K., Moller, H., Bibby, B., Vilstrup, H., George, J., Gronbaek, H. (2015). Reply. Hepatology, 61(2), 735-735. [More Information]
- Goland, S., Perelman, S., Asalih, N., Shimoni, S., Walfish, O., Hallak, M., Hagay, Z., George, J., Shotan, A., Blondheim, D. (2015). Shortness of Breath during Pregnancy: Could a Cardiac Factor Be Involved? Clinical Cardiology, 38(10), 598-603. [More Information]
- Mahady, S., Schlub, T., Bero, L., Moher, D., Tovey, D., George, J., Craig, J. (2015). Side effects are incompletely reported among systematic reviews in gastroenterology. Journal of Clinical Epidemiology, 68(2), 144-153. [More Information]
- Reddy, K., Zeuzem, S., Zoulim, F., Weiland, O., Horban, A., Stanciu, C., Villamil, F., Andreone, P., George, J., Dammers, E., et al (2015). Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. The Lancet Infectious Diseases, 15(1), 27-35. [More Information]
- Meledin, V., Gandelman, G., Derazne, E., Kogan, Y., George, J., Shimoni, S. (2015). Stroke volume adjusted to afterload for assessment of cardiac performance in patients with severe aortic stenosis and preserved left ventricular ejection fraction. Cardiology, 130(4), 260-266. [More Information]
- Zhou, G., Wilson, G., George, J., Qiao, L. (2015). Targeting cancer stem cells as a therapeutic approach in liver cancer. Current Gene Therapy, 15(2), 161-170. [More Information]
- Keating, S., George, J., Johnson, N. (2015). The benefits of exercise for patients with non-alcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 9(10), 1247-1250. [More Information]
- Bhala, N., George, J. (2015). The Burden of Non-alcoholic Fatty Liver Disease (NAFLD) in the Asia Pacific Region. Current Hepatology Reports, 14(2), 77-86. [More Information]
- Sublette, V., Smith, S., George, J., McCaffery, K., Douglas, M. (2015). The Hepatitis C treatment experience: Patients' perceptions of the facilitators of and barriers to uptake, adherence and completion. Psychology & Health, 30(8), 987-1004. [More Information]
- Read, S., Tay, E., Shahidi, M., McLauchlan, J., George, J., Douglas, M. (2015). The Mechanism of Interferon Refractoriness During Hepatitis C Virus Infection and Its Reversal with a Peroxisome Proliferator-Activated Receptor [alpha] Agonist. Journal of Interferon and Cytokine Research, 35(6), 486-497. [More Information]
- Duong, H., Dong, Z., Su, L., Boyer, C., George, J., Davis, T., Wang, J. (2015). The Use of Nanoparticles to Deliver Nitric Oxide to Hepatic Stellate Cells for Treating Liver Fibrosis and Portal Hypertension. Small, 11(19), 2291-2304. [More Information]
- Charach, G., Michowitz, Y., Rogowski, O., Charach, L., Argov, O., George, J., Grosskopf, I. (2015). Usefulness of antibodies to oxidized low-density lipoproteins as predictors of morbidity and prognosis in heart failure patients aged ≥65 years. American Journal of Cardiology, 116(9), 1379-1384. [More Information]
2014
- Douglas, M., Esmaili, S., George, J. (2014). A new role for IKK-alpha in Hepatitis C virus induced lipogenesis. Hepatology, 59(5), 2046-2049. [More Information]
- Muir, A., Arora, S., Everson, G., Flisiak, R., George, J., Ghalib, R., Gordon, S., Gray, T., Greenbloom, S., Hassanein, T., et al (2014). A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. Journal of Hepatology, 61(6), 1238-1246. [More Information]
- Bhide, R., Barman, A., Varghese, S., Chatterjee, A., Mammen, S., George, J., Thomas, R. (2014). A rare presentation of subacute progressive ascending myelopathy secondary to cement leakage in percutaneous vertebroplasty. American Journal of Physical Medicine & Rehabilitation, 93(5), 431-436. [More Information]
- Beard, M., Ffrench, R., Gowans, E., Helbig, K., Eyre, N., Douglas, M., Grebely, J., Ahlenstiel, G., Locarnini, S., George, J., et al (2014). A Summary of the 20(th) International Symposium on Hepatitis C Virus and Related Viruses. Gastroenterology, 147(1), e1-e4. [More Information]
- Kraus, S., Naumov, I., Shapira, S., Kazanov, D., Aroch, I., Afek, A., Eisenberg, O., George, J., Arber, N., Finkelstein, A. (2014). Aspirin but not meloxicam attenuates early atherosclerosis in apolipoprotein E knockout mice. IMAJ, 16(4), 233-238.
- Musso, G., Gambino, R., Tabibian, J., Ekstedt, M., Kechagias, S., Hamaguchi, M., Hultcrantz, R., Hagstrom, H., Yoon, S., Charatcharoenwitthaya, P., George, J., Barrera Martinez, F., et al (2014). Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. PLoS Medicine, 11(7), 1-26. [More Information]
- Shimoni, S., Bar, I., Zilberman, L., George, J. (2014). Autoantibodies to oxidized low-density lipoprotein in patients with aortic regurgitation: Association with aortic diameter size. Cardiology, 128(1), 54-61. [More Information]
- George, J., Matucci-Cerinic, M., Bar, I., Shimoni, S. (2014). Circulating autoantibodies to endothelial progenitor cells: Binding characteristics and association with risk factors for atherosclerosis. PloS One, 9(6). [More Information]
- Witham, M., George, J. (2014). Clinical trial design for older people-time for a rethink. QJM, 107(1), 15-16. [More Information]
- Poustchi, H., Katoonizadeh, A., Ostovaneh, M., Moossavi, S., Sharafkhah, M., Esmaili, S., Pourshams, A., Mohamadkhani, A., Besharat, S., Merat, S., George, J., et al (2014). Cohort profile: Golestan Hepatitis B Cohort Study- A Prospective Long Term Study in Northern Iran ​. Middle East Journal of Digestive Diseases, 6(4), 186-194.
- Robotin, M., George, J. (2014). Community-based hepatitis B screening: what works? Hepatology International, 8(4), 478-492. [More Information]
- Robotin, M., Kansil, M., Porwal, M., Penman, A., George, J. (2014). Community-based prevention of hepatitis-B-related liver cancer: Australian insights. Bulletin of the World Health Organization, 92(5), 374-379. [More Information]
- O'Connor, K., George, J., Booth, D., Ahlenstiel, G. (2014). Dendritic cells in hepatitis C virus infection: Key players in the IFNL3-genotype response. World Journal of Gastroenterology, 20(47), 17830-17838. [More Information]
- Flynn, J., Sacks-Davis, R., Higgs, P., Aitken, C., Moneer, S., Suppiah, V., Tracy, L., Ffrench, R., Bowden, S., Drummer, H., George, J., et al (2014). Detection of HCV-Specific IFN-gamma Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users. Hepatitis Monthly, 14(1), 1-14. [More Information]
- Roberts, S., Mitchell, J., Leung, R., Booth, D., Bollipo, S., Ostapowicz, G., Sloss, A., McCaughan, G., Dore, G., Thompson, A., George, J., et al (2014). Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies. Journal of Gastroenterology and Hepatology, 29(1), 179-184. [More Information]
- Heeboll, S., Thomsen, K., Pedersen, S., Vilstrup, H., George, J., Gronbaek, H. (2014). Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World Journal of Hepatology, 6(4), 188-198. [More Information]
- Parker, H., O'Connor, H., Keating, S., Cohn, J., Garg, M., Caterson, I., George, J., Johnson, N. (2014). Efficacy of the Omega-3 Index in predicting NAFLD in overweight and obese adults: a pilot study. 2014 Australian and New Zealand Obesity Society Annual Scientific Meeting, Sydney, Australia: Australian and New Zealand Obesity Society.
- Shahidi, M., Tay, E., Read, S., Ramezani-Moghadam, M., Chayama, K., George, J., Douglas, M. (2014). Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents. Journal of General Virology, 95(11), 2468-2479. [More Information]
- Milner, K., Jenkins, A., Trenell, M., Tid-Ang, J., Samocha-Bonet, D., Weltman, M., Xu, A., George, J., Chisholm, D. (2014). Eradicating hepatitis C virus ameliorates insulin resistance without change in adipose depots. Journal of Viral Hepatitis, 21(5), 325-332. [More Information]
- Sharir, R., Semo, J., Shimoni, S., Ben-Mordechai, T., Landa-Rouben, N., Maysel-Auslender, S., Shaish, A., Entin-Meer, M., Keren, G., George, J. (2014). Experimental myocardial infarction induces altered regulatory T cell hemostasis, and adoptive transfer attenuates subsequent remodeling. PloS One, 9(12). [More Information]
- Thomsen, K., Gronbaek, H., Glavind, E., Hebbard, L., Jessen, N., Clouston, A., George, J., Vilstrup, H. (2014). Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function. American Journal of Physiology: Gastrointestinal and Liver Physiology, 307(3), G295-G301. [More Information]
- O'Connor, K., Parnell, G., Patrick, E., Ahlenstiel, G., Suppiah, V., van der Poorten, D., Read, S., Leung, R., Douglas, M., Yang, J., Stewart, G., Liddle, C., George, J., Booth, D. (2014). Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. Genes and Immunity, 15(2), 88-94. [More Information]
- Read, S., Tay, E., Shahidi, M., George, J., Douglas, M. (2014). Hepatitis C virus infection mediates cholesteryl ester synthesis to facilitate infectious particle production. Journal of General Virology, 95(9), 1900-1910. [More Information]
- George, J., Mackle, G., Manoharan, A., Khan, F., Struthers, A. (2014). High BNP levels in rheumatoid arthritis are related to inflammation but not to left ventricular abnormalities: A prospective case-control study. International Journal of Cardiology, 172(1). [More Information]
- O'Connor, K., Ahlenstiel, G., Suppiah, V., Schibeci, S., Ong, A., Leung, R., van der Poorten, D., Douglas, M., Weltman, M., Stewart, G., Liddle, C., George, J., Booth, D. (2014). IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis. Innate Immunity, 20(6), 598-605. [More Information]
- Eslam, M., Leung, R., Romero-Gomez, M., Mangia, A., Irving, W., Sheridan, D., Spengler, U., Mollison, L., Cheng, W., Bugianesi, E., Douglas, M., Booth, D., George, J., Ahlenstiel, G., et al (2014). IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. Journal of Hepatology, 61(2), 235-241. [More Information]
- Kitson, M., George, J., Dore, G., Leung, R., Button, P., McCaughan, G., Crawford, D., Sievert, W., Weltman, M., Cheng, W., et al (2014). Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection. Journal of Gastroenterology and Hepatology, 29, 1458-1462. [More Information]
- Benton, G., Arnaoutova, I., George, J., Kleinman, H., Koblinski, J. (2014). Matrigel: From discovery and ECM mimicry to assays and models for cancer research. Advanced Drug Delivery Reviews, 79, 3-18. [More Information]
- George, J., Struthers, A., Lang, C. (2014). Modulation of the renin-angiotensin-aldosterone system in heart failure. Current Atherosclerosis Reports, 16(4). [More Information]
- Thomsen, K., Hebbard, L., Glavind, E., Clouston, A., Vilstrup, H., George, J., Grønbæk, H. (2014). Non-alcoholic steatohepatitis weakens the acute phase response to endotoxin in rats. Liver International, 34(10), 1584-1592. [More Information]
- Parker, H., O'Connor, H., Keating, S., Cohn, J., Garg, M., Caterson, I., George, J., Johnson, N. (2014). Omega-3 Index and liver fat: an unexpected relationship. Nutrition Society of Australia 2014 Annual Scientific Meeting, Australia.
- Sen, S., Chacko, J., Karl, S., Mathai, J., Thomas, R., Dastidar, A., Kishore, B., Ninan, P., George, J. (2014). Pediatric bladder augmentation in developing country: Lessons learnt from an experience of 195 cases. Journal International Medical Sciences Academy, 27(2), 79-83.
- Wilson, G., George, J. (2014). Physical and Chemical Insults Induce Inflammation and Gastrointestinal Cancers. Cancer Letters, 345(2), 190-195. [More Information]
- Barrera, F., George, J. (2014). Prothrombotic Factors and Nonalcoholic Fatty Liver Disease: An Additional Link to Cardiovascular Risk? Hepatology, 59(1), 16-18. [More Information]
- Sharir, R., Semo, J., Shaish, A., Landa-Rouben, N., Entin-Meer, M., Keren, G., George, J. (2014). Regulatory T cells influence blood flow recovery in experimental hindlimb ischaemia in an IL-10-dependentmanner. Cardiovascular Research, 103(4), 585-596. [More Information]
- Angulo, P., George, J., Day, C., Vanni, E., Russell, L., De la Cruz, A., Liaquat, H., Mezzabotta, L., Lee, E., Bugianesi, E. (2014). Serum Ferritin Levels Lack Diagnostic Accuracy for Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 12(7), 1163-1169. [More Information]
- Dai, Y., Wilson, G., Huang, B., Peng, M., Teng, G., Zhang, D., Zhang, R., Ebert, M., Chen, J., Wong, B., George, J., Qiao, L., et al (2014). Silencing of Jagged1 inhibits cell growth and invasion in colorectal cancer. Cell Death and Disease, 5, 1-9. [More Information]
- Kazankov, K., Barrera Martinez, F., Møller, H., Bibby, B., Vilstrup, H., George, J., Grønbæk, H. (2014). Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology, 60(2), 521-530. [More Information]
- Tian, A., Wilson, G., Lie, S., Wu, G., Hu, Z., Hebbard, L., Duan, W., George, J., Qiao, L. (2014). Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells. Cancer Letters, 351(2), 232-241. [More Information]
- Semo, J., Sharir, R., Afek, A., Avivi, C., Barshack, I., Maysel-Auslender, S., Krelin, Y., Kain, D., Entin-Meer, M., Keren, G., et al (2014). The 106b∼25 microRNA cluster is essential for neovascularization after hindlimb ischaemia in mice. European Heart Journal, 35(45), 3212-3223. [More Information]
- Volodarsky, I., Shimoni, S., George, J. (2014). The current status of transcutaneous aortic valve implantation. Expert Review of Cardiovascular Therapy, 12(10), 1205-1218. [More Information]
- Grebely, J., Page, K., Sacks-Davis, R., Schim van der Loeff, M., Rice, T., Bruneau, J., Morris, M., Hajarizadeh, B., Amin, J., Cox, A., George, J., et al (2014). The Effects of Female Sex, Viral Genotype, and IL28B Genotype on Spontaneous Clearance of Acute Hepatitis C Virus Infection. Hepatology, 59(1), 109-120. [More Information]
- Saeed, E., Xu, A., George, J. (2014). The multifaceted and controversial immunometabolic actions of adiponectin. Trends in Endocrinology and Metabolism, 25(9), 444-451. [More Information]
- Barrera Martinez, F., George, J. (2014). The Role of Diet and Nutritional Intervention for the Management of Patients with NAFLD. Clinics in Liver Disease, 18(1), 91-112. [More Information]
- George, J., Khan, F., Struthers, A. (2014). The source of BNP in rheumatoid arthritis. International Journal of Cardiology, 174(3), 740. [More Information]
- Mendel, I., Feige, E., Yacov, N., Salem, Y., Levi, I., Propheta-Meiran, O., Shoham, A., Ishai, E., George, J., Harats, D., et al (2014). VB-201, an oxidized phospholipid small molecule, inhibits CD14- and Toll-like receptor-2-dependent innate cell activation and constrains atherosclerosis. Clinical and Experimental Immunology, 175(1), 126-137. [More Information]
2013
- Nair, S., George, J., Kumar, S., Gracious, N., Das, M. (2013). A case of Goodpasture's syndrome complicating pregnancy with dialysis requiring renal failure responding to plasmapheresis and termination of pregnancy. Renal Failure, 35(8), 1173-1175. [More Information]
- Szwejkowski, B., Gandy, S., Rekhraj, S., Houston, J., Lang, C., Morris, A., George, J., Struthers, A. (2013). Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. Journal of the American College of Cardiology, 62(24), 2284-2293. [More Information]
- Beveridge, L., Ramage, L., Mcmurdo, M., George, J., Witham, M. (2013). Allopurinol use is associated with greater functional gains in older rehabilitation patients. Age and Ageing, 42(3), 400-404. [More Information]
- Fischer, J., Bohm, S., Muller, T., Witt, H., Sarrazin, C., Susser, S., Migaud, P., Schott, E., Stewart, G., Brodzinski, A., George, J., et al (2013). Association of IFNL3 rs12979860 and rs8099917 with Biochemical Predictors of Interferon Responsiveness in Chronic Hepatitis C Virus Infection. PloS One, 8(10), 1-11. [More Information]
- Fahrtash, F., Kariyawasam, V., Gray, T., Byth Wilson, K., George, J., Douglas, M. (2013). Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B. World Journal of Gastroenterology, 19(5), 721-726. [More Information]
- Suppiah, V., Armstrong, N., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Dore, G., Irving, W., Stewart, G., George, J., Booth, D., Ahlenstiel, G., et al (2013). CCR5-Delta32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. Genes and Immunity, 14(5), 286-290. [More Information]
- Shimoni, S., Bar, I., Zilberman, L., Goland, S., Edri, O., Gandelman, G., Afek, A., Shamiss, A., George, J. (2013). Circulating progenitor and apoptotic progenitor cells in patients with aortic regurgitation. Circulation Journal, 77(3), 764-771. [More Information]
- Carulli, L., Maurantonio, M., Hebbard, L., Baldelli, E., Loria, P., George, J. (2013). Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD. Current Pharmaceutical Design, 19(29), 5280-5296. [More Information]
- Kim, M., Lee, K., Iseli, T., Hoy, A., George, J., Grewal, T., Roufogalis, B. (2013). Compound K modulates fatty acid-induced lipid droplet formation and expression of proteins involved in lipid metabolism in hepatocytes. Liver International, 33(10), 1583-1593. [More Information]
- Hu, L., George, J., Wang, J. (2013). Current concepts on the role of nitric oxide in portal hypertension. World Journal of Gastroenterology, 19(11), 1707-1717. [More Information]
- Foster, G., Zeuzem, S., Pianko, S., Sarin, S., Piratvisuth, T., Shah, S., Andreone, P., Sood, A., Chuang, W., Lee, C., George, J., et al (2013). Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. Journal of Viral Hepatitis, 20(4), e115-e123. [More Information]
- Petta, S., Rosso, C., Leung, R., Abate, M., Booth, D., Solomone, F., Gambino, R., Rizzetto, M., Caviglia, P., Smedile, A., George, J., et al (2013). Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients with Genotype 1 Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 11(3), 311-317. [More Information]
- Wilson, G., Hu, Z., Duan, W., Tian, A., Wang, X., McCleod, D., Lam, V., George, J., Qiao, L. (2013). Efficacy of Using Cancer Stem Cell Markers in Isolating and Characterising Liver Cancer Stem Cells. Stem Cells and Development, 22(19), 2655-2664. [More Information]
- George, J., George, R., Dixit, R., Gupta, R., Gupta, N. (2013). Fat embolism syndrome. Lung India, 30(1), 47-53. [More Information]
- Robotin, M., Patton, Y., George, J. (2013). Getting it right: The impact of a continuing medical education program on hepatitis B knowledge of Australian primary care providers. International Journal of General Medicine, 6, 115-122. [More Information]
- Barman, A., Bhide, R., Viswanathan, A., George, J., Thomas, R., Tharion, G. (2013). Gorham's disease of the spine. NeuroRehabilitation, 33(1), 121-126. [More Information]
- van der Poorten, D., Samer, C., Ramezani-Moghadam, M., Coulter, S., Kacevska, M., Schrijnders, D., Wu, L., McLeod, D., Bugianesi, E., Komuta, M., Liddle, C., Hebbard, L., George, J., et al (2013). Hepatic Fat Loss in Advanced Nonalcoholic Steatohepatitis: Are Alterations in Serum Adiponectin the Cause? Hepatology, 57(6), 2180-2188. [More Information]
- Sacks-Davis, R., Atiken, C., Higgs, P., Spelman, T., Pedrana, A., Bowden, S., Bharadwaj, M., Nivarthi, U., Suppiah, V., George, J., et al (2013). High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: A prospective cohort study. PloS One, 8(11), 1-12. [More Information]
- Rekhraj, S., Gandy, S., Szwejkowski, B., Nadir, M., Noman, A., Houston, J., Lang, C., George, J., Struthers, A. (2013). High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. Journal of the American College of Cardiology, 61(9), 926-932. [More Information]
- Gelinas, J., Fabre, T., Willems, P., Leung, R., George, J., Willems, B., Bruneau, J., Shoukry, N. (2013). IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test. Immunogenetics, 65(6), 397-403. [More Information]
- Fischer, J., Bohm, S., George, J., Sarrazin, C., Berg, T. (2013). Impact of cohort size and host factors on combined analysis of interleukin 28B rs12979860 and rs8099917 in hepatitis c virus infection. Hepatology, 57(1), 416-417. [More Information]
- Feige, E., Yacov, N., Salem, Y., Levi, I., Mendel, I., Propheta-Meiran, O., Shoham, A., Hait-Darshan, R., Polonsky, O., George, J., et al (2013). Inhibition of monocyte chemotaxis by VB-201, a small molecule lecinoxoid, hinders atherosclerosis development in ApoE-/- mice. Atherosclerosis, 229(2), 430-439. [More Information]
- Eslam, M., Booth, D., George, J., Ahlenstiel, G. (2013). Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection. World Journal of Gastroenterology, 19(41), 7055-7061. [More Information]
- Anderson, W., Lipworth, B., Rekhraj, S., Struthers, A., George, J. (2013). Left ventricular hypertrophy in COPD without hypoxemia: The elephant in the room? Chest, 143(1), 91-97. [More Information]
- Booth, D., George, J. (2013). Loss of function of the new interferon IFN-λ4 may confer protection from hepatitis C. Nature Genetics, 45(2), 119-120. [More Information]
- Schwartzenberg, S., Meledin, V., Zilberman, L., Goland, S., George, J., Shimoni, S. (2013). Low circulating monocyte count is associated with severe aortic valve stenosis. IMAJ, 15(9), 568-572.
- Charach, G., Rabinovich, A., Ori, A., Weksler, D., Sheps, D., Charach, L., Weintraub, M., George, J. (2013). Low levels of low-density lipoprotein cholesterol: A negative predictor of survival in elderly patients with advanced heart failure. Cardiology, 127(1), 45-50. [More Information]
- Barrera Martinez, F., George, J. (2013). Non-alcoholic fatty liver disease: more than just ectopic fat accumulation. Drug Discovery Today: Disease Mechanisms, 10(1-2), e47-e54. [More Information]
- Hashemi, S., van der Poorten, D., Barrera Martinez, F., Bandara, P., Lux, O., Kench, J., George, J. (2013). Oxidative stress is closely associated with insulin resistance in genotypes 1 and 3 chronic hepatitis C. Hepatology International, 7(2), 516-523. [More Information]
- Grebely, J., Feld, J., Applegate, T., Matthews, G., Hellard, M., Sherker, A., Petoumenos, K., Zang, G., Shaw, I., Yeung, B., George, J., et al (2013). Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology, 57(6), 2124-2134. [More Information]
- Sublette, V., Douglas, M., McCaffery, K., George, J., Nicholson Perry, K. (2013). Psychological, lifestyle and social predictors of hepatitis c treatment response: a systematic review. Liver International, 33(6), 894-903. [More Information]
- Dong, Z., Su, L., Brymora, J., Bird, C., Xie, Q., George, J., Wang, J. (2013). Resistin mediates the hepatic stellate cell phenotype. World Journal of Gastroenterology, 19(28), 4475-4485. [More Information]
- Angulo, P., Bugianesi, E., Bjornsson, E., Charatcharoenwitthaya, P., Mills, P., Barrera Martinez, F., Haflidadottir, S., Day, C., George, J. (2013). Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology, 145(4), 782-789. [More Information]
- Mahady, S., George, J. (2013). The Future Liver of the Asia Pacific: Fatter and Firmer from More Fructose and Fortune? Journal of Clinical and Experimental Hepatology, 3(2), 106-113. [More Information]
- Poustchi, H., Eslami, M., Ostovaneh, M., Modabbernia, A., Saeedian, F., Taslimi, S., George, J., Malekzadeh, R., Zamani, F. (2013). Transient elastography in hepatitis C virus-infected patients with beta-thalassemia for assessment of fibrosis. Hepatology Research, 43(12), 1276-1283. [More Information]
- Wilson, G., Tian, A., Hebbard, L., Duan, W., George, J., Li, X., Qiao, L. (2013). Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro. Cancer Letters, 341(2), 224-230. [More Information]
- Vongsuvanh, R., George, J., Qiao, L., van der Poorten, D. (2013). Visceral adiposity in gastrointestinal and hepatic carcinogenesis. Cancer Letters, 330(1), 1-10. [More Information]
- Kitson, M., Dore, G., George, J., Button, P., McCaughan, G., Crawford, D., Sievert, W., Weltman, M., Cheng, W., Roberts, S. (2013). Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. Journal of Hepatology, 58(3), 467-472. [More Information]
2012
- Nguyen, V., George, J., van der Poorten, D. (2012). A maxillary mass in a HBV-cirrhotic patient. Liver International, 32(6), 988-988. [More Information]
- Rahman, W., Huang, P., Belov, L., Chrisp, J., Christopherson, R., Stapelberg, P., Warner, F., George, J., Bowen, D., Strasser, S., Koorey, D., Sharland, A., McCaughan, G., Shackel, N. (2012). Analysis of human liver disease using a cluster of differentiation (CD) antibody microarray. Liver International, 32(10), 1527-1534. [More Information]
- Walker, S., George, J., Hebbard, L. (2012). Animal Models of Hepatocellular Carcinoma. In Liang Qiao, Yumin Li, Xiang Yan and Jacob George (Eds.), Molecular Aspects of Hepatocellular Carcinoma, (pp. 116-128). Sharjah: Bentham Science Publishers. [More Information]
- Parker, H., Keating, S., O'Connor, H., Cohn, J., Caterson, I., George, J., Johnson, N. (2012). Can reported short-term dietary intake predict fatty liver? Nutrition Society of Australia 2012 Annual Scientific Meeting, Not-Known.
- Fischer, J., Bohm, S., Scholz, M., Muller, T., Witt, H., George, J., Sarrazin, C., Susser, S., Schott, E., Suppiah, V., Booth, D., Stewart, G., et al (2012). Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology, 55(6), 1700-1710. [More Information]
- Raftopoulos, S., George, J., Bourliere, M., Rossi, E., de Boer, W., Jeffrey, G., Bulsara, M., Speers, D., MacQuillan, G., Ching, H., McLeod, D., et al (2012). Comparison of noninvasive models of fibrosis in chronic hepatitis B. Hepatology International, 6(2), 457-467. [More Information]
- Robotin, M., Patton, Y., Kansil, M., Penman, A., George, J. (2012). Cost of treating chronic hepatitis B: Comparison of current treatment guidelines. World Journal of Gastroenterology, 18(42), 6106-6113. [More Information]
- Johnson, N., van Overbeek, D., Chapman, P., Thompson, M., Sachinwalla, T., George, J. (2012). Effect of prolonged exercise and pre-exercise dietary manipulation on hepatic triglycerides in trained men. European Journal of Applied Physiology, 112(5), 1817-1825. [More Information]
- Keating, S., Hackett, D., George, J., Johnson, N. (2012). Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Hepatology, 57(1), 157-166. [More Information]
- Johnson, N., Keating, S., George, J. (2012). Exercise and the Liver: Implications for Therapy in Fatty Liver Disorders. Seminars in Liver Disease, 32(1), 65-79. [More Information]
- Patin, E., Kutalik, Z., Guergnon, J., Bibert, S., Nalpas, B., Jouanguy, E., Munteanu, M., Bousquet, L., Argiro, L., Halfon, P., Suppiah, V., Stewart, G., Booth, D., George, J., et al (2012). Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection. Gastroenterology, 143(5), 1244-1252. [More Information]
- Gidding, H., Law, M., Amin, J., Ostapowicz, G., Weltman, M., Macdonald, G., Sasadeusz, J., Haber, P., George, J., Dore, G. (2012). Hepatitis C treatment outcomes in Australian clinics. Medical Journal of Australia, 196(10), 633-637. [More Information]
- Mahady, S., George, J. (2012). Management of nonalcoholic steatohepatitis: an evidence-based approach. Clinics in Liver Disease, 16(3), 631-645. [More Information]
- Qiao, L., Li, Y., Yan, X., George, J. (2012). Molecular Aspects of Hepatocellular Carcinoma. Sharjah: Bentham Science Publishers.
- Parker, H., Johnson, N., Burdon, C., Cohn, J., O'Connor, H., George, J. (2012). Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Hepatology, 56(4), 944-951. [More Information]
- Booth, D., Ahlenstiel, G., George, J. (2012). Pharmacogenomics of hepatitis C infections: personalizing therapy. Genome Medicine, 4(12), 1-10. [More Information]
- Mahady, S., Wong, G., Craig, J., George, J. (2012). Pioglitazone and Vitamin E for Nonalcoholic Steatohepatitis: A Cost Utility Analysis. Hepatology, 56(6), 2172-2179. [More Information]
- Pianko, S., Zeuzem, S., Chuang, W., Foster, G., Sarin, S., Flisiak, R., Lee, C., Andreone, P., Piratvisuth, T., Shah, S., George, J., et al (2012). Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. Journal of Viral Hepatitis, 19(9), 623-634. [More Information]
- Poutschi, H., George, J. (2012). Reply. Hepatology, 55(6), 2039-2040. [More Information]
- Parker, H., Johnson, N., George, J. (2012). Reply to: "The optimal dose of omega-3 supplementation for non-alcoholic fatty liver disease". Journal of Hepatology, 57(2), 469-470. [More Information]
- Thein, H., Walter, S., Gidding, H., Amin, J., Law, M., George, J., Dore, G. (2012). Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort. Hepatology Research, 42(12), 1175-1186. [More Information]
- Pattullo, V., George, J. (2012). The Problem of Insulin Resistance and its Effect on Therapy. In Geoffrey W. McCaughan, John G. McHutchison, Jean-Michel Pawlotsky (Eds.), Advanced Therapy for Hepatitis C, (pp. 169-176). Chichester, United Kingdom: Wiley-Blackwell Publishing. [More Information]
- Grebely, J., Hellard, M., Applegate, T., Petoumenos, K., Yeung, B., Feld, J., Rawlinson, W., Lloyd, A., George, J., Kaldor, J., et al (2012). Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. AIDS, 26(13), 1653-1661. [More Information]
- Vongsuvanh, R., George, J., McLeod, D., van der Poorten, D. (2012). Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 57(2), 392-398. [More Information]
- Ahlenstiel, G., Booth, D., George, J. (2012). Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms? Antiviral Therapy, 17(6 Pt B), 1163-1170. [More Information]
2011
- Hebbard, L., George, J. (2011). Animal models of nonalcoholic fatty liver disease. Nature Reviews. Gastroenterology & Hepatology, 8(1), 35-44. [More Information]
- Ahlenstiel, G., Booth, D., George, J. (2011). Clinical significance of IL28B gene variation in hepatitis C virus infection. Hot Topics in viral Hepatitis, (20), 17-24. [More Information]
- Adams, L., George, J., Bugianesi, E., Rossi, E., de Boer, W., van der Poorten, D., Ching, H., Bulsara, M., Jeffrey, G. (2011). Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology, 26(10), 1536-1543. [More Information]
- Poustchi, H., Farrell, G., Strasser, S., Lee, A., McCaughan, G., George, J. (2011). Feasibility of conducting a randomised control trial for liver cancer screening: Is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology, 54(6), 1998-2004. [More Information]
- Poustchi, H., George, J., Esmaili, S., Esna-Ashari, F., Ardalan, G., Sepanlou, G., Alavian, S. (2011). Gender differences in healthy ranges for serum alanine aminotransferase levels in adolescence. PloS One, 6(6), e21178-1-e21178-7. [More Information]
- Smith, K., Suppiah, V., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Matthews, G., Irving, W., Ahlenstiel, G., Stewart, G., George, J., Booth, D., et al (2011). Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Medicine, 3(8), 57-1-57-13. [More Information]
- Suppiah, V., Gaudieri, S., Armstrong, N., O'Connor, K., Berg, T., Weltman, M., Abate, M., Spengler, U., Bassendine, M., Dore, G., Ahlenstiel, G., Stewart, G., George, J., Booth, D., et al (2011). IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study. PLoS Medicine, 8(9), e1001092-1-e1001092-8. [More Information]
- Liu, Y., Brymora, J., Zhang, H., Smith, B., Ramezani-Moghadam, M., George, J., Wang, J. (2011). Leptin and Acetaldehyde Synergistically Promotes aSMA Expression in Hepatic Stellate Cells by an Interleukin 6-Dependent Mechanism. Alcoholism: Clinical and Experimental Research, 35(5), 921-928. [More Information]
- Park, G., Wiseman, E., George, J., Katelaris, P., Seow, F., Fung, C., Ngu, M. (2011). Non-invasive Estimation of Liver Fibrosis in Non-alcoholic Fatty Liver Disease Using the (13) C-Caffeine Breath Test. Journal of Gastroenterology and Hepatology, 26(9), 1411-1416. [More Information]
- Parker, H., Burdon, C., O'Connor, H., George, J., Cohn, J., Johnson, N. (2011). Omega-3 fatty acid supplementation for non-alcoholic fatty liver disease in humans: a systematic review and meta- analysis. International Conference on the Science of Nutrition in Medicine and Healthcare 2011, Sydney, Australia: The Science of Nutrition in Medicine and Healthcare.
- Patel, K., Jhaveri, R., George, J., Qiang, G., Kenedi, C., Brown, K., Cates, C., Zekry, A., Tillmann, H., Elliott, L., et al (2011). Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C. Journal of Viral Hepatitis, 18(5), 331-337. [More Information]
- Pattullo, V., Douglas, M., George, J. (2011). Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis? Expert Review of Gastroenterology and Hepatology, 5(2), 265-277. [More Information]
- Gidding, H., Law, M., Amin, J., Macdonald, G., Sasadeusz, J., Jones, T., Strasser, S., George, J., Dore, G. (2011). Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Medical Journal of Australia, 194(8), 398-402. [More Information]
- Walter, S., Thein, H., Gidding, H., Amin, J., Law, M., George, J., Dore, G. (2011). Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. Journal of Gastroenterology and Hepatology, 26(12), 1757-1764. [More Information]
- Jacobson, I., McHutchison, J., Dusheiko, G., Di Bisceglie, A., Reddy, K., Bzowej, N., Marcellin, P., Muir, A., Ferenci, P., Flisiak, R., George, J., et al (2011). Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection. New England Journal of Medicine, 364(25), 2405-2416. [More Information]
- Bhala, N., Angulo, P., van der Poorten, D., Lee, E., Hui, J., Saracco, G., Adams, L., Charatcharoenwitthaya, P., Topping, J., Bugianesi, E., George, J., et al (2011). The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study. Hepatology, 54(4), 1208-1216. [More Information]
- Mahady, S., Webster, A., Walker, S., Sanyal, A., George, J. (2011). The role of thiazolidinediones in non-alcoholic steatohepatitis - A systematic review and meta analysis. Journal of Hepatology, 55(6), 1383-1390. [More Information]
- Thein, H., Walter, S., Gidding, H., Amin, J., Law, M., George, J., Dore, G. (2011). Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992-2007. Journal of Viral Hepatitis, 18(7), e232-e241. [More Information]
- Walter, S., Thein, H., Amin, J., Gidding, H., Ward, K., Law, M., George, J., Dore, G. (2011). Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. Journal of Hepatology, 54(5), 879-886. [More Information]
2010
- Johnson, N., George, J. (2010). An Active Part in Treating Liver Disease. Exercise In Medical Conditions: Exercise And Non-Alcoholic Fatty Liver Disease. SportEx Health, 25, 18-20.
- Milner, K., van der Poorten, D., Trenell, M., Jenkins, A., Xu, A., Smythe, G., Dore, G., Zekry, A., Weltman, M., Fragomeli, V., George, J., et al (2010). Chronic Hepatitis C is Associated with Peripheral rather than Hepatic Insulin Resistance. Gastroenterology, 138(3), 932-941. [More Information]
- Johnson, N., George, J. (2010). Fitness Versus Fatness: Moving Beyond Weight Loss in Nonalcoholic Fatty Liver Disease. Hepatology, 52(1), 370-381. [More Information]
- van der Poorten, D., Shahidi, M., Tay, E., Sesha, J., Tran, K., McLeod, D., Milliken, J., Ho, V., Hebbard, L., Douglas, M., George, J. (2010). Hepatitis C Virus Induces the Cannabinoid Receptor 1. PloS One, 5(9), 1-10. [More Information]
- Mahady, S., George, J. (2010). How to Treat: Hepatitis C infection. Australian Doctor, , 1-6.
- Ahlenstiel, G., Booth, D., George, J. (2010). IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. Journal of Gastroenterology and Hepatology, 45(9), 903-910. [More Information]
- Pattullo, V., George, J. (2010). Managing the Patient with Chronic Viral Hepatitis Receiving Chemotherapy. In Monica Robotin, Ian Olver, Afaf Girgis (Eds.), When Cancer Crosses Disciplines: A Physicians Handbook, (pp. 813-832). London: Imperial College Press. [More Information]
- Bhala, N., Usherwood, T., George, J. (2010). Nichtalkoholische Fettlebererkrankung [Non-alcoholic fatty liver]. Praxis, 99(3), 187-189. [More Information]
- Grebely, J., Petoumenos, K., Hellard, M., Matthews, G., Suppiah, V., Applegate, T., Yeung, B., Marks, P., Rawlinson, W., Lloyd, A., Booth, D., George, J., et al (2010). Potential Role for Interleukin-28B Genotype in Treatment Decision-Making in Recent Hepatitis C Virus Infection. Hepatology, 52(4), 1216-1224. [More Information]
- Patterson, S., George, J., Strasser, S., Lee, A., Sievert, W., Nicoll, A., Desmond, P., Roberts, S., Locarnini, S., Bowden, S., et al (2010). Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut, 60(2), 247-254. [More Information]
- Hebbard, L., George, J. (2010). The chicken or the egg: adipocytes and hepatic insulin resistance. Hepatology, 51(3), 1076-1079. [More Information]
- Robotin, M., Kansil, M., George, J., Howard, K., Tipper, S., Levy, M., Phung, N., Penman, A. (2010). Using a population-based approach to prevent hepatocellular cancer in New South Wales, Australia: effects on health services utilisation. BMC Health Services Research, 10, 215-224. [More Information]
2009
- Milner, K., van der Poorten, D., Xu, A., Bugianesi, E., Kench, J., Lam, K., Chisholm, D., George, J. (2009). Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology, 49(6), 1926-1934. [More Information]
- Smith, B., George, J. (2009). Adipocyte-hepatocyte crosstalk and the pathogenesis of nonalcoholic fatty liver disease. Hepatology, 49(5), 1765-1767. [More Information]
- Johnson, N., Sachinwalla, T., Walton, D., Smith, K., Armstrong, A., Thompson, M., George, J. (2009). Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology, 50(4), 1105-1112. [More Information]
- Robotin, M., Kansil, M., Howard, K., George, J., Tipper, S., Dore, G., Levy, M., Penman, A. (2009). Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. Journal of Hepatology, 50(5), 990-998. [More Information]
- Booth, M., Dobbins, T., Aitken, R., Denney-Wilson, E., Hardy, L., Okely, A., George, J., Sullivan, D., Cowell, C. (2009). Costs of managing conditions associated with obesity among Australian teenagers. Journal of Paediatrics and Child Health, 45(7-8), 448-456. [More Information]
- van der Poorten, D., Milner, K., George, J. (2009). Effect of adipokines on liver disease in females. In Ichiro Shimizu (Eds.), Female Hepatology: Impact of female sex against progression of liver disease, (pp. 191-212). India: Research Signpost.
- Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M., Bassendine, M., Spengler, U., Dore, G., Powell, E., Stewart, G., Booth, D., George, J., et al (2009). IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature Genetics, 41(10), 1100-1104. [More Information]
- Johnson, N., St George, A., George, J. (2009). Impact of lifestyle modification on patients with chronic liver disease. Hot Topics in viral Hepatitis, 5(14), 17-22. [More Information]
- St George, A., Bauman, A., Johnston, A., Farrell, G., Chey, T., George, J. (2009). Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology, 50(1), 68-76. [More Information]
- Wang, J., Leclercq, I., Brymora, J., Xu, N., Ramezani-Moghadam, M., London, R., Brigstock, D., George, J. (2009). Kupffer Cells Mediate Leptin-Induced Liver Fibrosis. Gastroenterology, 137(2), 713-723. [More Information]
- Douglas, M., George, J. (2009). Molecular mechanisms of insulin resistance in chronic hepatitis C. World Journal of Gastroenterology, 15(35). [More Information]
- Bhala, N., Usherwood, T., George, J. (2009). Non-alcoholic fatty liver disease. BMJ: British Medical Journal, 339(b2474), 513-514. [More Information]
- George, J., Robotin, M. (2009). Overview: Hepatocellular carcinoma - the future starts now. Cancer Forum, 33(2), 83-87.
- Phung, T., Pera, N., Farrell, G., Leclercq, I., Hou, J., George, J. (2009). Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. International Journal of Molecular Medicine, 24, 171-180. [More Information]
- Milner, K., Chisholm, D., George, J. (2009). The many faces of hepatitis C: liver disease and type 2 diabetes. Hepatology, 50(3), 668-670. [More Information]
- Van Hazel, G., Pavlakis, N., Goldstein, D., Olver, I., Tapner, M., Price, D., Bower, G., Briggs, G., Rossleigh, M., Taylor, D., George, J. (2009). Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy. Journal of Clinical Oncology, 27(25), 4089-4095. [More Information]
2008
- Poustchi, H., Mohamadkhani, A., Bowden, S., Montazeri, G., Ayres, A., Revill, P., Farrell, G., Locarnini, S., George, J., Malekzadeh, R. (2008). Clinical significance of precore and core promoter mutations in genotype D hepatitis B-related chronic liver disease. Journal of Viral Hepatitis, 15(10), 753-760. [More Information]
- van der Poorten, D., George, J. (2008). Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. Clinics in Liver Disease, 12(4), 805-824. [More Information]
- St George, A., Bauman, A., Johnston, A., Farrell, G., Chey, T., George, J. (2008). Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. Hepatology, 24(3), 399-407. [More Information]
- George, J., Talley, N., Segal, I., Weltman, M. (2008). Evaluating abnormal liver tests. In N Talley, I Segal, M Weltman (Eds.), Gastroenterology and Hepatology: a clinical handbook, (pp. 316-326). Australia: Elsevier.
- Cua, I., Hui, J., Kench, J., George, J. (2008). Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology, 48(3), 723-731. [More Information]
- Poustchi, H., Negro, F., Hui, J., Cua, I., Brandt, L., Kench, J., George, J. (2008). Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. Journal of Hepatology, 48(1), 28-34. [More Information]
- Cua, I., George, J. (2008). Insulin resistance, adipocytokines and HCV infection: A missing link? Hepatology, 47, 760-761.
- George, J., Liddle, C. (2008). Nonalcoholic fatty liver disease: Pathogenesis and potential for nuclear receptors as therapeutic targets. Molecular Pharmaceutics, 5(1), 49-59. [More Information]
- van der Poorten, D., George, J. (2008). Nonalcoholic steatohepatitis is frequently acompanied by metabolic diseases: Reply to the Editor. Hepatology, 48(5), 1729. [More Information]
- Johnson, N., Walton, D., Sachinwalla, T., Thompson, C., Smith, K., Ruell, P., Stannard, S., George, J. (2008). Noninvasive assessment of hepatic lipid composition: advancing understanding and management of fatty liver disorders. Hepatology, 47, 1513-1523. [More Information]
- van der Poorten, D., Kenny, D., George, J. (2008). Prevalence of and risk factors for hepatitis C in Aboriginal and non-Aboriginal adolescent offenders. Medical Journal of Australia, 188(10), 610-614. [More Information]
- Robotin, M., George, J., Supramaniam, R., Sitas, F., Penman, A. (2008). Preventing primary liver cancer: how well are we faring towards a national hepatitis B strategy? Medical Journal of Australia, 188(6), 363-365. [More Information]
- Johnson, N., Sachinwalla, T., George, J. (2008). Reply: In Vitro Proton Magnetic Resonance Spectroscopy of Liver Tissue Informs In Vivo Hepatic Proton Magnetic Resonance Spectroscopy Studies. Hepatology, 48(3), 1016-1017. [More Information]
- Wang, J., Brymora, J., George, J. (2008). Roles of adipokines in liver injury and fibrosis. Expert Review of Gastroenterology and Hepatology, 2(1), 47-57. [More Information]
- George, J., Denney-Wilson, E., Okely, A., Hardy, L., Aitken, R. (2008). The population distributions, upper normal limits and correlations between liver tests among Australian adolescents. Journal of Paediatrics and Child Health, 44(10), 579-585. [More Information]
- Booth, M., George, J., Denney-Wilson, E., Okely, A., Hardy, L., Aitken, R., Dobbins, T. (2008). The population prevalence of adverse concentrations and associations with adiposity of liver tests among Australian adolescents. Journal of Paediatrics and Child Health, 44(12), 686-691. [More Information]
- Yan, K., Guirgis, M., Dinh, T., George, J., Dev, A., Lee, A., Zekry, A. (2008). Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World Journal of Gastroenterology, 14(21), 3416-3420. [More Information]
- van der Poorten, D., Milner, K., Hui, J., Hodge, A., Trenell, M., Kench, J., London, R., Peduto, A., Chisholm, D., George, J. (2008). Visceral fat: A key mediator of steatohepatitis in metabolic liver disease. Hepatology, 48(2), 449-457. [More Information]
2007
- van der Poorten, D., Kenny, D., George, J. (2007). A new upper limit for alanine aminotransferase and risk factors for raised alt and hepatitis C in adolescents: a study of 439 male adolescent offenders on community orders. Journal of Gastroenterology and Hepatology, 22(Supplement 3), A344-A344.
- Teoh, N., George, J. (2007). Abnormal Liver Function Tests. In N Talley, I Segal, M Weltman (Eds.), Gastroenterology and Hepatology: a clinical handbook. Australia: Elsevier.
- Angulo, P., George, J., Marchesini, G., Bugianesi, E., Farrell, G., Day, C. (2007). Author's reply: Non-invasive markers of advanced histology in nonalcoholic fatty liver disease. Gastroenterology, 133(4), 1377-1378.
- van der Poorten, D., George, J. (2007). Current and novel therapies for the treatment of nonalcoholic steatohepatitis. Hepatology International, 1(3), 343-354. [More Information]
- Cua, I., Hui, J., Bandara, P., Kench, J., Farrell, G., McCaughan, G., George, J. (2007). Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology, 46(1), 66-73. [More Information]
- van der Poorten, D., Kenny, D., Butler, T., George, J. (2007). Liver disease in adolescents: A cohort study of high-risk individuals. Hepatology, 46(6), 1750-1758. [More Information]
- Razali, K., Thein, H., Bell, J., Cooper-Stanbury, M., Dolan, K., Dore, G., George, J., Kaldore, J., Karvelas, M., Li, J., Weltman, M., et al (2007). Modelling the hepatitis C virus epidemic in Australia. Drug and Alcohol Dependence, 91(39509), 228-235. [More Information]
- London, R., George, J. (2007). Pathogenesis of NASH: Animal Models. Clinics in Liver Disease, 11(1), 55-74. [More Information]
- Cua, I., George, J. (2007). Reply. Hepatology, 46(6), 2051. [More Information]
- Angulo, P., Hui, J., Marchesini, G., Bugianesi, E., George, J., Farrell, G., Enders, F., Saksena, S., Burt, A., Bida, J., Kench, J., et al (2007). The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 45(4), 846-854. [More Information]
2006
- George, J. (2006). Angiopoietin-like proteins: Another player in the metabolic field. Journal of Hepatology, 44(4), 832-834. [More Information]
- Bugianesi, E., Marchesini, G., Gentilcore, E., Cua, I., Vanni, E., Rizzetto, M., George, J. (2006). Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology, 44(6), 1648-1655. [More Information]
- Salmond, S., George, J., Strasser, S., Batey, R. (2006). Hep573 study of complementary medicine for chronic hepatitis C. Journal Of Clinical Virology, 36(Supplement 2), S134-S135.
- Chitturi, S., George, J. (2006). Hepatitis C and overweight. Hot Topics in viral Hepatitis, 2, 15-21.
- Cua, I., George, J. (2006). Interpretation of abnormal liver tests in patients with diabetes. Diabetes Management Journal, 14, 30-31.
- Cua, I., George, J. (2006). Interpretation of abnormal liver tests in patients with diabetes. Diabetes Management Journal, 14, 30.
- Cua, I., Hui, J., Bandara, P., Kench, J., McCaughan, G., George, J. (2006). Is insulin resistance and liver injury in chronic hepatitis C associated with virus-specific alteration in the levels of serum adipocytokines? Journal of Gastroenterology and Hepatology, 21, A22-A22.
- St George, A., Johnston, A., Bauman, A., Iverson, D., Tapsell, L., McCaughan, G., Strasser, S., McGrath, L., Green, J., Farrell, G., George, J. (2006). Lifestyle intervention in early liver disease: metabolic changes at 3 months. Journal of Gastroenterology and Hepatology, 21(Suppl. 4), A315.
- Cua, I., Kwan, V., Henriquez, M., Kench, J., George, J. (2006). Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis. Gut, 55(10), 1521-1522. [More Information]
- Leandro, G., Mangia, A., Hui, J., Fabris, P., Rubbia-Brandt, L., Colloredo, G., Adinolfi, L., Asselah, T., Jonsson, J., Smedile, A., George, J., et al (2006). Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology, 130(6), 1636-1642. [More Information]
- Wang, J., Batey, R., George, J. (2006). Role of ethanol in the regulation of hepatic stellate cell function. World Journal of Gastroenterology, 12(43), 6926-6932. [More Information]
- Poustchi, H., George, J., Farrell, G. (2006). The efficacy of a liver cancer screening program on cancer detection and patient survival. Journal of Gastroenterology and Hepatology, 21, A52-A52.
2005
- Helbig, K., George, J., Beard, M. (2005). A novel I-TAC promoter polymorphic variant is functional in the presence of replicating HCV in vitro. Journal Of Clinical Virology, 32(2), 137-143. [More Information]
- Bandara, P., George, J., McCaughan, G., Naidoo, D., Lux, O., Salonikas, C., Kench, J., Byth Wilson, K., Farrell, G. (2005). Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C. Liver International, 25(3), 518-526. [More Information]
- Perry, J., Poustchi, H., George, J., Farrell, G., McCaughan, G., Strasser, S. (2005). Current approaches to the diagnosis and management of hepatocellular carcinoma. Clinical and Experimental Medicine, 5(1), 1-13. [More Information]
- Adams, L., Bulsara, M., Rossi, E., DeBoer, B., Speers, D., George, J., Kench, J., Farrell, G., McCaughan, G., Jeffrey, G. (2005). Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clinical Chemistry, 51(10), 1867-1873. [More Information]
- Kumar, U., Farrell, G., Kench, J., George, J. (2005). Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. Journal of Gastroenterology and Hepatology, 20(9), 1395-1400. [More Information]
- Dela Pena, A., Leclercq, I., Field, J., George, J., Jones, B., Farrell, G. (2005). NF-kappa B activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology, 129(5), 1663-1674. [More Information]
- Cua, I., George, J. (2005). Non-alcoholic fatty liver disease. British Journal of Hospital Medicine, 66(2), 106-111. [More Information]
- Hui, J., George, J. (2005). Reply: Adiponectin – Tipping the scales from NAFLD to NASH. Gastroenterology, 128(2), 513-513. [More Information]
- Hui, J., George, J. (2005). Reply: Reduced plasma adiponectin: central obesity as an underestimated causative risk factor. Hepatology, 41, 401-402. [More Information]
2004
- Hui, J., Hodge, A., Farrell, G., Kench, J., Kriketos, A., George, J. (2004). Beyond Insulin Resistance In Nash: Tnf-Alpha Or Adiponectin? Hepatology, 40(1), 46-54. [More Information]
- Coverdale, S., Khan, M., Byth Wilson, K., Lin, R., Weltman, M., George, J., Samarasinghe, D., Liddle, C., Farrell, G., Kench, J., Crewe, E. (2004). Effects Of Interferon Treatment Response On Liver Complications Of Chronic Hepatitis C: 9-Year Follow-Up Study. American Journal of Gastroenterology, 99(4), 636-644. [More Information]
- McCaughan, G., George, J. (2004). Fibrosis Progression In Chronic Hepatitis C Virus Infection. Gut, 53(3), 318-321. [More Information]
- Hui, J., Farrell, G., Kench, J., George, J. (2004). High sensitivity C-reactive protein values do not reliably predict the severity of histological change in NAFLD. Hepatology, 39(5), 1458-1459. [More Information]
- Sud, A., Hui, J., Farrell, G., Bandara, P., Kench, J., Fung, C., Lin, R., Samarasinghe, D., Liddle, C., McCaughan, G., George, J. (2004). Improved Prediction Of Fibrosis In Chronic Hepatitis C Using Measures Of Insulin Resistance In A Probability Index. Hepatology, 39(5), 1239-1247. [More Information]
- Kwan, V., George, J. (2004). Liver Disease Due To Parenteral And Enteral Nutrition. Clinics in Liver Disease, 8(4), 893-913, ix-x.
- Chitturi, S., Farrell, G., George, J. (2004). Non-Alcoholic Steatohepatitis In The Asia-Pacific Region: Future Shock? Journal of Gastroenterology and Hepatology, 19(4), 368-374. [More Information]
- Zeuzem, S., Diago, M., Gane, E., Reddy, K., Pockros, P., Prati, D., Shiffman, M., Farci, P., Gitlin, N., O'Brien, C., George, J., et al (2004). Peginterferon Alfa-2a (40 Kilodaltons) and Ribavirin in Patients With Chronic Hepatitis C and Normal Aminotransferase Levels. Gastroenterology, 127(6), 1724-1732. [More Information]
2003
- Shao, R., Shi, Z., Gotwals, P., Koteliansky, V., George, J., Rockey, D. (2003). Cell and molecular regulation of endothelin-1 production during hepatic wound healing. Molecular Biology of the Cell, 14(6), 2327-2341. [More Information]
- Coverdale, S., Samarasinghe, D., Lin, R., Kench, J., Byth Wilson, K., Khan, M., Crewe, E., Liddle, C., George, J., Farrell, G. (2003). Changes in Antipyrine Clearance and Platelet Count, but Not Conventional Liver Tests, Correlate With Fibrotic Change in Chronic Hepatitis C: Value for Predicting Fibrotic Progression. American Journal of Gastroenterology, 98(6), 1384-1390. [More Information]
- Kumar, D., Wallington-Beddoe, C., George, J., Lin, R., Samarasinghe, D., Liddle, C., Farrell, G. (2003). Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hapatitis c in a clinic setting. Medical Journal of Australia, 178(6), 267-271.
- Hui, J., Sud, A., Farrell, G., Bandara, P., Byth Wilson, K., Kench, J., McCaughan, G., George, J. (2003). Insulin resistance is associated with chronic Hepatitis C and virus infection fibrosis progression. Gastroenterology, 125(6), 1695-1704. [More Information]
- Chitturi, S., George, J. (2003). Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Current Gastroenterology, 5(1), 18-25. [More Information]
- George, J. (2003). Invited Book Review – Hepatitis C: An Australian perspective. Eds. N Crofts, G Dore and S Locarnini. Internal Medicine Journal, 33(1), 64-64.
- George, J., Pera, N., Phung, T., Leclercq, I., Hou, J., Farrell, G. (2003). Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. Journal of Hepatology, 39(5), 756-764. [More Information]
- Hui, J., Kench, J., Chitturi, S., Sud, A., Farrell, G., Blyth, K., Hall, P., Khan, M., George, J. (2003). Long term outcomes of cirrhosis in nonalcoholic steatohepatitis compares with hepatitis c. Hepatology, 38(2), 420-427. [More Information]
- Perry, J., Strasser, S., George, J., Farrell, G., McCaughan, G. (2003). Pharmacotherapy of hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 4(12), 2175-2185. [More Information]
- Chitturi, S., Farrell, G., George, J. (2003). Reply: Iron and HFE mutations in nonalcoholic steatohepatitis: Innocent bystanders or accessories to the crime? Gastroenterology, 125(2), 616-616.
- Lee, D., Chitturi, S., Kench, J., George, J., Fuller, S., Bradstock, K., Lin, R., Wong, K., Young, N. (2003). Transjugular liver biopsy effecting changes in clinical management. Journal of Medical Imaging and Radiation Oncology, 47(2), 117-120. [More Information]
2002
- Hui, J., George, J., Liddle, C., Lin, R., Samarasinghe, D., Crewe, E., Farrell, G. (2002). Changes in Serum Albumin During Treatment of Chronic Hepatitis B With Lamivudine: Effects of Response and Emergence of Drug Resistance. American Journal of Gastroenterology, 97(4), 1003-1009. [More Information]
- Singal, D., George, J. (2002). Chronic hepatitis C. Australian Doctor.
- Teoh, N., George, J. (2002). Evaluating patients who have abnormal liver tests. Medicine Today, 3(10), 58-67.
- Chitturi, S., George, J., Ranjitkumar, S., Kench, J., Benson, W. (2002). Exchange Transfusion for Severe Intrahepatic Cholestasis Associated With Sickle Cell Disease. Journal of Clinical Gastroenterology, 35(4), 362-363. [More Information]
- Alonso, C., George, J., Pesce, C., Bissell, D., Kornblihtt, A. (2002). Fibronectin transcription in liver cells: promoter occupation and function in sinusoidal endothelial cells and hepatocytes. Biochemical and Biophysical Research Communications, 295(5), 1077-1084. [More Information]
- Hui, J., Kench, J., Farrell, G., Lin, R., Samarasinghe, D., Liddle, C., Byth, K., George, J. (2002). Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. Journal of Gastroenterology and Hepatology, 17(8), 873-881. [More Information]
- Chitturi, S., Le, V., Kench, J., Loh, C., George, J. (2002). Gliclazide-Induced Acute Hepatitis with Hypersensitivity Features. Digestive Diseases and Sciences, 47(5), 1107-1110. [More Information]
- Hui, J., Farrell, G., Lin, R., Samarasinghe, D., Liddle, C., George, J., Kench, J., Byth, K. (2002). Hepatic Steatosis in Chronic Hepatitis C Infection. Journal of Gastroenterology and Hepatology, 17(8), 873-881.
- Kumar, S., Farrell, G., Fung, C., George, J. (2002). Hepatitis C Virus Genotype 3 is Cytopathic to Hepatocytes: Reversal of Hepatic Steatosis after Sustained Therapeutic Response. Hepatology, 36(5), 1266-1272. [More Information]
- Chitturi, S., George, J. (2002). Hepatotoxicity of Commonly Used Drugs: nonsteroidal Anti-Inflammatory Drugs, Antihypertensives, Antidiabetic Agents, Anticonvulsants, Lipid-Lowering Agents, Psychotropic Drugs. Seminars in Liver Disease, 22(2), 169-183. [More Information]
- Chitturi, S., Weltman, M., Farrell, G., McDonald, D., Liddle, C., Samarasinghe, D., Lin, R., Abeygunasekera, S., George, J. (2002). HFE Mutations, Hepatic Iron, and Fibrosis: Ethnic-Specification Association of NASH with C282Y but not with Fibrotic Severity. Hepatology, 36(1), 142-149. [More Information]
- Chitturi, S., Abeygunasekera, S., Farrell, G., Holmes-Walker, J., Hui, J., Fung, C., Karim, R., Lin, R., Samarasinghe, D., Liddle, C., Weltman, M., George, J. (2002). NASH and Insulin Resistance: Insulin Hypersecretion and Specific Association with the Insulin Resistance Syndrome. Hepatology, 35(2), 373-379. [More Information]
- Chitturi, S., Farrell, G., Frost, L., Kriketos, A., Lin, R., Liddle, C., Samarasinghe, D., George, J. (2002). Serum Leptin in NASH Correlates with Hepatic Steatosis but not Fibrosis: A Manifestation of Lipotoxicity? Hepatology, 36(2), 403-409. [More Information]
- Farrell, G., Phung, T., Ip, E., Dela Pena, A., Robertson, G., Pera, N., George, J., Leclercq, I. (2002). Sources of oxidant stress in fatty liver disorders. Interactive mechanisms, and relevance to fibrosing steatohepatitis. AASLD Single Topic Conference NASH – Nonalcoholic Steatohepatitis.
- Wong, V., Fu, A., George, J., Cheung, N. (2002). Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clinical Endocrinology, 56(6), 793-798. [More Information]
2001
- Chitturi, S., Hui, J., Salisbury, E., Mitchell, D., George, J. (2001). Abdominal pain in an intrauterine contraceptive devise user. Postgraduate Medical Journal, 77, 602-610.
- Phung, T., Farrell, G., Robertson, G., George, J. (2001). Antioxidant therapy with vitamin E ameliorates hepatic fibrosis in MCDD-associated NASH. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
- Chitturi, S., Abeygunasekera, S., Fung, C., Samarasinghe, D., Lin, R., McDonald, D., Weltman, M., Farrell, G., George, J. (2001). Haemochromatosis gene mutations, hepatic iron content and nonalcoholic steatohepatitis. Hepatology, 19, 1768-1778.
- Leclercq, I., George, J., Farrell, G., Robertson, G., Field, J. (2001). Leptin is an essential mediator of hepatic fibrogenesis and liver regeneration in chronic CCl4-induced liver injury. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
- Pera, N., Phung, H., Leclercq, I., Farrell, G., George, J. (2001). Oxidative stress and the evolution of hepatic fibrogenesis in a rodent model of nonalcoholic steatohepatitis. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
- Coverdale, S., Samarasinghe, D., Lin, R., Liddle, C., George, J., Farrell, G., Kench, J., Byth, K., Khan, M., Crewe, E. (2001). Prediction of histological progression in chronic hepatitis C. Asia Pacific Digestive Week 2001, : World Scientific Publishing.
- George, J., Hui, J., Farrell, G., Lin, R., Samarasinghe, D., Kench, J. (2001). Predictors for steatosis and fibrosis in chronic hepatitis C. Journal of Hepatology, 34, 153-153.
- Farrell, G., Liddle, C., Samarasinghe, D., Lin, R., George, J., Chitturi, S., Frost, L. (2001). Serum Leptin: An independent predictor of hepatic steatosis but not fibrotic severity in nonalcoholic steatohepatitis. Hepatology, 34, 752-752.
- Pera, N., Phung, H., Leclercq, I., Farrell, G., George, J. (2001). The role of oxidative stress in the evolution of hepatic fibrogenesis in a rodent model of nonalcoholic steatohepatitis. The American Association for the Study of Liver Diseases 52nd Annual Meeting, : World Scientific Publishing.
- Pera, N., Phung, H., Leclercq, I., Farrell, G., George, J. (2001). This role of oxidative stress in the evolution of hepatic fibrogenesis in a rodent model of nonalcoholic steatohepatitis. Hepatology, 34, 1132-1132.
- Bissell,, D., Roulot, D., George, J. (2001). Transforming growth factor B and the liver. Hepatology, 34(5), 859-867.
- Phung, T., Farrell, G., Robertson, G., George, J. (2001). Vitamin E but not glutathione precursors ameliorates hepatic fibrosis in experimental NASH. Journal of Gastroenterology and Hepatology, 16.
- Phung, T., Farrell, G., Robertson, G., George, J. (2001). Vitamin E but not glutathione precursors inhibits hepatic fibrosis in experimental NASH exhibiting oxidative stress and mitochondrial abnormalities. Hepatology, 34, 756-756.
Selected Grants
2022
- Building active surveillance systems to track hepatitis C virusepidemiology and antiviral resistance, Douglas M, Kok J, Eden J, Tu T, Cunningham A, George J, Australian Centre for HIV and Hepatitis Virology Research (ACH2)/Research Support
- A flagship lightsheet, confocal and live cell 4D microscope to turbocharge translational cancer research at the Westmead Health Precinct, George J, Graham J, Robinson P, O'Neill G, Hau E, Fernandez Penas P, Gottlieb D, Ahern V, Cesare A, Schlegel P, Cancer Institute NSW/Equipment Grant
2021
- Oncofetal ecosystem in advanced Hepatocellular Carcinoma: Implications for Identifying Immunotherapy response, Sharma A, Wallace M, Lucas M, Ginhoux F, Chow P, Yeoh G, Gunawardena D, George J, National Health and Medical Research Council (NHMRC)/Ideas Grant
- Reducing liver cancer burden, George J, Cancer Council NSW/Sally Crossing AM Award
- The APRICA program- Accelerated translational research in PRImary Liver Cancer, George J, McCaughan G, Reddel R, Bertolino P, Palendira M, Eslam M, Usherwood T, Cancer Institute NSW/Accelerated Translational Research Grant
- The Role of Metabolic Dysfunction-Associated Fatty Liver Disease in the Development of Hyperglycaemia in Pregnancy, Cheung N, George J, Pasupathy D, Diabetes Australia Research Trust (DART)/Diabetes Research Grant Program
2020
- Delineating the clinical and molecular heterogeneity of fatty liver disease to inform treatment, George J, National Health and Medical Research Council (NHMRC)/Investigator Grant
- Development of a diagnostic assay to measure hepatitis B virus cccDNA, Douglas M, Tu T, George J, Australian Centre for HIV and Hepatitis Virology Research (ACH2)/Research Support
2019
- Quantifying integrated and episomal HBV DNA in fine needle aspirate liver biopsies, Tu T, Douglas M, George J, Australian Centre for HIV and Hepatitis Virology Research (ACH2)/Research Support
2018
- Nutrition and Complexity, George J, Simpson S, Le Couteur D, Gunton J, Raubenheimer D, Durrant-Whyte H, National Health and Medical Research Council (NHMRC)/Program Grants
- Reach Out: Maximising cures for HCV infection in marginalised communities: Microelimination, George J, McCaughan G, Department of Health and Aged Care (Federal)/MRFF - Rapid Applied Research Translation (RART) - Sydney Health Partners
- epMotion 5075 Automated Liquid Handling Workstation Upgrade: Enabling New High Throughput Applications and Enhancing High Quality Research in the Westmead Precinct., George J, Mann G, deFazio A, National Health and Medical Research Council (NHMRC)/Equipment Grant
2017
- BD FACSymphony A5 High Parameter Cytometer: Enabling high quality research in the Westmead Precinct, Cunningham A, Mann G, George J, National Health and Medical Research Council (NHMRC)/Equipment Grant
- Aptamer-mediated targeting of cancer stem cells to treat liver cancer, George J, Cancer Council NSW/Research Grant
- Maximising cures for HCV in marginalised communities, George J, McCaughan G, Qiao L, Department of Health and Aged Care (Federal)/MRFF - Rapid Applied Research Translation (RART) - Sydney Health Partners
- BD FACSymphony A5 High Parameter Flow Cytometer for Westmead Research Hub at Westmead Precinct, Mann G, deFazio A, Bendall L, George J, Gottlieb D, Clarke C, Byrne J, Shaw P, Reddel R, Ling S, Cancer Institute NSW/Equipment Grant
2016
- Implementing and enhancing evidence-based research and practice in hepatology, George J, National Health and Medical Research Council (NHMRC)/Career Awards: Practitioner Fellowships
- Sydney West Translational Cancer Research Centre SW-TCRC, Harnett P, deFazio A, Shaw T, George J, Mann G, Balleine R, Flynn P, Cancer Institute NSW/Translational Cancer Research Centre
- Targeting metabolic and vascular health with high intensity exercise training in type 2 diabetes, Johnson N, Baker M, Chuter V, Keating S, George J, Caterson I, Byrne N, Collaborative Research Network for Advancing Exercise & Sports Science (CRN-AESS)/Research Capacity Building Seeding Grant Scheme
2015
- 3D cell explorer, Chrzanowski W, King N, Weiss A, George J, Boddy A, National Health and Medical Research Council (NHMRC)/Equipment Grant
- Seahorse XFe24 Analyser , Mann G, O'Connell P, Gunton J, George J, Liddle C, University of Sydney/Equipment Grant
- Covaris Evolution Adaptive Focused Acoustic Ultrasonicator for enhancement of cancer research within the Sydney West Hub, Graham J, Clarke C, Mann G, deFazio A, George J, Liddle C, Booth D, Sintchenko V, Cancer Institute NSW/Equipment Grant
- HCC Outcomes mitigation and disease PrEvention through Clinical Partnerships (HOPE), George J, Robotin M, Thompson A, Cancer Australia/Priority Driven Collaborative Cancer Research Scheme
2014
- Ultra high performance liquid chromatography (UPLC) system, Liddle C, Byrne J, George J, Robinson P, Gunton J, National Health and Medical Research Council (NHMRC)/Equipment Grant
- A novel stem cell immunotherapy approach to target liver cancer, George J, University of Sydney/SMS- Medical Foundation
2013
- Hepatitis C infection: epidemiology, pathogenesis, and treatment, Lloyd A, George J, Beard M, National Health and Medical Research Council (NHMRC)/Program Grants
- NanoString nCounter Platform, deFazio A, Alexander I, Booth D, Byrne J, Christodoulou J, Clarke C, Cunningham A, George J, Graham J, Harman A, Liddle C, Mann G, National Health and Medical Research Council (NHMRC)/Equipment Grant
- A pilot study of fenofibrate to improve hepatitis C virus treatment response - Australian Centre for HIV and Hepatitis Virology Research (ACH2), Douglas M, George J, Commonwealth Department of Health and Ageing/Health Surveillance Fund
2012
- Characterization of ARL6IP5 in hepatitis C-related liver cancer, Qiao L, Douglas M, George J, National Health and Medical Research Council (NHMRC)/Project Grants
- Adiponectin and cholesterol a driving force in NASH immunopathogenesis, George J, Hebbard L, Bendall L, National Health and Medical Research Council (NHMRC)/Project Grants
- Building multidisciplinary research linkages - the University of Sydney and Chulalongkorn University Symposium, Chaisamran U, Chindamporn A, Dietz H, Freckelton L, George J, Gurney H, Hyett J, Meyer W, Napathorn S, Snowdon J, Srikiatkhachorn A, Office of Global Engagement/IPDF Grant
- Developing functional research partnerships and student exchange, focused on relevant infectious diseases with the Eijkman Institute and Hasanuddin University, Indonesia, Douglas M, George J, Marais B, Muljono D, Sorrell T, Yusuf I, Office of Global Engagement/IPDF Grant
2011
- Small Rodent Airlaw Caging System, Cunningham A, Djordjevic J, Fletcher J, George J, Harris D, Hawthorne W, Hebbard L, Liddle C, Little D, O'Connell P, National Health and Medical Research Council (NHMRC)/Equipment Grant
- Defining the role of T-Cadherin (T-CAD) in Adiponectin (APN) mediated protection against vascular injury and angiogenesis, Ayer J, George J, Clive & Vera Ramaciotti Foundation/Awards for Biomedical Research: Establishment Gifts
2010
- The BD Influx High Speed Cell Sorter, Cunningham A, George J, Rizos H, Clarke C, Reddel R, Kefford R, North K, Stewart G, Jones C, Tam P, Alexander S, Gottlieb D, Bradstock K, Bryan T, Booth D, Bendall L, Brilot-Turville F, Hebbard L, Cooper S, Wang Y, Wang X, National Health and Medical Research Council (NHMRC)/Equipment Grant
- Role of adiponectin in hepatic carcinogenesis, George J, Hebbard L, National Health and Medical Research Council (NHMRC)/Project Grants
- Novel molecular targets for treatment of hepatocellular cancer (HCC), Hebbard L, George J, Cancer Council NSW/Innovator Grant
- The role of adiponectin-mediated nitric oxide on portal hypertension and liver fibrosis, George J, Wang J, National Health and Medical Research Council (NHMRC)/Project Grants
- Objective Measurement of Physical Activity and Sedentary Behaviou, Baur L, George J, Cunningham A, Djordjevic J, Fletcher J, Harris D, Hawthorne W, Hebbard L, Liddle C, Little D, O'Connell P, National Health and Medical Research Council (NHMRC)/Equipment Grant
- Exercise and liver fat reduction in pre-diabetes: moving beyond weight loss, Johnson N, Caterson I, George J, O'Connor H, Diabetes Australia Research Trust (DART)/Research Grants
- The effect of IL28B haplotype on hepatitis C virus infection and treatment response, Booth D, Ahlenstiel G, Stewart G, George J, National Health and Medical Research Council (NHMRC)/Project Grants
- The role of endocannabinoids in chronic hepatitis C, George J, Douglas M, National Health and Medical Research Council (NHMRC)/Project Grants
2009
- The role of adiponectin receptors in liver fibrosis formation, George J, Hebbard L, National Health and Medical Research Council (NHMRC)/Project Grants
2008
- Functional Genomics to Predict and Enhance Response to Interferon, Bahlo M, George J, Kingston D, Suppiah V, Yang J, McKay F, Booth D, Stewart G, Bahlo M, Australian Research Council (ARC)/Linkage Projects (LP)
- High-Throughput virtual microscopy and data warehouse system, Balleine R, Catchpoole D, Clarke C, deFazio A, George J, Henderson B, Mann G, Schifter M, Cancer Institute NSW/Equipment Grant
2007
- Epidemiology, prevention and management of liver cancer in NSW: Towards a strategic research partnership, George J, Strasser S, McCaughan G, Dore G, Liddle C, Strasser S, Cancer Council NSW/Strategic Research Partnership (STREP) Grants
- Epidemiology, prevention and management of liver cancer in NSW: Towards a strategic research partner, Dore G, George J, Liddle C, McCaughan G, Strasser S, Cancer Council NSW/Strategic Research Partnership (STREP) Grants
2005
- Host factors affecting of Hepatitis C-associated liver disease, Booth D, George J, Stewart G, Thomas D, National Health and Medical Research Council (NHMRC)/Project Grants
- The Development of a National Centre for Clinical Islet Transplantation, Dado M, George J, Hawthorne W, Kay T, O'Connell P, Russ G, Wilson M, Juvenile Diabetes Research Foundation/Project Support
2004
- Medical Foundation funding to support a NHMRC Program Grant No 358398. Entitled - Molecular & cellular pathogenesis of liver disease, Farrell G, George J, McCaughan G, University of Sydney/Internal Research Grant Allocations - Medicine
- Molecular and cellular pathogenesis of liver disease, George J, McCaughan G, National Health and Medical Research Council (NHMRC)/Program Grants
- Physiological basis of insulin resistance in chronic hepatitis C virus infection, George J, University of Sydney/Internal Research Grant Allocations - Faculty of Medicine
2002
- Molecular and cellular pathogenesis of nonalcoholic steatohepatitis: insights from human studies, Farrell G, George J, Leclercq I, National Health and Medical Research Council (NHMRC)/Project Grants
- Cellular and molecular mechanisms of the profibrogenic effect of leptin in the liver, Farrell G, George J, Leclercq I, National Health and Medical Research Council (NHMRC)/Project Grants
- Centre of clinical research excellence to improve outcomes in chronic liver disease, Donaghy A, Donaghy A, Farrell G, George J, McCaughan G, Strasser S, Strasser S, National Health and Medical Research Council (NHMRC)/Centres of Clinical Research Excellence
2000
- Pathogenesis of liver injury and hepatic fibrosis in non-alcoholic steatohepatitis, NASH, Farrell G, George J, Leclercq I, Robertson G, National Health and Medical Research Council (NHMRC)/Project Grants
1999
- Hepatic fibrosis in non alcoholic steatohepatitis, George J, Clive & Vera Ramaciotti Foundation/Research Grant